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Abstract 
 
Dendritic cells (DCs) play important roles at the interface between innate and 
adaptive immunity by priming and directing T cell responses. Much of our current 
knowledge of DC biology has come from mouse models in which DCs can be 
genetically manipulated, labelled or ablated. Here, novel models are presented 
using a strategy that targets DC precursors via genetic editing of the Clec9a locus. 
While validating a novel mouse model to inducibly deplete DCs using diphtheria 
toxin receptor (DTR) expression driven by Clec9a, it became clear that these 
Clec9a+/CreROSAiDTR mice suffer from unexpected lymph node (LN) hypocellularity 
and reduced frequencies of DCs in LNs, even in the absence of diphtheria toxin 
(DT) injection. This phenotype turned out to be a common feature of other mouse 
models in which DTR is expressed on DCs (e.g. CD11c-DTR and Langerin-DTR 
mice) and raises questions about the interpretation of results obtained with such 
animals. Therefore, in an alternative approach, mice were developed to 
constitutively lack DCs by expressing the diphtheria toxin alpha (DTA) subunit 
under control of the Clec9a locus. Unfortunately, these mice still harboured DCs 
and only showed partial reduction of one DC subset.  
 
Finally, seeding of tissues by DC precursors was examined. 
Clec9a+/CreROSA+/confetti mice were generated in which DC precursors stochastically 
express one of four fluorescent proteins, which is inherited by its daughter cells. 8-
Colour microscopy of tissue sections and histo-cytometry analysis of the images 
was developed to analyse these mice. This approach will be used to determine 
how many daughter cells are produced when a single DC precursor seeds the 
small intestine (clonal burst size), whether these daughters are found among 
different DC subsets and whether seeding changes during inflammation.  
 
In summary, manipulation of the Clec9a locus proves to be an excellent way to 
study the DC lineage and DC precursor behaviour in the mouse. 
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Chapter 1. Introduction 
The mononuclear phagocyte system comprises monocytes, macrophages and 
dendritic cells that were historically thought to share morphological features, 
immune functions and ontogeny. The first mononuclear phagocyte to be discovered 
was the Langerhans cell in 1869, identified by and named after Paul Langerhans. 
Due to its dendritic morphology and resemblance to nerve cells, it was originally 
categorised as being part of the nervous system. In the late 19th century Ilya 
Metchnikoff described the process of phagocytosis and identified macrophages as 
key phagocytic cells, thereby starting the research on mononuclear phagocytes. 
However, it was only in the 1970s that Ralph Steinman and Zanvil Cohn discovered, 
described and named the dendritic cell (DC) in a series of seminal papers 
(Steinman and Cohn, 1973; Steinman, Lustig and Cohn, 1974; Steinman and 
Cohn, 1974; Steinman, Adams and Cohn, 1975). Ralph Steinman also identified 
the first functional properties of DCs by showing that DCs are the key inducers of 
mixed leukocyte reactions (Steinman and Witmer, 1978; Steinman et al., 1983). 
Research in the past forty years has greatly expanded our understanding of DC 
functions, ontogeny, localisation and marker expression, both in mice and humans. 
This introduction will discuss current knowledge on different murine DC subsets, 
their function and ontogeny and will pay special attention to transgenic mouse 
models that are used to study DC biology in vivo.  
1.1 Dendritic cells in the mouse 
1.1.1 Dendritic cell subsets 
DCs are antigen-presenting cells with roles in innate and adaptive immune 
responses. They comprise a heterogeneous group of cells and, therefore, are 
commonly classified into subsets based on select functional attributes, differences 
in levels of expression of certain cell-surface markers, localisation in the body and 
ontogenetic relationships (Geissmann, Manz, et al., 2010; Steinman and Idoyaga, 
2010; Hashimoto, J. Miller and Merad, 2011; Merad et al., 2013; Schraml and Reis 
e Sousa, 2014). DCs are generally characterised by expression of the integrin 
CD11c and major histocompatibility complex class II (MHCII), although these 
markers are not unique to DCs. DCs can be broadly subdivided into two main 
Chapter 1 Introduction 
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groups: plasmacytoid DCs (pDCs), which are generally characterised by their rapid 
production of interferon-α upon Toll-like receptor (TLR) 7, 8 and 9 engagement; 
and conventional DCs (cDCs) that are superior in initiating and directing T cell 
responses (Geissmann, Manz, et al., 2010; Steinman and Idoyaga, 2010; 
Hashimoto, J. Miller and Merad, 2011; Schraml et al., 2013; Merad et al., 2013).  
cDCs can be further divided into those normally resident at lymphoid tissues 
(resDCs) versus those that have immigrated from elsewhere (migDCs) 
(Geissmann, Gordon, et al., 2010; Steinman and Idoyaga, 2010; Hashimoto, J. 
Miller and Merad, 2011; Merad et al., 2013). The latter normally reside in non-
lymphoid tissues but migrate to the draining LNs via afferent lymphatics in the 
steady state and, prominently, during inflammation. Both resDCs and migDCs are 
present in LNs, while other lymphoid structures, such as spleen, thymus and 
Peyer’s patches only harbour resDCs, as these tissues lack an afferent lymph 
supply.  
Both resDCs and migDCs consist of different subsets. The CD8α-like subset of 
cDCs comprises the CD8α+ resDCs in lymphoid organs and their CD103+ CD11b- 
counterparts in tissues, which can migrate to LNs where they appear as CD103+ 
CD11b- migDCs. These cells can additionally be characterised by their expression 
of Dendritic cell NK lectin group receptor-1 (DNGR-1, also called CLEC9A) and 
XCR1 (Sancho et al., 2008; 2009; Crozat et al., 2011; Bachem et al., 2012; Becher 
et al., 2014). CD8α-like DCs are thought to possess a superior capacity to cross-
present exogenous antigens to CD8+ T cells. They also share gene expression 
patterns and have similar transcription factor dependencies (Geissmann, Manz, et 
al., 2010; Steinman and Idoyaga, 2010; Edelson et al., 2010; Hashimoto, J. Miller 
and Merad, 2011; Merad et al., 2013). Their counterparts are the more 
heterogeneous group of CD11b-expressing resDCs in lymphoid tissues and 
CD11b+ DCs in non-lymphoid tissues that migrate to LNs, where they appear as 
CD11b+ migDCs (Geissmann, Manz, et al., 2010; Hashimoto, J. Miller and Merad, 
2011; Merad et al., 2013; Becher et al., 2014). Langerhans cells (LCs) are often 
considered to be a subset of DCs. However, LCs differ considerably from DCs in 
terms of ontogeny, growth factor and transcription factor dependency, and should 
therefore be treated as a unique macrophage-type of cell that resides in the 
epidermis and migrates to skin-draining LNs (sdLNs) (Merad et al., 2013; Malissen, 
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Tamoutounour and Henri, 2014). A table summarising surface marker expression 
of the different steady state DC subsets and LCs is included in Table 1. 
 
DCs also share many traits with macrophages and monocytes, and especially in 
peripheral tissues and under inflammatory conditions the different mononuclear 
phagocytes can be hard to distinguish from one another. These difficulties have led 
to considerable debate in the field regarding the classification of certain cells as 
DCs, macrophages and/or monocyte-derived cells.  
 
marker resDC migDC pDC LC 
 CD8α+ CD11b+ CD103+ 
CD11b- 
CD103+ 
CD11b+ 
(intestinal) 
CD103- 
CD11b+ 
CD11c ++ ++ ++ ++ ++ + ++ 
MHCII ++ ++ ++ ++ ++ + ++ 
CD8α + - - - - subset - 
CD11b - ++ - ++ ++ - + 
CD103 subset - ++ ++ - - - 
CD207 
(Langerin) 
subset - + - - - ++ 
DNGR-1 
(CLEC9A) 
++ - ++ - - + - 
CD205 
(DEC205) 
subset - + - - - + 
Xcr1 + - + - - - - 
CD172a 
(Sirpα) 
- ++ - - ++ + + 
CD4 - subset - - - + ? 
B220 - - - - - + - 
SiglecH - - - - - + - 
Table 1: Surface marker expression of DC subsets and LCs. 
-: marker not expressed, +: marker expressed, ++: marker highly expressed, ?: not 
determined, subset: marker only expressed on a subset of population.  
(Alvarez, Vollmann and Andrian, 2008; J. C. Miller et al., 2012; Merad et al., 2013) 
 
1.1.1.1 Mononuclear phagocytes in the spleen and LNs 
Since the discovery of DCs about forty years ago, most research in the mouse has 
focussed on spleen and LN DCs. These secondary lymphoid organs are relatively 
easy to obtain and process for analysis and exhibit the highest frequency of DCs 
relative to all nucleated cells. The spleen lacks an afferent lymph supply and filters 
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the blood for pathogens and senescent red blood cells. The red pulp comprises the 
largest part of the spleen and is the main site for red blood cell recycling. 
Lymphocytes cluster together in the white pulp of the spleen that is organised 
around arterioles. The white pulp contains distinct T cell and B cell areas, with T 
cells residing in the periarteriolar lymphoid sheath and B cells in the lymphoid 
follicles with the surrounding marginal zone. LNs have afferent lymph supply that 
delivers a continuous flow of lymph from the tissues to the LNs. The LN is also 
organised into B cell areas, called follicles that lie in the outer cortex, and a T cell 
area, called the T cell zone in the paracortical area. Naïve lymphocytes and other 
leukocytes enter the LN via specialised blood vessels called high endothelial 
venules (HEVs) 
 
The spleen only harbours resident DCs, which express the prototypical DC markers 
CD11c and MHCII (Figure 1.1). Splenic DCs can be further divided into pDCs, 
CD8α+ DCs and CD11b+ DCs. At steady state splenic pDCs express low levels of 
CD11c, MHCII and DNGR-1 and are positive for B220, Ly6c, SiglecH and PDCA-1 
(Zhang et al., 2006; Blasius et al., 2006; Sancho et al., 2008). CD8α+ DCs express 
DNGR-1 and lack CD11b or CD4 expression and may be positive for langerin 
(Sancho et al., 2008; J. C. Miller et al., 2012; Becher et al., 2014). Although most 
CD8α+ DCs are CD103+ CD205+ and negative for the chemokine receptor CX3CR1, 
a smaller population lacks CD103 and CD205 expression, but are positive for 
CX3CR1 (Bar-On et al., 2010). These latter cells were reported to functionally and 
phenotypically resemble pDCs rather than CD8α-like DCs, although more recent 
studies have questioned this conclusion, based on lineage tracing data (Bar-On et 
al., 2010; Satpathy, KC, et al., 2012; Schraml et al., 2013). CD11b+ DCs in the 
spleen lack CD8α and CD103 expression and a subset expresses CD4 (J. C. Miller 
et al., 2012; Becher et al., 2014). CD4 has been used to identify a CD4+ DC 
population in the spleen, however, both older and more recent data indicate that 
CD4 expression is not discriminatory, and CD11b+ CD4+ DCs and CD11b+ CD4- 
DCs are highly similar in expression levels of other DC markers and in transcription 
factor dependencies (Edwards et al., 2003; Becher et al., 2014). ESAM expression 
also identifies two different CD11b+ DC subsets in the spleen, and in this case 
ESAMhi and ESAMlow CD11b+ DCs do show differential expression of various other 
markers such as CD4, CD11c, CX3CR1 and Flt3, show differences in Notch2 and 
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lymphotoxin β receptor dependency and are functionally distinct (Lewis et al., 2011). 
In the original report it was suggested that ESAMhi but not ESAMlow CD11b+ DCs 
develop from committed DC precursors, although more recent lineage tracing data 
suggest that committed DC precursors can give rise to both subsets (Lewis et al., 
2011; Schraml et al., 2013). In the spleen CD11b+ DCs are located in the T cell 
zone of the white pulp, while CD8α+ DCs reside both in the white pulp and the 
marginal zone (Nolte et al., 2000; Qiu et al., 2009; Idoyaga et al., 2009). 
 
ResDCs in the LNs show a similar organisation as splenic DCs and are divided into 
pDCs, CD8α+ resDCs and CD11b+ resDCs, which largely express the same 
surface markers as their splenic equivalents (Figure 1.1). In addition, LNs contain 
migDCs that have migrated from peripheral tissues. The exact composition of the 
migDC compartment depends on what sites the LN is draining. However, in general 
migDCs contain a CD8α-like subset and a CD11b+ subset. A more detailed 
description of migDCs originating from the skin, intestine and lung is given in 
subsequent sections (1.1.1.2, 1.1.1.3 and 1.1.1.4). CD8α+ resDCs localise 
predominantly to the T cell zone in LNs, while CD11b+ resDCs tend to be found 
around lymphatic regions (Gerner et al., 2012; Gerner, Torabi-Parizi and Germain, 
2015). CD103+ migDCs also tend to be found in the T cell zone, while CD11b+ 
migDCs cluster in the interfollicular areas (Gerner et al., 2012). 
 
The marginal zone of the spleen contains two macrophage populations, the 
marginal zone macrophages and the metallophilic macrophages. A third 
macrophage population, the red pulp macrophage, can be found in the red pulp of 
the spleen (Haan and Kraal, 2012). Marginal zone macrophages lack MHCII and 
F4/80 expression, but do express CD68, SIGN-R1 and MARCO and are large 
phagocytic cells (Hashimoto, J. Miller and Merad, 2011; Davies et al., 2013). 
Metallophilic macrophages also lack F4/80 expression but can be identified via 
CD169 and CD68 expression and are not very phagocytic (Hashimoto, J. Miller and 
Merad, 2011; Davies et al., 2013). Red pulp macrophages express high levels of 
F4/80, the mannose receptor (CD206) and are low for CD11b, MHCII and CD169 
(Hashimoto, J. Miller and Merad, 2011; Davies et al., 2013). 
In the LN, macrophage populations can be found lining the subcapsular sinus and 
the medullar sinus. Subcapsular sinus macrophages are low for F4/80 and CD11c 
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and express CD11b, CD169 and MARCO. Medullar sinus macrophages express 
high levels of F4/80, low levels of CD11c and are positive for CD169, CD11b and 
MARCO (Hashimoto, J. Miller and Merad, 2011; Gray and Cyster, 2012). 
 
The spleen harbours one of the largest monocyte pools of the body (Swirski et al., 
2009). These monocytes express CD11b and CD115 and can be divided into a 
Ly6chi and Ly6clow subset. They are located in the cords of the subcapsular red 
pulp and can be released into the blood in response to an inflammatory stimulus 
(Swirski et al., 2009). Steady state LNs contain hardly any monocytes. 
 
 
Figure 1.1 Overview of mononuclear phagocytes in spleen and lymph node 
Schematic illustration of mononuclear phagocyte subsets in steady state spleen 
and LN. DC: dendritic cell, LC: Langerhans cell, MØ: macrophage, MZ MØ: 
marginal zone macrophage, mono: monocyte, pDC: plasmacytoid DC, SCS MØ: 
subcapsular sinus macrophage. 
 
Inflammation can change surface marker expression of mononuclear phagocytes in 
spleen and LN and may also prompt the appearance of novel subsets of 
mononuclear phagocytes. Upon systemic infection with Listeria monocytogenes 
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monocytes differentiate into DC-like cells that have been called TNF/iNOS-
producing DCs (Tip DCs), although these cells do not belong to the DC lineage 
(Serbina, Salazar-Mather, et al., 2003; Serbina, Kuziel, et al., 2003). They express 
CD163 and Ly6c and intermediate levels of MHCII, CD11c and CD11b, and they 
produce high amounts of TNFα and iNOS (Serbina, Kuziel, et al., 2003). Similar 
cells were found upon systemic infection with Brucella melitensis (Copin et al., 
2007). 
Systemic LPS challenge leads to the appearance in skin-draining LNs (sdLNs) of a 
monocyte-derived cell with DC-like properties that expresses CD11c, MHCII, the C-
type lectin DC-SIGN (CD209) and the mannose receptor (CD206) (Cheong et al., 
2010). Like resDCs, these DC-SIGN+ cells located to the T cell zone in LNs 
(Cheong et al., 2010). Although it was shown that DC-SIGN+ cells derive from 
monocytes, they failed to develop in Flt3l-/- mice and expressed the transcription 
factor Zbtb46, which are considered to be properties of DCs (Meredith, Liu, 
Darrasse-Jeze, et al., 2012). Leishmania major infection in the footpad also leads 
to the appearance of a monocyte-derived cell resembling the splenic Tip DCs found 
upon systemic Listeria monocytogenes infection (De Trez et al., 2009). These cells 
in the LNs are positive for CD11c, MHCII, CD11b and Ly6c, and produce iNOS and 
to a lesser extend TNFα (De Trez et al., 2009). Although most inflammatory 
monocytes in LN are thought to have migrated from peripheral sites, inflammatory 
monocytes can also enter LNs directly from the blood (Nakano et al., 2009). In 
germinal centres a special type of macrophage, termed the tangible body 
macrophage, can be found that clears up apoptotic cells during the germinal centre 
reaction and expresses CD68 (Haan and Kraal, 2012).  
1.1.1.2 Mononuclear phagocytes in the skin  
The skin comprises an epidermal and dermal layer. The epidermis is a stratified 
squamous epithelium and is mainly composed of keratinocytes that proliferate and 
differentiate into an enucleated, organised structure that protects from the external 
environment. The epidermis does not contain blood and lymph vessels. A 
basement membrane separates the epidermis from the dermis. The dermis is 
made of connective tissue and does contain blood vessels, lymphatics and nerve 
Chapter 1 Introduction 
21 
 
endings. Hair follicles are also present in the skin and are the production sites of 
hair, sweat and sebum. 
In the steady state epidermis only a population of well-characterised Langerhans 
cells (LCs) is found (Figure 1.2). LCs are radioresistant cells that express 
Epithelial-cell adhesion molecule (EpCAM), the C-type lectin langerin (CD207) and 
Birkbeck granules that can be identified microscopically and whose formation is 
induced by langerin (Birbeck, Breathnach and Everall, 1961; Wolff, 1967; 
Valladeau et al., 2000). LCs migrate from the epidermis, via the dermis into afferent 
lymphatics that take them to draining sdLNs. In order to migrate, LCs downregulate 
E-cadherin expression to relieve homotypic interactions with E-cadherin molecules 
on keratinocytes in the epidermis (A. Tang et al., 1993; Jakob and Udey, 1998). 
LCs also produce enzymes that facilitate the degradation of the basement 
membrane that separates epidermis from dermis, such as matrix 
metalloproteinases (MMP) 2 and 9 (Y. Kobayashi et al., 1999; Ratzinger et al., 
2002). In addition, the chemokine receptor CXCR4 expressed on LCs and it ligand 
CXCL12 are critical for LC migration from the epidermis to the dermis (Ouwehand 
et al., 2008). Once in the dermis, migration to the draining LNs is predominantly 
dependent on the chemokine receptor CCR7, which can bind both CCL19 and 
CCL21 (Ohl et al., 2004), while the CXCR4-CXCL12 chemokine receptor-
chemokine pair has also been shown to contribute to the migration of LCs in the 
dermis (Kabashima et al., 2007). 
 
Various radiosensitive DC subsets can be found in the dermis, in addition to the 
radioresistant LCs that are in transit from the epidermis to dermal lymphatics, as 
well as monocytes and a macrophage population (Figure 1.2) (Malissen, 
Tamoutounour and Henri, 2014). The dermis contains a subset of DCs that 
expresses langerin, which has been overlooked for a long time, as langerin was 
thought to be an exclusive marker for LCs (Poulin et al., 2007; Bursch et al., 2007; 
Henri et al., 2010). These cells correspond to the CD8α-like subset of DCs in the 
skin and express CD103 in addition to langerin, while lacking CD11b expression. 
They will be called CD103+ dermal DCs here. In addition, the dermis contains a 
large CD11b+ dermal DC population that lacks expression of CD103 and langerin, 
and a DC population that is negative for CD103 and langerin and expresses very 
little to no CD11b (Henri et al., 2010; Tamoutounour et al., 2013; Mollah et al., 
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2014). At least some of the CD11b+ dermal DCs express the C-type lectin CD301b 
(Kumamoto et al., 2009). However, interpretation of many studies on the latter two 
subsets has been complicated by the fact that CD11b+ dermal DC and marker-
negative dermal DC populations are often contaminated with monocytes and 
macrophages (Tamoutounour et al., 2013). Recent advancements in identifying 
additional surface markers to separate monocytes and macrophages from DCs 
have shown that dermal DCs are negative for Ly6c, CD64 and MerTK, while 
monocytes and macrophages express varying amounts of at least one of these 
markers (Tamoutounour et al., 2013). These observations should aid future studies 
of CD11b+ dermal DCs and marker-negative dermal DCs. 
Henri et al. (Henri et al., 2010) identified a fourth DC population in the dermis that is 
radiosensitive and positive for langerin, expresses low levels of CD11b but is 
negative for CD103 and negative to low for EpCAM. The difference between this 
subset and the CD103+ dermal DCs is solely based on differential CD103 
expression, while expression of additional markers for the CD8α-like subset of DCs, 
such as DNGR-1 or XCR1, was not assessed. Furthermore, CD103 expression on 
CD8α-like DCs is regulated by GM-CSF and correlates with cross-presentation 
ability of the cells (Zhan et al., 2011). CD103+ dermal DCs (which are langerin+) 
and langerin+ CD103- dermal DCs may therefore both represent the CD8α-like DCs 
in the dermis, at different stages of maturation. 
 
Migration of dermal DCs from the skin to draining sdLNs is well studied due to the 
good accessibility of both the non-lymphoid tissue (skin) and the draining LNs in 
vivo. Dermal DCs migrate from the skin to the draining sdLNs via lymphatics in a 
manner that is largely dependent on CCR7 and its ligands CCL19 and CCL21. In 
addition to CCR7-CCL19/21, CXCR4-CXCL12 has also been implicated in aiding 
DC migration towards LNs (Kabashima et al., 2007). Soluble CCL19 and 
haptotactic CCL21 gradients provide directional cues for dermal DCs to migrate 
towards the blind-ended tips of lymphatic vessels (Robbiani et al., 2000; Ohl et al., 
2004; Tal et al., 2011; Weber et al., 2013). The basal membrane of the ends of 
lymphatic vessels is discontinuous and the gaps, named portals, can serve as entry 
points for migrating DCs (Pflicke and Sixt, 2009). These portals are coated with 
immobilised CCL21 that likely aids the docking and transmigration of DCs into the 
vessel (Tal et al., 2011). Once inside the initial lymphatics, crawling of DCs on the 
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endothelial cells is facilitated by the C-type lectin receptor CLEC2 on DCs and its 
ligand podoplanin that is expressed on the endothelial cells (Acton et al., 2012), 
while directionality is provided by CCL19 and the lymph flow in the vessel (Tal et 
al., 2011). In the larger collecting lymphatics migrating DCs are transported by the 
lymph flow in a passive way (Miteva et al., 2010; Tal et al., 2011).  
 
Both monocytes and macrophages can be found at steady state in the dermis of 
the skin (Figure 1.2). Monocytes express low to intermediate levels of CD64 and 
are positive for CCR2. When expression of Ly6c is plotted against MHCII 
expression, dermal monocytes show a classical ‘monocyte waterfall’ distribution, 
with cells that are Ly6chi MHCII-, Ly6chi-intMHCII+ and Ly6clow MHCII+ 
(Tamoutounour et al., 2012; 2013; Bain et al., 2013). These cells show close 
developmental relationships, with blood Ly6chi monocytes generating subsequently 
Ly6chi MHCII-, Ly6chi-intMHCII+ and Ly6clow MHCII+ cells (Tamoutounour et al., 
2013). One study has shown that monocytes can acquire a DC-like transcriptional 
signature in addition to the monocyte signature (Tamoutounour et al., 2013), while 
another study did not find the DC signature (Jakubzick et al., 2013). In addition, a 
small fraction of the dermal monocytes can migrate to draining sdLNs, but under 
steady state conditions they are vastly outnumbered by dermal DCs 
(Tamoutounour et al., 2013; Jakubzick et al., 2013). Dermal macrophages are large 
and highly autofluorescent, express high levels of CD64 and are positive for MerTK, 
while they express low levels of CD11b and Ly6c (Tamoutounour et al., 2013; 
Jakubzick et al., 2013). Macrophages do not migrate to draining sdLNs.  
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Schematic illustration of mononuclear phagocyte subsets in the steady state 
skin. DC: dendritic cell, LC: Langerhands cell, MØ: macrophage, 
mono: monocyte, pDC: plasmacytoid DC.
 
Figure 1.2 Overview of mononuclear phagocytes in the skin 
Schematic illustration of mononuclear phagocyte subsets in the steady state skin. 
DC: dendritic cell, LC: Langerhans cell, MØ: macrophage, mono: monocyte, pDC: 
plasmacytoid DC. 
 
Inflammatory conditions induce the influx of monocytes into the skin in a CCR2-
dependent manner (Rodero et al., 2014). These monocytes can replenish the LC 
pool in the epidermis, but not the macrophage pool in the dermis, and can also 
differentiate into a DC-like cell (Ginhoux et al., 2006; León, López-Bravo and 
Ardavín, 2007; Eidsmo et al., 2009; Tamoutounour et al., 2013). The latter are 
often called monocyte-derived DCs or inflammatory DCs, although they do not 
originate from a DC precursor, which makes this nomenclature confusing 
(Guilliams et al., 2014) (a more detailed description of the ontogeny of DCs and 
monocytes can be found in 1.1.3). At least in a model for allergic contact dermatitis 
these cells continue to express varying levels of Ly6c and CD64, which 
distinguishes them from dermal DCs that remain negative for Ly6c and CD64 under 
inflammatory conditions (Tamoutounour et al., 2013). Inflammation may also attract 
pDCs, a DC population normally not present in the steady state skin (Farkas et al., 
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2001; Wollenberg et al., 2002; Nestle et al., 2005; van der Fits et al., 2009). pDCs 
express the pDC markers SiglecH and PDCA-1 and low levels of CD11c. 
Inflammation induces the migration of dermal DCs and LCs from the skin to the 
draining sdLNs. Dermal DCs arrive in the LNs with faster kinetics than LCs, and 
dermal DC numbers peak at day 2, while LC numbers peak at day 4 after the 
induction of skin inflammation (Kissenpfennig et al., 2005). DC-like monocytes can 
also migrate to draining sdLNs during inflammation, although their migratory 
capacity is clearly inferior to dermal DCs and LCs, while dermal macrophages fail 
to migrate altogether (Tamoutounour et al., 2013). Therefore, most monocytes that 
enter the skin during inflammation remain tissue-resident, as the dermal 
macrophages.  
1.1.1.3 Mononuclear phagocytes in the intestine  
The intestine is anatomically organised into the duodenum, jejunum and ileum, 
which together form the small intestine, and the large intestine comprising the 
caecum and colon. The small intestine displays villi, which extend into the lumen 
and increase the surface area of the intestine many fold, while the large intestine 
lacks these structures. A layer of columnar epithelial cells forms the lining of the 
intestine and separates the lumen from the loose connective tissue, termed lamina 
propria. The epithelium is largely protected from the intestinal microbiota by a layer 
of mucus produced by goblet cells. Crypts are found along the whole intestine and 
are the home of stem cells that repopulate the epithelial layer. In the small intestine, 
but not colon, organised lymphoid structures can be found that are termed Peyer’s 
patches. Specialised cells called M cells sample the lumen for antigens and 
microorganisms for presentation to the mucosal immune system of the Peyer’s 
patch. Smaller clusters of immune cells termed solitary isolated lymphoid tissues 
(SILT) can be found throughout the small intestine and colon and range in size 
from small cryptopatches to isolated lymphoid follicles. Additionally, many immune 
cells can be found dispersed throughout the lamina propria and epithelium. 
Lymphatic vessels are dispersed throughout the intestine and transport antigens 
and immune cells to draining LNs. The mesenteric lymph nodes (mesLNs) drain 
the majority of the intestine, but small LNs in the pancreas and the caudal LN also 
drain part of the intestine (Carter and Collins, 1974).  
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The intestine contains three subsets of DCs, namely CD103+ CD11b- DCs, CD103- 
CD11b+ DCs and CD103+ CD11b+ DCs (Figure 1.3). All three subsets express 
CD11c, MHCII and CD24, but lack CD64 and MerTK expression and are negative 
or low for CX3CR1 (Tamoutounour et al., 2012; Schlitzer et al., 2013). The CD103+ 
CD11b- DC subset represents the CD8α-like DCs in the intestine (Olga Schulz et 
al., 2009; Crozat et al., 2011; Satpathy, KC, et al., 2012). Like in the dermis, 
CD103- CD11b+ DCs are more heterogeneous and are likely to be contaminated 
with cells with a monocytic origin if additional markers such as CD64 are not used 
to select against the latter (Bogunovic et al., 2009; Satpathy, KC, et al., 2012; 
Tamoutounour et al., 2012; Cerovic et al., 2013; Schlitzer et al., 2013). CD103+ 
CD11b+ DCs are unique to the intestine and are more closely related to CD11b+ 
DCs than to CD8α-like DCs (Satpathy, KC, et al., 2012; Persson, Uronen-Hansson, 
et al., 2013; Schlitzer et al., 2013). All three intestinal DC subset migrate to the 
draining mesLNs and are therefore represented in mesLN migDC subsets 
(Johansson-Lindbom, 2005; Olga Schulz et al., 2009; Cerovic et al., 2013). Like for 
skin DC subsets, CCR7 is essential for migration of intestinal DCs to mesLNs 
(Johansson-Lindbom, 2005; Jang et al., 2006; Bogunovic et al., 2009). However, 
details of this migratory process are less well studied for intestinal DCs compared 
with skin DCs, due to the relative inaccessibility of the intestine to experimental 
techniques like intravital microscopy.  
A large pool of intestinal macrophages is present in the lamina propria of the small 
intestine and colon (Figure 1.3). These cells express CD11c and CD11b, but also 
the macrophage markers CD64, F4/80 and MerTK and high levels of CX3CR1, 
show an anti-inflammatory phenotype and do not normally migrate to the mesLNs, 
although they can upregulate CCR7 and migrate under certain conditions (Olga 
Schulz et al., 2009; Tamoutounour et al., 2012; Rivollier et al., 2012; Zigmond et 
al., 2012). Monocytes are continuously recruited to the lamina propria and express 
intermediate levels of CX3CR1, CD11b and are low to intermediate for CD64 
(Tamoutounour et al., 2012). They show the characteristic ‘monocyte waterfall’, 
with Ly6chi MHCII-, Ly6chi-intMHCII+ and Ly6clow MHCII+ cells that are 
developmentally linked (Tamoutounour et al., 2012). In addition to DCs, monocytes 
and macrophages, a steady state population of pDCs is also present in the 
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intestine and these cells can be found in both the epithelium and lamina propria, 
and in the Peyer’s patches (Wendland et al., 2007).  
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Figure 1.3 Overview of mononuclear phagocytes in the intestine 
Schematic illustration of mononuclear phagocyte subsets in the steady state 
intestine. DC: dendritic cell, MØ: macrophage, mono: monocyte, pDC: 
plasmacytoid DC. 
 
The lamina propria contains CD103+ CD11b- DCs, most of the CD103- CD11b+ 
DCs and CD103+ CD11b+ DCs and all macrophages, while these cells are normally 
not found in the epithelium (Bogunovic et al., 2009; Rivollier et al., 2012). The 
abundance of macrophages and CD103+ CD11b- DCs progressively increases 
from the duodenum to the colon, while the CD103+ CD11b+ DC frequency 
decreases when moving down the intestinal tract (Denning et al., 2011; Mowat and 
Agace, 2014). Peyer’s patches and isolated lymphoid follicles contain a CD8α-like 
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DC population that expresses both CD8α and CD103, but lacks CD11b expression, 
and a CD11b DC population that lacks CD8α expression but may express CD103 
(Iwasaki and Kelsall, 2000; Anjuère et al., 2004; Jang et al., 2006; Bogunovic et al., 
2009; Rivollier et al., 2012).  
 
Under inflammatory settings extravasated monocytes differentiate into pro-
inflammatory macrophages expressing CD64 and intermediate levels of CX3CR1 
and into cells with a DC-like phenotype expressing CD11c and CD11b, 
intermediate levels of CX3CR1 and low levels of Ly6c (Zigmond et al., 2012; 
Tamoutounour et al., 2012; Rivollier et al., 2012). The latter can migrate to draining 
mesLNs, while the former are tissue resident (Zigmond et al., 2012; Tamoutounour 
et al., 2012; Rivollier et al., 2012). In addition, inflammation increases the influx of 
CD103+ CD11b- DCs, CD103- CD11b+ DCs and CD103+ CD11b+ DC into the 
lamina propria and also causes their mobilisation (Anjuère et al., 2004; Denning et 
al., 2011). pDC influx into the lamina propria and epithelium is also increased in 
response to inflammatory stimuli (Wendland et al., 2007).  
1.1.1.4 Mononuclear phagocytes in the lung and airways 
The airway system can be divided into the conducting airways comprising nose, 
pharynx, larynx, trachea, bronchi and bronchioles, and the lung parenchyma where 
the gas exchange takes place. Alveoli of the lung parenchyma are lined with an 
epithelial layer of pneumocytes that is separated from the endothelial cells of the 
blood capillaries by a basement membrane. The lymphatic network in the lung 
drains to the mediastinal LN (medLN). 
 
Lung DCs express CD11c, MHCII and CD24, lack CD64, F4/80 and MerTK 
expression, and can be divided into a CD103-expressing subset and a CD11b-
expressing subset (Figure 1.4) (Schlitzer et al., 2013; Becher et al., 2014). CD103+ 
lung DCs express langerin and CD24, do not express CD11b and form the CD8α-
like DC population of the lung, while CD11b+ lung DCs are a classical CD11b-
expressing DC population and some of these cells express CD24 (Sung et al., 
2006; del Rio et al., 2007; Schlitzer et al., 2013). However, as is the case in the 
skin and intestine, lung CD11b+ DCs may be contaminated with monocyte-derived 
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cells if additional markers like CD64 and MerTK are not used to exclude the latter 
(Gautier et al., 2012). pDCs expressing low levels of CD11c, SiglecH and PDCA-1 
are also found in steady state lungs (de Heer, 2004). CD103+ DCs are present in 
the epithelium of the conducting airway, while CD11b+ DCs reside in the lamina 
propria below the basement membrane (Sung et al., 2006). Both DC subsets and 
pDCs can be found in the lung interstitium from where they access the alveolar 
lumen to sample antigen (de Heer, 2004; Sung et al., 2006). In addition, CD103+ 
DCs and CD11b+ DCs can be found lining the bronchioles and vessel walls. pDCs 
are also present in the conducting airways (GeurtsvanKessel et al., 2008).  
 
Monocytes enter the lung during steady state conditions and can differentiate into a 
cell with DC-like properties that resembles CD11b+ lung DCs (Figure 1.4) 
(Plantinga et al., 2013). This small population of monocyte-derived cells is positive 
for CD64 and the high-affinity IgE receptor FcεRIα chain and may express Ly6c, 
while CD11b+ lung DCs are negative for these surface markers (Plantinga et al., 
2013). At least three types of macrophages can be found in the lung. Alveolar 
macrophages are located in the air space of the alveoli, interstitial macrophages 
reside in the interstitium between alveoli and bronchial macrophages are found in 
the bronchi. All lung macrophages express F4/80 and MerTK. Alveolar 
macrophages are positive for CD11c, express low levels of MHCII and CD11b, are 
highly autofluorescent and express the lectin SiglecF, while interstitial 
macrophages express CD11c, are high for MHCII and CD11b, but are negative for 
SiglecF and CD24 (Becher et al., 2014). 
Of all mononuclear phagocytes found in the lung, only CD103+ DCs and CD11b+ 
DCs migrate from the lung to the medLN in a CCR7-dependent manner under 
steady state conditions (del Rio et al., 2007; Plantinga et al., 2013). Other factors 
that have been implicated in DC migration from the lung to the medLN are 
prostaglandin D2 and the D prostanoid receptor 1, Chemokine CC motif receptor-
like 2 (CCRL2) and CCR8 (Hammad et al., 2003; Jakubzick et al., 2006; Otero et 
al., 2010). 
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Figure 1.4 Overview of mononuclear phagocytes in the lung 
Schematic illustration of mononuclear phagocyte subsets in the steady state lung. 
DC: dendritic cell, MØ: macrophage, mono: monocyte, pDC: plasmacytoid DC. 
 
Airway inflammation, such as during Mycobacterium tuberculosis, influenza A or 
fungal infections, induce the differentiation of monocytes into inflammatory 
monocytes that can acquire DC-like properties (Aldridge et al., 2009; Osterholzer et 
al., 2009; Mayer-Barber et al., 2011; Fei et al., 2011). Monocyte-derived cells can 
still be discerned from CD11b+ DCs by virtue of CD64, FcεRIα chain and 
sometimes Ly6c expression (Plantinga et al., 2013). In addition, inflammation 
induces the migration of these cells to the medLN (Plantinga et al., 2013). CD103+ 
DC, CD11b+ DC and pDC numbers also increase in the lung upon exposure to 
inflammatory stimuli, with a greater accumulation of CD11b+ DCs than CD103+ DCs 
(GeurtsvanKessel et al., 2008; Plantinga et al., 2013). Both DC subsets show 
increased migratory kinetics to the draining medLN during the early stages of 
inflammation, with migration rates returning to baseline level at later stages (Legge 
and Braciale, 2003). 
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1.1.2 Cytokine and transcription factor dependency of dendritic cell subsets 
The process of distinguishing DCs from other mononuclear phagocytes and 
demystifying the relationships among DC subsets found in different tissues has 
greatly benefited from work mapping the dependency of DCs on specific cytokines 
and transcription factors, akin to using transcription factor dependency to define T 
cell subtypes. Indeed, in certain cases the transcription factor has become 
synonymous to a DC subset, as is the case for ‘Batf3 DCs’ that is synonymous with 
CD8α-like DCs.  
1.1.2.1 Cytokine control of DC development 
The key growth factor and regulator of lineage commitment for DCs is Flt3l, which 
binds the receptor Flt3 (CD135). pDCs, CD11b-like DCs as well as CD8α-like DCs 
can be generated in vitro when total BM is cultured with Flt3l (Brasel et al., 2000; 
Naik et al., 2005). Flt3 is expressed on differentiated DCs and on restricted DC 
progenitors (CDP and preDC) (Karsunky et al., 2003; Onai et al., 2007; Naik et al., 
2007; K. Liu et al., 2009). Interestingly, Flt3 is also expressed at earlier stages of 
haematopoiesis, such as on early HSCs and MDPs, but is absent from progenitors 
that have lost the ability to generate DCs (Adolfsson et al., 2001; Karsunky et al., 
2003; Waskow et al., 2008). Flt3 signalling is crucial for the development and 
maintenance of DCs in vivo and loss of Flt3 or Flt3l results in a severe reduction of 
total DCs, while injection or overexpression of Flt3l greatly expands the DC 
population (Maraskovsky et al., 1996; McKenna et al., 2000; Manfra et al., 2003; 
Waskow et al., 2008; Kingston et al., 2009). Interestingly, Flt3-/- and Flt3l-/- mice 
show subtle differences in phenotype, as Flt3l-/- but not Flt3-/- mice have reduced 
leukocytes and B cell progenitors in the bone marrow and a deficiency in NK cells 
in the spleen (Mackarehtschian et al., 1995; McKenna et al., 2000; Sitnicka et al., 
2002; Waskow et al., 2008).  
GM-CSF is important for myeloid lineage commitment, but can also act on 
differentiated mononuclear phagocytes, and several DC subsets express the 
receptor for GM-CSF (Metcalf, 2008; Kingston et al., 2009; Greter, Helft, et al., 
2012). Indeed, GM-CSF is widely used to differentiate MHCII+ CD11c+ cells from 
total BM in in vitro cultures (Inaba et al., 1992; Lutz et al., 1999). However, this 
culture method generates a more heterogeneous cell population than the Flt3l 
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cultures, including granulocytes, macrophages, monocytes and DC-like cells that 
can be traced back to distinct precursors (Helft et al., 2015). A lack of GM-CSF 
signalling has little effect on lymphoid DC subsets in vivo though, but does impact 
on CD8α-like DCs and CD11b+ DCs in peripheral tissues (Kingston et al., 2009; 
King, Kroenke and Segal, 2010; Greter, Helft, et al., 2012). Furthermore, GM-CSF 
signalling induces CD103 expression on CD8α-like DCs and is thought to promote 
the cross-presenting capabilities of these cells (Zhan et al., 2011; Sathe et al., 
2011). 
 
LC development is independent of both Flt3l and GM-CSF, but requires IL-34 
signalling via the M-CSFR (CD115) and autocrine TGFβ1 production, which are 
dispensable for cDC homeostasis (Borkowski et al., 1996; Kaplan et al., 2007; Y. 
Wang et al., 2012; Greter, Lelios, et al., 2012). The development of splenic ESAMhi 
CD11b+ DCs is dependent on lymphotoxin α1β2 signalling via the lymphotoxin β 
receptor and the transcription factor RelB, as mice lacking either one of these 
components have reduced ESAMhi CD11b+ DCs in the spleen (L. Wu et al., 1998; 
Q. Wu et al., 1999; Y.-G. Wang et al., 2005; Kabashima et al., 2005; Lewis et al., 
2011). The influence of lymphotoxin signalling on CD11b+ DCs outside of the 
spleen remains to be investigated. 
1.1.2.2 Transcription factor control of DC development 
Transcription factor expression and dependency have emerged as powerful tools to 
define DC subsets across tissues. Although a substantial number of subset-specific 
transcription factors have been described over the years, surprisingly few specific 
pan-DC transcription factors have been identified. Loss of Gfi1, Ikaros, Pu.1, 
STAT3 and Runx1 and Cbfβ negatively impact on DC development, but absence of 
these transcription factors also affects many other hematopoietic lineages (L. Wu et 
al., 1997; Anderson et al., 2000; Laouar et al., 2003; Rathinam et al., 2005; Carotta 
et al., 2010; Satpathy et al., 2014). More recently, expression of the transcription 
factor L-Myc has been implicated in regulating DC homeostasis (Kc et al., 2014). 
Within the immune compartment L-Myc expression is specific for the DC lineage. 
Its expression is driven by IRF8 and mice lacking L-Myc show reductions in certain 
DC subsets, such as CD103+ DCs in the lung (Kc et al., 2014). Zbtb46 (Btbd4, 
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zDC) was identified as a transcription factor specifically expressed in cDCs and 
pre-DCs (but not pDCs and LCs), although its expression was also found to be 
induced in activated monocytes (Meredith, Liu, Darrasse-Jeze, et al., 2012; 
Satpathy, KC, et al., 2012). However, contrary to expectations, deletion of Zbtb46 
does not affect DC development in vivo (Satpathy, KC, et al., 2012; Meredith, Liu, 
Kamphorst, et al., 2012). Instead, Zbtb46 appears to be a negative regulator of DC 
maturation and is rapidly downregulated upon TLR stimulation (Meredith, Liu, 
Kamphorst, et al., 2012). 
 
The development of pDCs is critically dependent on the transcription factor E2-2 
and a constitutive loss of E2-2 in the haematopoietic system results in the absence 
of pDCs, while deletion of E2-2 from mature pDCs induces spontaneous 
differentiation into a cDC-like cell, probably via the derepression of the transcription 
factor Id2 (Cisse et al., 2008; Ghosh et al., 2010). Furthermore, E2-2 shows 
haploinsufficiency and heterozygous E2-2+/- animals harbour reduced pDC 
numbers and the remaining pDCs show impaired IFN responses and aberrant 
surface marker expression (Cisse et al., 2008).  
 
CD8α-like DCs rely on Id2, IRF8, Nfil3 and Batf3 for their development and deletion 
of any of these transcription factors results in the loss of all CD8α-like DCs, while 
CD11b+ DCs are spared (Aliberti et al., 2003; Hacker et al., 2003; Hildner et al., 
2008; Ginhoux et al., 2009; Kashiwada et al., 2011). In addition to a loss of CD8α-
like DCs, Id2-/- mice also lack LCs, NK cells and certain secondary lymphoid tissues 
(Yokota et al., 1999; Hacker et al., 2003). Nfil3-/- also exhibit a defect in NK cell 
development and show a B cell intrinsic impairment in IgE class switching 
(Gascoyne et al., 2009; Kamizono et al., 2009; Kashiwada et al., 2010). Although 
Batf3 is expressed in all cDCs, only CD8α-like DCs are negatively affected in Batf3-
/- mice (Hildner et al., 2008). The effect of Batf3 deletion on CD8α-like DCs 
depends on the background strain of the mice, as the Batf3-/- 129S6/SvEv strain 
has a more complete reduction of CD8α-like DCs than Batf3-/- on the C57Bl/6 
background (Hildner et al., 2008; Edelson et al., 2010; 2011). Furthermore, 
infection with intracellular pathogens such as Toxoplasma gondii can induce CD8α+ 
DC development independently of Batf3 (Tussiwand et al., 2012). It was 
subsequently shown that Batf and Batf2, which are members of the same family of 
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transcription factors, can compensate for Batf3 loss under certain conditions 
(Tussiwand et al., 2012).  
Loss of IRF8 not only leads to a complete absence of CD8α-like DCs, but also of 
pDCs, and causes a myeloproliferative disorder due to a bias towards granulocyte 
production at the expense of other myeloid lineages (Holtschke et al., 1996; 
Tamura et al., 2000; Tsujimura et al., 2002; Tsujimura, Tamura and Ozato, 2003). 
Interestingly, mice that harbour a spontaneous point mutation in the gene encoding 
IRF8 also show a loss of CD8α-like DCs and develop a myeloproliferative disorder, 
but unlike IRF8-/- mice have normal pDC numbers (Tailor et al., 2008). IRF8 
deficiency not only impacts on cell development, but also on function, as a lack of 
IRF8 results in impaired migration of LCs and other dermal myeloid cells (Schiavoni 
et al., 2004). 
Although Id2-/- mice, Nfil3-/- mice and Batf3-/- mice show a more pronounced 
reduction of CD8α-like DCs, these DCs can still develop from BM in short-term in 
vitro or in vivo experiments in the absence of Id2, Nfil3 or Batf3, while IRF8-/- BM 
completely fails to generate CD8α-like DCs in any setting (Seillet et al., 2013). 
These results indicate that IRF8 is probably the main transcription factor driving 
CD8α-like DC development, acting upstream of Id2, Nfil3 and Batf3. 
 
Transcription factors implicated in the development and homeostasis of CD11b+ 
DCs include RelB, TRAF6, Notch, RBP-J, IRF2, IRF4 and Klf4 (L. Wu et al., 1998; 
T. Kobayashi et al., 2003; Ichikawa et al., 2004; Suzuki et al., 2004; Caton, Smith-
Raska and Reizis, 2007; Lewis et al., 2011; Persson, Scott, et al., 2013; Schlitzer 
et al., 2013; Tussiwand et al., 2015). Mice deficient in either RelB or TRAF6 show a 
phenotype similar to lymphotoxin β receptor knockout mice with reduced CD11b+ 
DCs, but not CD8α+ DCs, in the spleen (L. Wu et al., 1998; T. Kobayashi et al., 
2003; Kabashima et al., 2005). As the lymphotoxin β receptor signals through RelB 
and TRAF6, it is likely that deficiency in RelB, TRAF6 and lymphotoxin β receptor 
all affect the same pathway in CD11b+ DC development. Signalling via the Notch-
RBP-J pathway is also important for CD11b+ DC development and mice lacking 
RBP-J in CD11c+ cells show reduced CD11b+ splenic DCs, while in mice lacking 
Notch in CD11c+ cells the lack of CD11b+ DCs is confined to the ESAMhi subset in 
the spleen and CD103+ CD11b+ DCs in the intestine (Caton, Smith-Raska and 
Reizis, 2007; Lewis et al., 2011). However, absence of Notch signalling in all 
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hematopoietic cells not only affects CD11b+ DCs but also many other leukocyte 
populations, such as T cells and B cells (Maillard, Fang and Pear, 2005). CD11b+ 
DCs are reduced in the spleen of IRF2-/- mice and in addition these mice display 
defects in LCs and NK cells (Ichikawa et al., 2004). IRF4 is another member of the 
IFN-regulatory factor family involved in CD11b+ DC development and function. 
IRF4-/- mice have reduced CD11b+ DCs in the spleen, and defects in the T cell and 
B cell lineages (Suzuki et al., 2004). More recently it was shown that IRF4 is also 
important for the development and survival of CD103+ CD11b+ DCs in the intestine 
and CD11b+ DCs in the lung (Persson, Uronen-Hansson, et al., 2013; Schlitzer et 
al., 2013). Additionally, IRF4 has been implicated in promoting migration of CD11b+ 
DCs and modulating their ability to prime Th2 responses via increased MHCII 
antigen presentation and cytokine production (Bajana et al., 2012; Williams et al., 
2013; Vander Lugt et al., 2014). IRF4-expressing DCs, including CD11b+ splenic 
DCs, CD103+ CD11b+ intestinal DCs and CD11b+ lung DCs, are also reduced in 
mice that lack the transcription factor Klf4 in the hematopoietic system or in CD11c-
expressing cells (Tussiwand et al., 2015). 
1.1.3 Dendritic cell ontogeny 
In the mouse the hematopoietic system develops in two waves. The first one starts 
around embryonic day 7 (E7) in the yolk sack and is called primitive 
haematopoiesis. A first wave of macrophage progenitors is formed from the 
primitive ectoderm around this time, together with nucleated erythrocytes. Definitive 
haematopoiesis originates from the aorta-gonad-mesonephros in the embryo itself 
and is initiated at E10.5. These stem cells subsequently move to the foetal liver 
where the haematopoietic stem cells (HSCs) expand and produce erythrocytes, 
lymphocytes and myeloid cells. At around E13-14 the HSCs temporarily move to 
the spleen and just before birth HSCs finally colonise the bone marrow (BM) where 
they maintain haematopoiesis throughout life. 
 
In recent years several lines of research have greatly expanded our knowledge on 
the ontogeny of different mononuclear phagocytes. One major paradigm shift is the 
notion that many macrophage populations in adult tissues do not necessarily rely 
on monocytic input from the BM for their homeostasis, but originate from embryonic 
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populations that are maintained locally. Indeed, the earliest macrophages appear 
around E9 in the yolk sac, without the need for a monocytic intermediate and 
colonise the embryo upon establishment of the blood circulation (McGrath et al., 
2003; C Schulz et al., 2012). These cells also colonise the brain, epidermis and 
liver and exclusively give rise to F4/80hi CD11blow microglia in the brain that remain 
of yolk sac origin throughout life (Alliot, Godin and Pessac, 1999; Ginhoux et al., 
2010; C Schulz et al., 2012). F4/80hi CD11blow macrophages in other adult tissues 
such as the spleen, kidney, lung and heart are likely a mixture of yolk sac-derived 
cells and foetal liver-derived cells that may gradually replace the former ones over 
time (Ginhoux et al., 2010; C Schulz et al., 2012; Epelman et al., 2014). Two more 
recent studies further refined this view on macrophage ontogeny by showing that 
yolk sac-derived progenitors can colonise the foetal liver and continue to contribute 
to embryonic tissue macrophages independent of HSCs until at least E16.5 
(Perdiguero et al., 2014; Hoeffel et al., 2015). Early yolk-sac derived erythro-
myeloid progenitors seed the embryo with macrophages, without a monocytic 
intermediate, while a later wave of yolk-sac derived erythro-myeloid progenitors 
colonise the fetal liver and give rise to embryonic macrophages via a monocytic 
intermediate (Hoeffel et al., 2015). However, an even more recent study challenged 
this idea, claiming that the second wave of macrophage precursors is not yolk sac-
derived, but originates from very early HSCs (Sheng, Ruedl and Karjalainen, 2015). 
All three studies agreed that microglia in the brain remain of early yolk-sac derived 
erythro-myeloid progenitor origin throughout adult life. Kupffer cells, alveolar 
macrophages and red pulp macrophages in the adult originate from later embryonic 
progenitors that are derived from either a second wave of yolk-sac progenitors, or 
early HSCs (Perdiguero et al., 2014; Hoeffel et al., 2015; Sheng, Ruedl and 
Karjalainen, 2015). Adult LCs predominantly originate from this later wave of yolk 
sac-derived or HSC-derived embryonic progenitors, although a minority of adult 
LCs may originate from early yolk sac progenitors. (Perdiguero et al., 2014; Hoeffel 
et al., 2015; Sheng, Ruedl and Karjalainen, 2015). Microglia, Kupffer cells, red pulp 
macrophages and LCs are only marginally replaced by HSC-derived cells during 
adult life (Perdiguero et al., 2014; Hoeffel et al., 2015; Sheng, Ruedl and 
Karjalainen, 2015). Alveolar macrophages are predominantly yolk sac-derived in 
young adults, but may be slowly replaced by HSC-derived cells during life 
(Perdiguero et al., 2014). 
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A second type of macrophage is F4/80low CD11bhi, can be found in many organs 
such as spleen, liver and lung and depends on definitive haematopoiesis for their 
development (C Schulz et al., 2012). Another fate-mapping study revealed that 
under steady-state conditions most tissue-resident macrophage populations are 
established before birth (either from primitive or definitive haematopoiesis) and do 
not require input from monocytes to maintain homeostasis (Yona et al., 2012). This 
notion was further supported by parabiosis experiments showing that BM-derived 
cells do not substantially contribute to adult tissue-resident macrophages 
(Hashimoto et al., 2013). For LCs it has been suggested that the epidermal LC 
network is maintained by local precursors that replenish terminally differentiated 
LCs (Ghigo et al., 2013). Furthermore, even after a substantial reduction of local 
macrophages, for example upon irradiation, tissue-resident macrophages can have 
the ability to repopulate the tissue via self-renewal without the requirement for BM 
input (Hashimoto et al., 2013). However, the ability to self renew may depend on 
the specific inflammatory setting, as for LCs both local self renewal and 
replacement by BM-derived cells has been reported under inflammatory conditions 
(Merad et al., 2002; Ginhoux et al., 2006; Chorro et al., 2009; Nagao et al., 2012; 
Ghigo et al., 2013). Interestingly, intestinal macrophages appear to be the 
exception to the rule that tissues macrophages are maintained by self-renewal 
under steady-state conditions (Bain et al., 2014). The intestine of neonatal mice is 
seeded by embryonic macrophages, but they are steadily replaced by monocyte-
derived cells in a process that is dependent on the microbiota, so that in the adult 
intestine virtually all macrophages are of monocytic origin (Bain et al., 2014).  
 
Adult haematopoiesis relies on HSCs in the BM, whose daughter cells expand and 
gradually lose their multipotency and become more restricted to certain lineages. 
Lymphoid-primed multipotent progenitors (LMPPs) still share the ability to generate 
both lymphoid and myeloid lineages, but have lost the ability to generate erythroid 
and megakaryocyte cells (Adolfsson et al., 2005). Mononuclear phagocytes share a 
common precursor called the macrophage and DC precursor (MDP) that only gives 
rise to monocytes, DCs and macrophages and has lost the potential to generate 
other leukocyte populations (Figure 1.5) (Fogg, 2006; Varol, Mildner and Jung, 
2015). MDPs further differentiate in the BM into a monocyte and macrophage 
restricted progenitor called the common monocyte progenitor (cMoP), which 
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subsequently generates Ly6chi monocytes that can exit the BM in a CCR2-
dependent manner (Hettinger et al., 2013). Both in BM and in blood Ly6chi 
monocytes give rise to Ly6clow monocytes (Yona et al., 2012). In addition, Ly6chi 
monocytes are recruited to peripheral tissues where they differentiate into effector 
cells that may resemble monocytes, DC-like cells or macrophages, depending on 
the local environment (Varol, Mildner and Jung, 2015).  
MDPs also differentiate into common dendritic cell precursors (CDPs), which are 
the earliest precursors fully committed to the DC lineage and were initially reported 
to generate both pDCs and cDCs (Figure 1.5) (K. Liu et al., 2009). Interestingly, 
expression of the transcription factor Zbtb46 or the C-type lectin DNGR-1 on a 
subpopulation of CDPs seems to identify a precursor population that is restricted to 
the cDC lineage (Satpathy, KC, et al., 2012; Schraml et al., 2013). Conversely, a 
precursor population with a predominant pDC potential has been described that, 
contrary to MDPs and CDPs, does not express M-CSFR (CD115) but does express 
Flt3 (Onai et al., 2013). 
CDPs give rise to preDCs that subsequently leave the BM and travel via the blood 
to peripheral tissues, where they differentiate into DC subsets (Naik et al., 2006; K. 
Liu et al., 2009). Interestingly, preDCs already appear to commit in the BM to 
differentiate into a specific DC subset when they later reach the periphery. PreDCs 
in the BM can be divided into two subpopulations based on transcriptional 
signatures and surface marker expression, and this division is maintained in 
preDCs in the spleen (Naik et al., 2006; Grajales-Reyes et al., 2015; Schlitzer, 
McGovern and Ginhoux, 2015). When isolated and cultured in vitro with Flt3l or 
transferred into mice, these preDC subpopulations either exclusively give rise to 
CD8α-like DCs, or to CD11b+ DCs, indicating that the preDC can be divided into a 
CD8α-committed preDC and a CD11b-committed preDC and that lineage 
commitment takes place in the BM (Naik et al., 2006; Schlitzer, McGovern and 
Ginhoux, 2015; Grajales-Reyes et al., 2015). 
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Figure 1.5 Ontogeny of mononuclear phagocytes 
Schematic illustration of mononuclear phagocyte ontogeny. cMoP: common 
monocyte progenitor, DC: dendritic cell, HSC: haematopoietic stem cell, LC: 
Langerhans cell, LMPP: lymphoid-primed multipotent progenitor, MDP: 
macrophage and DC precursor, MØ: macrophage, mono: monocyte, pDC: 
plasmacytoid DC, YS: yolk sac p ecurs r. 
 
Although the ‘conventional’ ontogonetic model in which uncommitted HSCs 
develop into CDPs and preDCs or cMoPs and monocytes via an MDP intermediate 
is currently most widely accepted, recent studies have challenged this view. 
Specifically, tracing the fate of single HSCs and LMPPs via a barcoding strategy 
revealed that although most HSCs still retained true multipotency on a single cell 
basis, LMPPs are a highly heterogeneous population with many single cells already 
showing lineage bias (Naik et al., 2013; Perié et al., 2014). These findings may 
indicate that lineage commitment occurs much earlier than in the conventional 
ontogenetic model, where single precursors already start to commit to certain 
lineages after the HSC stage.  
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Another recent study questioned the existence of the MDP on a single cell basis 
(Sathe et al., 2014). By combining data from adoptive transfer experiments, clonal 
assays and limiting dilution assays it was shown that the BM fraction commonly 
identified as MDP mainly contained monocyte and macrophage restricted 
precursors, some DC-restricted precursors and a small fraction of multipotent 
progenitors that also gave rise to granulocytes, but no cells with restricted 
monocyte/macrophage and DC potential. (Sathe et al., 2014).  
Collectively, these studies suggest that monocyte/macrophage or DC commitment 
takes place earlier during haematopoiesis than currently thought, starting at the 
HSC to LMPP transition. Precursor commitment may initially be quite weak and 
easily overcome by extrinsic factors, but could grow stronger during precursor 
development and differentiation. Although this alternative view of haematopoiesis is 
attractive to explain the barcoding results and does not require a committed MDP, 
more research on single cell progenitors is warranted to establish the early 
commitment of precursors.  
 
PreDCs have a very short half-life in the blood and quickly exit circulation to seed 
tissues (K. Liu et al., 2007). Therefore, preDCs show incomplete equilibration in 
parabiosis experiments that plateaus at around 15-30%, even after prolonged 
parabiosis (K. Liu et al., 2007; Ginhoux et al., 2009). In line with these findings, 
DCs in spleen and LNs show a similar degree of exchange in parabionts and also 
reach about 15-30% chimaerism after three weeks (Kabashima et al., 2005; K. Liu 
et al., 2007; Ginhoux et al., 2009). Separation of the parabionts revealed that pDCs 
have a very short half-life of 1-2 days and cDCs in lymphoid organs, liver and 
kidney have a half life of 5-7 days (K. Liu et al., 2007). Interestingly, the life span of 
DCs in the lung was much longer, with a half-life of around 15 days for CD11b+ 
DCs and about 30 days for CD103+ DCs (Ginhoux et al., 2009).  
BrdU labelling experiments have revealed that DCs rapidly turn over for most 
tissues and that at any given moment about 5% of all cDCs are cycling or originate 
from a recently divided precursor (Kamath et al., 2002; Kabashima et al., 2005; K. 
Liu et al., 2007; Waskow et al., 2008; Ginhoux et al., 2009; C. L. Scott et al., 2015). 
Furthermore, for a given tissue different cDC subsets show similar labelling kinetics, 
which indicate similar proliferation rates (C. L. Scott et al., 2015). One exception is 
the kidney, where CD11b+ DCs incorporated BrdU with slower kinetics than 
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CD103+ DCs, although contamination of the CD11b+ DC subset with monocytes or 
macrophages cannot be ruled out (Ginhoux et al., 2009). Specifically, BrdU pulse-
chase experiments suggest a short half-life for all DC subsets in the small intestine 
and mesLNs (Jaensson et al., 2008; C. L. Scott et al., 2015). Intestinal 
macrophages have a half life of around three weeks, which is uniquely short 
compared with other macrophage subsets (Samokhvalov, Samokhvalova and 
Nishikawa, 2007; Jaensson et al., 2008; Varol et al., 2009). 
1.1.4 Functions of dendritic cells 
Historically, one of the defining features of DCs as compared to other mononuclear 
phagocytes is their superior ability to initiate T cell responses. However, with the 
advancement of knowledge on DC biology, it has become clear that DCs are not 
only critically involved in directing CD8 T cell responses and inducing CD4 T cell 
differentiation, but also in mediating immune tolerance via the regulation of Tregs. 
In addition to these ‘classical’ T cell mediated functions, DCs can influence 
functions of other innate immune cells and interact with non-immune cells in tissues, 
modulating their behaviour.  
To appropriately perform all these classical and non-classical functions, DCs are 
equipped with a wealth of receptors to recognise both pathogen-associated 
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). 
Such receptors expressed by DCs include toll-like receptors (TLRs), NOD-like 
receptors (NLRs), C-type lectin receptors (CLRs) and RIG-I-like receptors (RLRs). 
The distribution of these receptors differs among DC subsets and may additionally 
change during inflammatory settings. In the mouse, most TLRs are found in all DC 
subsets in the spleen. However, CD8α+ DCs selectively lack TLR5 and TLR7 
expression, but instead preferentially express TLR3 (Edwards et al., 2003; Reis e 
Sousa, 2004; Luber et al., 2010). Furthermore, CD8α+ DCs express lower levels of 
the RLRs RIG-I and MDA-5 compared to other splenic DC populations (Luber et 
al., 2010). CLRs are widely expressed among mononuclear phagocytes, however, 
the expression pattern of a given CLRs is often confined to specific cell types. 
These CLRs are frequently used as surface markers to identify different 
mononuclear phagocytes. For example, the expression of the CLR DNGR-1 is 
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confined to CD8α-like DCs, pDCs and DC precursors, while the CLR langerin is 
found on LCs and on some CD8α-like DCs.  
1.1.4.1 Regulation of T cell responses 
DCs are specialised in taking up exogenous antigen, and processing and 
presenting both exogenous and endogenous antigen via major histocompatibility 
complex class I (MHCI) and MHCII to CD8+ T cells and CD4+ T cells, respectively. 
Contrarily to most other phagocytes, DCs can control and delay lysosomal 
degradation of antigen to preserve peptides for presentation to T cells (Savina et 
al., 2006). Activation of DCs via for example TLR stimulation temporarily enhances 
macropinocytosis and accelerates antigen degradation (Trombetta et al., 2003; 
West et al., 2004). Furthermore, inflammatory stimuli boost MHCII synthesis in 
antigen presenting cells and increase cell surface expression of peptide-loaded 
MHCII (Cella et al., 1997; Pierre et al., 1997). 
MHCII expression is restricted to antigen presenting cells that endocytose 
extracellular antigen, which is then digested in lysosomes to facilitate peptide 
loading on MHCII, before the MHCII molecules are transported to the cell surface. 
On the contrary, nearly every nucleated cell can present cytosolic antigens, 
whether endogenous or exogenous (e.g. following direct viral infection) via MHCI. 
DCs are no exception in this respect and can readily present cytosolic antigens to 
CD8+ T cells via MHCI. However, DCs employ a second mechanism, called cross-
presentation, in which exogenous antigen is either shuttled from endosomes and 
phagosomes into the cytoplasm for presentation on MHCI, or, alternatively, 
exogenous antigen is degraded in the phagosome where the peptides are directly 
loaded onto MHCI. The major cross-presenting cells in vivo are DCs. Direct 
infection of DCs with a pathogen allows for direct presentation of pathogen-derived 
antigens, in addition to cross-presentation. For example, for vaccinia virus infection 
it was shown that cross presentation is dispensable for CD8+ T cell activation when 
DCs are directly infected with the virus (Xu et al., 2010). A third mechanism, 
besides direct presentation and cross-presentation, by which DCs can stimulate 
memory CD8+ T cell responses is via the acquisition of pre-loaded peptide-MHCI 
complexes from other infected cells via membrane exchange, which is called cross-
dressing (Wakim and Bevan, 2011).  
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When naïve T cells recognise their cognate antigen in the context of MHCI or 
MHCII and the right combination of co-stimulatory molecules and cytokines is 
present, the T cells start proliferating and differentiate into effector T cells. Upon 
removal of the antigenic source the antigen-specific T cell pool contracts 
substantially and the remaining cells persist as memory T cells. Thus far, three 
types of memory T cells have been identified: central memory T cells, effector 
memory T cells and tissue-resident memory T cells. Central memory T cells home 
to the T cell zones of secondary lymphoid organs, ready to proliferate when 
activated with cognate antigen. Effector memory T cells are the only memory cells 
recirculating through the body and migrate to inflamed tissues to provide immediate 
protection. Tissue resident memory T cells were discovered relatively recently and 
are non-circulating cells that reside in tissues where they respond rapidly to 
cognate antigen.  
 
T cells primed in LNs in response to a local challenge in the draining tissue should 
exit these LNs and preferentially migrate back to that same tissue. T cells use 
specific homing receptors to accomplish this task and DCs have been shown to be 
key regulators of this process. DCs that originate from the intestine express retinoid 
dehydrogenase enzymes that convert vitamin A into retinoic acid, which is a main 
driver of CCR9 and integrin α4β7 expression on T cells, which in turn impose gut 
tropism on the T cells (Mora et al., 2003; Johansson-Lindbom, 2005; Jaensson et 
al., 2008). Interestingly, it seems that retinoic acid in the bile is responsible for the 
induction of retinoid dehydrogenase enzymes specifically in intestinal DCs and 
therefore for the ability of these DCs to induce gut homing molecules on T cells 
(Jaensson-Gyllenbäck et al., 2011). In a similar fashion DCs originating from the 
skin induce the skin-homing molecules E-selectin ligand and P-selectin ligand on T 
cells (D. J. Campbell and Butcher, 2002; Dudda, Simon and Martin, 2004). 
 
1.1.4.1.1 CD8+ T cells 
Cross-presentation of cognate antigen to cytotoxic CD8+ T cells is a key function of 
DCs and in most tissues the CD8α-like subset of DCs is superior to any other 
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mononuclear phagocyte in generating effector CTL responses. CD8α+ DCs in the 
spleen are particularly well-equipped in taking up dead cell-associated antigens for 
cross-presentation, as CD8α+ DCs express receptors such as DNGR-1 that 
specifically recognise dead cells (Oliver Schulz and Reis e Sousa, 2002; Iyoda et 
al., 2002; Schnorrer et al., 2006; Sancho et al., 2009). Additionally, even when the 
antigen is delivered in a form that permits similar uptake by all DC subsets, for 
example coupled to beads, splenic CD8α+ DCs are still superior at cross-
presentation in an in vitro setting, possibly because CD8α-like DCs express higher 
levels of components of the MHCI processing machinery than CD8α- DCs 
(Schnorrer et al., 2006; Dudziak et al., 2007). Furthermore, in vivo CD8α+ DCs 
appear to be the most efficient DC subset to take up and cross-present antigen in 
the spleen (Haan, Lehar and Bevan, 2000; Pooley, Heath and Shortman, 2001; 
Schnorrer et al., 2006; Dudziak et al., 2007). While delaying lysosomal degradation 
and reducing lysosomal acidification are essential for CD8α+ DCs to cross-present, 
these features also render CD8α+ DCs susceptible to infection with pathogens. 
Indeed, the intracellular bacterium Listeria monocytogenes highjacks CD8α+ DCs in 
the spleen to migrate into deeper splenic regions and establish infection, hence 
mice lacking splenic CD8α+ DCs are protected from Listeria monocytogenes 
infection (Edelson et al., 2011). 
Activation of DCs induces the expression of chemokine receptors that prompts DCs 
to migrate to the T cell zones in secondary lymphoid structures, upregulates the 
expression of costimulatory molecules such as CD80 and CD86 and promotes 
cytokine production and release. In particular, IL-12 and IL-15 are important 
cytokines in the differentiation of CTLs and CD8α-like DCs are key producers of 
these two cytokines (Reis e Sousa et al., 1997; Maldonado-López et al., 1999; 
Mattei et al., 2001; Farrand et al., 2009). Recognition by naïve CD8+ T cells of their 
cognate antigen in the context of MHCI, leads in combination with these 
costimulatory molecules and cytokines to the generation of effector CTLs that have 
the ability to eliminate infected or transformed cells.  
 
Mice that lack the CD8α-like subset of DCs due to Batf3 deficiency are severely 
impaired in cross-presentation and the generation of effector CTL responses 
(Hildner et al., 2008). Batf3-/- mice show a significantly impaired CTL response in 
the spleen upon subcutaneous West Nile Virus infection and also fail to generate a 
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memory CD8+ T cell response against the virus (Hildner et al., 2008). Furthermore, 
CTL responses are compromised in Batf3-/- mice infected intranasally with influenza 
or Sendai virus and upon systemic infection with Toxoplasma gondii (Edelson et 
al., 2010; Mashayekhi et al., 2011; Waithman et al., 2013). In addition to impaired 
CTL responses to infections, Batf3-/- mice fail to mount an effector CD8+ T cell 
response to reject syngeneic fibrosarcoma tumour cells (Hildner et al., 2008). 
Furthermore, deletion of the CD8α-like subset of DCs in XCR1-DTR mice leads to 
reduced CTL responses against cell-associated antigen, soluble antigen with poly 
I:C immunisation, or systemic Listeria monocytogenes infection (Yamazaki et al., 
2013). 
During initial cutaneous HSV-1 infection via skin scarification, CD8α+ resDCs in 
draining sdLNs are the dominant cell type driving CTL responses (Allan et al., 
2006; Bedoui, Whitney, et al., 2009). However, upon viral recrudescence both 
CD103+ dermal DCs migrating to draining sdLNs and CD8α+ resDCs are capable of 
cross-presenting antigen to CD8+ T cells (Allan et al., 2006; Bedoui, Whitney, et al., 
2009). In line with these results in the skin, migratory CD103+ DCs in the lung are 
the key inducers of CD8+ T cell responses in the draining medLN upon intranasal 
influenza infection, in addition to CD8α+ resDCs in the medLNs that can also 
contribute to CD8+ T cell responses (GeurtsvanKessel et al., 2008; Helft et al., 
2012; Waithman et al., 2013). 
 
Although the CD8α-like subset of DCs is the key inducer of CD8+ T cell responses 
in most settings, CD11b+ DCs have also been reported to prime CD8+ T cells in 
certain inflammatory contexts. In an in vitro culture system splenic CD8α- DCs were 
shown to be superior to CD8α+ DCs in activating OT-I CD8+ T cells when incubated 
with ovalbumin (OVA)-expressing Saccharomyces cerevisiae (Backer et al., 2008). 
Furthermore, MHCII+ CD11b+ CD103- cells (either genuine DCs and/or monocyte-
derived cells) isolated from medLNs from influenza-infected mice were reported to 
be capable of driving CD8+ T cells proliferation ex vivo, albeit less efficiently than 
CD103+ migDCs (Kim and Braciale, 2009). Ballesteros-Tato et al. (Ballesteros-Tato 
et al., 2010) also reported on the ability of MHCII+ CD11b+ CD103- migratory cells 
in medLNs (probably monocyte-derived, as they also express Ly6c) to drive CD8+ 
T cell responses upon influenza infection. Interestingly, these authors found that 
the CD11b+ cells were more efficient than CD103+ migDCs in medLNs in activating 
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CD8+ T cells (Ballesteros-Tato et al., 2010). These findings are in apparent 
contradiction with reports that have described the CD103+ migDCs and/or CD8α+ 
resDCs in medLNs from influenza infected mice to be main drivers of CD8+ T cells 
proliferation ex vivo and with the fact that mice that lack CD8α-like DCs have 
severely impaired CTL responses upon influenza infection (GeurtsvanKessel et al., 
2008; Helft et al., 2012; Waithman et al., 2013). These differences may be 
explained by different time points upon infection looked at, the influenza strain used 
or the source of the CD8+ T cells (TCR transgenic T cells or natural T cells). 
However, whether CD11b+ cells play a role in priming CD8+ T cells in vivo during 
infections remains to be determined and most likely awaits mouse models to 
selectively ablate these cells. Furthermore, it remains to be elucidated whether 
CD11b+ DCs utilise direct presentation, cross-presentation and/or cross-dressing to 
generate peptide-loaded MHCI molecules and drive CD8+ T cell activation. In any 
case, even though CD11b+ DCs may induce CD8+ T cell responses under certain 
conditions, CD8α-like DCs have emerged as the main antigen presenting cell to 
prime CD8+ T cells.  
 
In the absence of activating stimuli, CD8α+ DCs can induce peripheral CD8+ T cell 
tolerance, instead of promoting cytotoxic CD8+ T cell reactions. In a process called 
cross-tolerance, CD8α+ DCs cross-present antigen to self-reactive CD8+ T cells 
and promote their activation and proliferation followed by apoptosis-mediated 
deletion (Kurts et al., 1998; Hawiger et al., 2001; Davey et al., 2002; Belz et al., 
2002; Bonifaz et al., 2002). These processes take place in the LN draining the site 
where the self-antigen is expressed (Scheinecker et al., 2002). However, most of 
these studies relied on the adoptive transfer of transgenic T cells into mice 
expressing a model antigen, usually OVA, under control of the rat insulin promoter, 
while it has been shown that the frequency of antigen-specific CD8+ T cells can 
have a profound influence on the outcome (tolerance or activation) of the immune 
response (Kurts et al., 1997; Morgan, Kreuwel and Sherman, 1999). In a different 
approach by Probst et al. (Probst et al., 2003) LCMV epitopes could be inducibly 
expressed in a small fraction of DCs, allowing for the assessment of cross-
tolerance of endogenous CD8+ T cells. Indeed, in the absence of activatory signals 
from DCs, cross-tolerance of endogenous CD8+ T cells was induced upon LCMV 
epitope expression, while cross-priming could be induced in the same mouse strain 
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by activating DCs with poly I:C or anti-CD40 antibody treatment while expressing 
the viral epitopes (Probst et al., 2003). In the same mouse model it was shown that 
cross-tolerance induced by DCs depended on PD-1 and CTLA-4 expression on 
CD8+ T cells (Probst, McCoy, et al., 2005). 
 
Primary encounter of an antigen usually not only generates and effector T cell 
response, but also a memory T cell response and many of the latter cells remain in 
peripheral tissues. Here, memory CD8+ T cells can be reactivated when cognate 
antigen is present. In the case of HSV-1 infection it was show that the reactivation 
occurs locally and is dependent on both resident CD4+ T cell and recruited 
inflammatory monocytes (Wakim et al., 2008). 
 
1.1.4.1.2 CD4+ T cells 
Naïve CD4+ T cells can differentiate into distinct Th cell subsets upon recognition of 
their cognate antigen in the context of MHCII. Decision of T cell fate is mainly 
guided by environmental clues and DCs play major roles in both antigen 
presentation on MHCII and the direction of Th cell differentiation. Initially two Th 
cell subsets were identified: Th1 and Th2 cells. Th1 cell differentiation is regulated 
by the master transcription factor T-bet and these cells tend to produce IFNγ, 
lymphotoxin and IL-2. Th2 cells depend on the transcription factor Gata3 and 
produce IL-4, IL-5 and IL-13. More recently other CD4+ T cell subsets have been 
defined, like Tregs, Th17 cells, Tfh cells and other less-well defined Th cell subsets. 
Tregs can be induced in the thymus (natural or nTregs) or in the periphery (induced 
or iTregs) and both rely on the transcription factor FoxP3 and produce IL-10 and 
TGFβ. On the other hand, the key transcription factor for Th17 cells is Rorγt and 
these cells produce IL-17A and IL-17F. Tfh cells depend on Bcl-6 and secrete IL-21.  
 
In general, CD11b+ DCs are better equipped for antigen presentation on MHCII 
than CD8α-like DCs, as they express higher levels of components of the MHCII 
processing machinery (Dudziak et al., 2007). Ex vivo CD4+ T cell stimulation 
assays with DCs isolated from immunised or infected mice also revealed that in 
most cases CD11b+ DCs are superior to CD8α-like DCs in driving CD4+ T cell 
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responses (Dudziak et al., 2007; Bedoui, Prato, et al., 2009; Plantinga et al., 2013). 
However, many studies did not address which Th subtype was induced in these ex 
vivo experiments. Results are also more mixed than with CD8+ T cell responses, 
and both CD11b+ DCs and CD8α-like DCs are likely to be involved in driving CD4+ 
T cell responses, depending on the setting and the type of Th cell induced. 
Importantly, a confounding factor in many of these studies is the presence of 
monocytes with a DC-like phenotype in the CD11b+ DC population, especially in 
models where inflammation is present, which complicates the attribution of certain 
functions to either monocytes or CD11b+ DCs, or both.  
 
Generation of Th1 responses is thought to depend on DCs. The Th1 response and 
control of parasitaemia upon systemic infection with Plasmodium chabaudi is 
dependent on CD11c-expressing cells (Borges da Silva et al., 2015). Furthermore, 
depletion of all DCs in genetically engineered zDC-DTR mice (see 1.2.2) leads to 
severely hampered Th1 responses to antigens targeted to CD205 or Treml4 and 
upon Toxoplasma gondii or Citrobacter rodentium infection (Meredith, Liu, 
Darrasse-Jeze, et al., 2012; Schreiber et al., 2013). 
Th1 cell differentiation is dependent on the cytokines IL-12 and IFNγ (Hsieh et al., 
1993; Lighvani et al., 2001) and CD8α-like DCs can produce substantial amounts 
of IL-12 (Reis e Sousa et al., 1997; Maldonado-López et al., 1999; O Schulz et al., 
2000; Farrand et al., 2009). Furthermore, splenic CD8α+ DCs, but not CD8α- DCs, 
pulsed ex vivo with KLH and transferred back into the footpad of a naïve mouse 
induce CD4+ T cell proliferation and Th1 cytokine production in the draining 
popliteal LN (Maldonado-López et al., 1999). Targeting of antigen to CD8α-like DCs 
via an anti-DNGR-1 antibody also induces a potent Th1 response when combined 
with poly I:C as adjuvant (Joffre et al., 2010). Likewise, similar results were 
obtained when antigen is coupled to an anti-XCR1 antibody or to XCL1, which both 
target XCR1 on CD8α-like DCs (Hartung et al., 2015; Fossum et al., 2015; Terhorst 
et al., 2015). Finally, CD8α-like DCs can be targeted via antibodies recognising 
CD205, although CD205 is also expressed on other antigen presenting cells, such 
as LCs. Antigen delivery via an anti-CD205 antibody induced CD4+ T cell 
proliferation and Th1 polarisation when administered together with adjuvant 
(Bonifaz et al., 2004; Boscardin et al., 2006; Idoyaga et al., 2011). 
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In the context of HSV-1 infection it was shown that T cell help is essential for the 
generation of a CTL response and it was suggested that splenic CD8α+ DCs have 
to directly present cognate antigen to CD4+ T cells via MHCII for the licencing of 
the DC to happen (C. M. Smith et al., 2004). However, other MHCII+ cells, like 
CD11b+ DCs, may have initially activated the CD4+ T cells before licensing 
occurred. Interestingly, in a model for topical Candida albicans infection CD103+ 
dermal DCs are required for the proliferation of TCR-transgenic CD4+ T cells and 
the generation of IFNγ-expressing Th1 cells in vivo. In the absence of the CD103+ 
dermal DCs Th1 cell differentiation is abrogated (Igyarto et al., 2011; Kashem et 
al., 2015). Similarly, in an EAE autoimmunity model CD103+ dermal DCs were 
shown to be necessary for Th1 cell differentiation, as the Th1 response is 
diminished and autoimmunity is delayed and less severe when CD103+ dermal 
DCs are depleted by DT injection of WT mice reconstituted with Langerin-DTR BM 
(King, Kroenke and Segal, 2010). However, these findings did not reproduce in 
Batf3-/- mice that constitutively lack CD103+ dermal DCs, as Batf3-/- mice are as 
sensitive as WT mice to EAE and have normal Th1 responses (Edelson et al., 
2011). It is unclear why these two studies report differential involvement of CD103+ 
dermal DCs in Th1 cell generation and EAE induction, although these contradictory 
findings may relate to the different mouse models used, as the former study 
employs irradiation chimeras and a DTR-based transgenic model, while the latter 
relies on a transcription factor knockout model and constitutive loss of CD103+ 
dermal DCs.  
In the context of cutaneous HSV-1 infection CD8α+ resDCs, CD103+ dermal 
migDCs, CD11b+ migDCs as well as LCs sorted from the draining LN are capable 
of driving CD4+ T cell proliferation and the induction of Th1 cytokines in an ex vivo 
setting (Bedoui, Whitney, et al., 2009). As all three DC subsets and LCs are 
capable of inducing a Th1 response in this context, it seems likely that the local 
environment created by the HSV-1 infection is more important than the specifics of 
the antigen presenting cell in driving CD4+ T cell polarisation. A similar finding was 
reported in an intranasal influenza infection model, where both CD11b+ migDCs 
and CD103+ migDCs sorted from medLNs of infected mice can induce CD4+ T cell 
proliferation and IFNγ production in an ex vivo setting (Kim et al., 2010). 
Upon subcutaneous immunisation with antigen, CD11b+ CD11c+ cells were shown 
to be the major cell type to present antigen locally in the skin to previously activated 
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CD4+ T cells and induce IFNγ production from Foxp3- T cells and IL-10 production 
from Foxp3+ Tregs (McLachlan et al., 2009). As these CD11b+ CD11c+ cells also 
express F4/80 and are present in an inflammatory environment, the majority of 
these cells are probably derived from infiltrating monocytes, with little input from 
DCs.  
In sum, both CD8α-like DCs and CD11b+ DCs, and probably monocyte-derived 
cells, have been shown to be capable of inducing Th1 responses. However, which 
subset(s) is dominant in a certain setting is likely to be context-specific, depending 
on factors such as the site of Th1 generation (e.g. spleen versus LN), the type of 
antigen, and the type and route of immunisation or infection.  
 
Factors involved in the generation of a Th2 response are less clear than those 
leading to a Th1 response. DCs are generally thought to play a key role in Th2 
differentiation via MHCII antigen presentation and cytokine secretion. Mice in which 
all CD11c-expressing cells are depleted during helminth infection show reduced 
Th2 responses (Phythian-Adams et al., 2010; K. A. Smith et al., 2011; 2012). Also, 
in an asthma model CD11c+ cell depletion diminishes the Th2 response and 
reduces clinical signs of asthma (van Rijt et al., 2005). These findings are in line 
with studies showing that the induction of Th2 immunity is abrogated when mice 
lacking CD11c+ cells are immunised with antigen and a NOD1 or NOD2 ligand, or 
with antigen and the cysteine protease papain (H. Tang et al., 2010; Magalhaes et 
al., 2011). However, in other settings, like vesicular stomatitis virus infection, the 
Th2 response is not affected by the absence of all CD11c+ cells (Ciavarra et al., 
2006). 
Attempts to determine which mononuclear phagocyte subsets are involved in 
driving Th2 responses have been hampered by problems to phenotypically 
distinguish different subsets during inflammation, especially CD11b+ DCs and 
monocyte-derived cells. Nonetheless, several studies have looked into this 
question utilising both in vitro and in vivo approaches. When splenic CD8α- DCs 
(corresponding to CD11b+ DCs) and CD8α+ DCs are pulsed ex vivo with antigen 
and returned to the footpad of naïve mice, both DC subsets induce CD4+ T cell 
proliferation in the draining LN, but only CD8α- DCs generate a Th2 cytokine 
response (Maldonado-López et al., 1999). Also, when cells from GM-CSF BM 
cultures are pulsed with soluble egg antigen from Schistosoma mansoni, they 
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induce a Th2 response both in vitro and in vivo (MacDonald et al., 2001). However, 
the soluble egg antigen is a potent Th2 inducer by itself and in this study the GM-
CSF cultures were not compared with DC subsets. It is therefore not possible to 
distinguish the Th2-inducing potency of the antigen preparation from that of the 
antigen presenting cell.  
In a model of house dust mite-driven asthma it was shown that under 
(physiological) conditions of low allergen availability the CD11b+ lung DCs that 
migrate to the medLN are necessary and sufficient to induce a Th2 allergic 
response. On the contrary, when allergen is abundantly present both CD11b+ lung 
DCs and inflammatory monocytes that migrated to the medLN can drive the Th2 
response (Hammad et al., 2010; Mesnil et al., 2012; Plantinga et al., 2013). 
Furthermore, during contact hypersensitivity CD11b+ dermal DCs that express the 
C-type lectin CD301b were shown to induce a Th2 response in vivo (Kumamoto et 
al., 2009; Murakami et al., 2013). Corroborating these results that CD11b+ DCs and 
possibly inflammatory monocytes are key inducers of Th2 responses, are findings 
that Th2 immunity is impaired in mice that lack the transcription factor IRF4, which 
is important for CD11b+ DC development (Suzuki et al., 2004). Mice that had IRF4 
deleted in CD11c-expressing cells show a lack of CD11b+ DCs and severely 
reduced Th2 responses to immunisation with antigen and papain, antigen and 
incomplete Freund’s adjuvant and nematode infection (Gao et al., 2013; Vander 
Lugt et al., 2014). In a cross of a different CD11c-Cre mouse line with IRF4fl/fl mice 
that deletes IRF4 later in DC development, CD11b+ DCs are not ablated, however, 
these mice still show impaired Th2 responses in the lung upon house dust mite 
challenge, indicating that IRF4 is not only important for CD11b+ DC development, 
but also for Th2 induction (Williams et al., 2013). Interestingly, in the context of 
nematode infection, both DCs and CD4+ T cells express CXCR5 and locate close 
to the B cell follicles, and this localisation is essential for the generation of a Th2 
response against the nematode (León et al., 2012).  
 
Development of Th17 cells depends on TGFβ and IL-6, which induce the master 
regulator of Th17 development RORγt. In the steady state Th17 development has 
mainly been studied in the intestine and associated mesLN. There, Th17 cells are 
induced by the microbiota with a dominant role for SFBs. Indeed, the presence of 
SFBs in the microbiota correlates with increased Th17 cells and colonisation of 
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mice with SFBs is sufficient to induce Th17 development (Ivanov et al., 2009; 
Gaboriau-Routhiau et al., 2009; Schnupf et al., 2015). The induction of SFB-
specific Th17 cells is dependent on MHCII expression on CD11c+ cells, although 
mice lacking MHCII on CD11c+ cells still harbour a population of Th17 cells that do 
not recognise SFBs (Goto et al., 2014). Furthermore, deletion of CD11c+ cells in 
the lamina propria largely abrogates the generation of a Th17 response (Denning 
et al., 2011). 
In one study only sorted CD103- CD11b+ DCs, and not CD103+ CD11b+ DCs or 
CD103+ CD11b- DCs, from the mesLN were capable of inducing Th17 responses in 
vitro when cultured with OT-II cells and OVA (Cerovic et al., 2013). However, in 
other studies that used sorted populations from the lamina propria, the CD103+ 
CD11b+ DCs were the most efficient in driving Th17 responses in vitro, although 
CD103- CD11b+ DCs were not included in the analysis (Uematsu et al., 2008; 
Denning et al., 2011; Fujimoto et al., 2011). Interestingly, a recent study reported 
that the CD103- CD11b+ DCs from the lamina propria can be divided into a larger 
CCR2- fraction and a smaller CCR2+ fraction, with the CCR2+ fraction being 
superior in driving Th17 differentiation in vitro (C. L. Scott et al., 2015). The same 
study also reported that this effect is masked when total CD103- CD11b+ DCs are 
used, which may explain the lack of Th17 induction by CD103- CD11b+ DCs in 
previous studies. Furthermore, when intestinal macrophages are added to the DC 
and T cell co-cultures, the induction of Th17 cells is inhibited, suggesting a 
regulatory role for intestinal macrophages on Th17 development (Denning et al., 
2011). Although in the aforementioned studies CD103+ CD11b- intestinal DCs 
failed to elicit any Th17 responses ex vivo, direct targeting of antigen to CD8α-like 
DCs via anti-DNGR-1 antibodies results in in vivo Th17 generation, but only when 
curdlan is co-administered as adjuvant with the antibody treatment (Joffre et al., 
2010). 
In the intestine the CD103+ CD11b+ DCs are thought to be the main drivers of Th17 
responses, as mice that lack IRF4 in CD11c+ cells harbour a reduction in CD103+ 
CD11b+ DCs and have a diminished Th17 population in steady state (Schlitzer et 
al., 2013). CD103+ CD11b+ DCs may regulate Th17 responses via the production 
of IL-6 and IL-23, although other mechanisms cannot be excluded (Persson, 
Uronen-Hansson, et al., 2013; Schlitzer et al., 2013). Mice with a deletion of Notch2 
in CD11c-expressing cells also have reduced CD103+ CD11b+ DCs in both lamina 
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propria and mesLNs and show a defect in intestinal Th17 cells under steady state 
conditions (Lewis et al., 2011). Additionally, mice that express DTA under control of 
the human langerin promoter completely lack CD103+ CD11b+ DCs in the lamina 
propria and have greatly reduced steady state Th17 cells, indicating that CD103+ 
CD11b+ DCs are required for Th17 development in vivo Altogether, these studies 
suggest that CD103+ CD11b+ DCs are important inducers of Th17 responses in the 
intestine. It is possible that the role for these cells might be indirect as MHCII 
expression on CD103+ CD11b+ DCs is dispensable for Th17 generation (Welty et 
al., 2013). Notably, these results do not exclude a role for CD103- CD11b+ DCs and 
CD103+ CD11b- DCs in intestinal Th17 responses, although lack of a Th17 
phenotype in Batf3-/- mice, in which CD103+ CD11b- DCs are absent, suggests that 
CD103+ CD11b- DCs are dispensable for Th17 development (Welty et al., 2013). 
Furthermore, Th17 induction is not necessarily confined to LNs, as experiments in 
mice that lack secondary lymphoid organs show that the priming of Th17 cells can 
take place locally in the lamina propria (Goto et al., 2014; Lécuyer et al., 2014). 
Although most studies have focussed on Th17 generation in the intestine, mice that 
lack IRF4 in CD11c-expressing cells have a severely reduced CD11b+ DC 
population in the lung and also show a reduction in steady state Th17 cells 
(Schlitzer et al., 2013). Furthermore, Th17 production upon challenge with the 
fungus Aspergillus fumigatus is reduced in these mice, indicating a role for CD11b+ 
lung DCs in Th17 generation (Schlitzer et al., 2013). Epicutaneous infection with 
Candida albicans yeast induces a strong protective Th17 response, the generation 
of which depends on recognition of Candida albicans by LCs in the epidermis 
(Igyarto et al., 2011; Kashem et al., 2015). LCs recognise Candida albicans via 
Dectin-1, which induces to the production of IL-6 that is essential for driving the 
Th17 response (Kashem et al., 2015).  
In sum, CD103- CD11b+ DCs and CD103+ CD11b+ DCs appear to be the dominant 
drivers of Th17 responses in vivo, while intestinal macrophages dampen this 
response, although other antigen-presenting cells are capable of inducing Th17 
cells under specific conditions (for example LCs in Candida albicans skin infection). 
 
Both Tregs derived in the thymus (nTregs) and in the periphery (iTregs) rely on the 
transcription factor FoxP3 and a lack of Tregs leads to spontaneous autoimmunity. 
iTregs are generated when naïve CD4+ T cells are activated in the presence of 
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TGFβ and IL-2. To assess if DCs are crucial in Treg formation and the control of 
spontaneous autoimmunity, two groups have crossed CD11c-Cre mice to two 
different strains of ROSA26-DTA mice, generating mice in which CD11c-
expressing cells are ablated through expression of DTA (Birnberg et al., 2008; 
Ohnmacht et al., 2009). Intriguingly, only one of these crosses developed 
spontaneous autoimmunity, while the other cross showed unaffected T cell 
homeostasis under steady-state conditions (Birnberg et al., 2008; Ohnmacht et al., 
2009). This discrepancy may be due to the different ROSA26-DTA strains used, be 
related to the environment the mice were housed in, or have a yet undefined cause. 
Furthermore, by using a Cre recombinase driven by CD11c, other cells in addition 
to DCs are ablated in these mice, which further complicates interpreting these 
experiments.  
In the periphery the expression of aldehyde dehydrogenase (which metabolises 
vitamin A into retinoic acid) by DCs is essential for the induction of Tregs (Sun et 
al., 2007; Coombes et al., 2007; Mucida et al., 2007). In the intestine and mesLN 
CD103+ CD11b+ DCs express high levels of aldehyde dehydrogenase and are 
efficient inducers of Tregs (Sun et al., 2007; Coombes et al., 2007). In addition to 
CD103+ CD11b+ DCs, intestinal macrophages also express considerable amounts 
of aldehyde dehydrogenase and are potent inducers of Treg responses (Denning et 
al., 2007). Furthermore, CX3CR1+ macrophages in the lamina propria are driving 
local expansion of Treg cells and deletion of CX3CR1 impairs local Treg expansion 
and oral tolerance (Hadis et al., 2011). In the skin and sdLNs a considerable 
fraction of the CD11b+ dermal DCs express aldehyde dehydrogenase and can 
convert OT-II cells into Tregs in in vitro culture setting (Guilliams et al., 2010). In 
the intestine it was shown that Wnt-signalling-induced β-catenin activation in DCs is 
mediating the expression of aldehyde dehydrogenase (and IL-10 and TGFβ), which 
subsequently drives Treg development (Manicassamy et al., 2010). 
CD8α-like DCs can induce Treg formation when antigen is directly and specifically 
delivered to these DCs by coupling of the antigen to an anti-DNGR-1 antibody 
(Joffre et al., 2010). Furthermore, inducible depletion of CD205+ CD8α+ DCs 
confers an impairment in the generation of Tregs from OT-II cells in the spleen 
upon subcutaneous immunisation with OVA protein in CFA (Fukaya et al., 2012). 
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Tfh cells are specialised in promoting the formation of germinal centres and are 
essential for the generation of high-affinity long-lived plasma cells and memory B 
cells. Although antigen presentation by B cells to Tfh cells is essential for Tfh 
differentiation and a proper germinal centre response, DCs are crucial for the initial 
activation of CD4+ T cells and Tfh cell commitment in an antigen-dependent 
manner (Poholek et al., 2010; Choi et al., 2011; Goenka et al., 2011). Research 
into the role of different DC subsets in the generation of Tfh cells is still in its 
infancy. In the skin both LCs and CD103+ dermal DCs are capable of inducing Tfh 
responses under steady state conditions when antigens are directly targeted to 
these cells via antibodies, with LCs being more efficient than CD103+ dermal DCs 
in generating Tfh responses (Yao et al., 2015). Additionally, targeting of antigen to 
CD8α-like DCs via an anti-DNGR-1 antibody can induce potent humoral responses, 
although the requirement for adjuvants depends on the antibody used (Caminschi 
et al., 2008; Joffre et al., 2010; Li et al., 2015). The response is dependent on T 
helper cells, and antibody targeting to DNGR-1 induces the differentiation of OT-II 
cells into Tfh cells (Caminschi et al., 2008; Lahoud et al., 2011). So, based on the 
limited data currently available, it seems that LCs and CD8α-like DCs can induce 
Tfh responses, at least as long as antigen is targeted directly to these cells. 
However, the role of CD11b+ DCs, the prototypical CD4+ T cell inducers, remains to 
be determined.  
1.1.4.2 Innate functions of DCs 
Since their discovery more than forty years ago, most of the research on DC 
function has focussed on their interaction with T cells. However, more recently the 
roles of DCs and DC subsets in directing innate immunity are being appreciated. 
Although many aspects of innate functions of DCs are still underexplored, DCs are 
appearing to not only orchestrate adaptive immunity, but also innate immunity. 
Especially the cytokines produced by DCs can instruct other types of innate 
immune cells.  
Early control of Toxoplasma gondii infection is critically dependent on IL-12-
mediated IFNγ production by NK cells and CD8α+ splenic DCs are excellent 
producers of IL-12 in response to T. gondii (Gazzinelli et al., 1993; Reis e Sousa et 
al., 1997). Indeed, mice that are depleted for DCs (via DT injection of CD11c-DTR 
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mice) show a high mortality during early T. gondii infection, which can be rescued 
by adoptively transferring WT DCs, but not IL-12 deficient DCs (C.-H. Liu et al., 
2006). Furthermore, Batf3-/- mice that lack CD8α-like DCs, show a similar high 
susceptibility to early T. gondii infection that can be rescued by the administration 
of IL-12 (Mashayekhi et al., 2011). These reports indicate a crucial innate role for 
CD8α-like DCs in early T. gondii infection via the production of IL-12.  
DCs present glycolipid antigens on CD1d to invariant NKT cells (Kawano et al., 
1997). It has been shown that splenic CD8α+ DCs are crucial for invariant NKT cell 
responses and Batf3-/- mice show increased bacterial burden upon infection with 
Streptococcus pneumonia, the clearance of which depends on invariant NKT cells 
(Arora et al., 2014). 
TLR5 activation by flagellin induces high IL-23 production by CD103+ CD11b+ 
intestinal DCs, which leads to IL-22-driven production of the antimicrobial peptide 
RegIIIγ by epithelial cells that is important for barrier integrity in the intestine 
(Kinnebrew et al., 2012). IL-22 is critical for controlling Citrobacter rodentium 
infection and lack of Notch2-dependent CD103+ CD11b+ DCs in the intestine leads 
to high susceptibility to oral Citrobacter rodentium infection, due to a lack of IL-23 
and consequently IL-22 (Satpathy et al., 2013). Conversely, these results could not 
be reproduced in huLangerin-DTA mice that also lack intestinal CD103+ CD11b+ 
DCs (Welty et al., 2013). The discrepancy between these studies is currently 
unresolved, but could be caused by (subtle) differences in DC subsets affected. 
Moreover, a recent study reported CD11c+ CX3CR1+ mononuclear phagocytes in 
the intestine to be the source of IL-23 that drives IL-22 production during 
Citrobacter rodentium infection (Longman et al., 2014). Although this finding does 
not preclude a crucial and non-redundant role for both CD11c+ CX3CR1+ cells and 
CD103+ CD11b+ DCs in producing IL-23 during Citrobacter rodentium infection, 
these conflicting results do warrant for a more detailed characterisation of the 
intestinal mononuclear phagocytes capable of producing IL-23. DCs also produce 
IL-23p19 in response to the detection of Candida albicans via CLRs and Syk 
signalling, and in this case IL-23p19 promotes GM-CSF production by NK cells, 
which in turn fully activates infiltrating neutrophils to kill the Candida (Whitney et al., 
2014). Indeed, mice that harbour a specific deletion of Syk in DCs are more 
susceptible to systemic Candida albicans infection, due to a lack of NK cell-
mediated neutrophil activation (Whitney et al., 2014). Furthermore, DCs also 
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directly influence NK cell homeostasis and function via the production of IL-15 and 
depletion of DCs results in reduced homeostatic proliferation of NK cells in vivo and 
reduced effector function upon TLR stimulation (Hochweller et al., 2008). 
 
During a local inflammatory response migDCs accumulate in the subcapsular sinus 
of LNs, Here, they are involved in temporarily disrupting the layer of subcapsular 
sinus macrophages, leading to impaired B cell responses to a subsequent 
challenge (Gaya et al., 2015). TLR signalling via MyD88 in migDCs is required for 
the disruption of macrophage organisation, but at present it is unknown whether 
DCs directly interact with the subcapsular sinus macrophages, or indirectly via an 
intermediate cell type, and what signalling molecules are involved in this interaction. 
1.1.4.3 Interactions of dendritic cells with stromal cells 
The stromal compartment has long been regarded as essential to provide structure 
to lymphoid structures, but otherwise not involved in immune responses. However, 
stromal cells are now acknowledged for actively taking part in immunological 
processes. Most of our current knowledge comes from studying the stromal 
compartment in LNs, where fibroblastic reticular cells (FRCs) in the T cell zone and 
follicular dendritic cells (FDCs) in the B cell follicles form a dense network that 
facilitates leukocyte trafficking and the transportation of antigens and signalling 
molecules. FRCs and FDCs also produce different sets of chemokines that are 
crucial for attracting lymphocytes and organising the B cell and T cell areas. Other 
major stromal compartments of LNs are blood endothelial cells (BECs) that form 
the vasculature and lymphatic endothelial cells (LECs) that form the lymphatic 
network.  
A few key publications have recently highlighted that DCs actively engage with 
stromal cells in LNs and modulate their functions to appropriately orchestrate an 
immune response. Naïve lymphocytes and other leukocytes enter the LN via 
specialised blood vessels called high endothelial venules (HEVs). Interestingly, 
DCs are crucial in maintaining HEV function and in the absence of DCs HEVs 
loose their ability to support leukocyte trafficking into the LN (Moussion and Girard, 
2011; Wendland et al., 2011). Mechanistically it is thought that DCs form a crucial 
source of LTβ receptor ligands that are essential for HEV homeostasis, and 
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vascular endothelial growth factor, which induces HEV proliferation (Moussion and 
Girard, 2011; Wendland et al., 2011; Chyou et al., 2011).  
Besides interacting with HEVs, DCs were recently also shown to control FRC 
function via CLEC2-podoplanin interactions (Acton et al., 2014; Astarita et al., 
2015). FRCs form a dense and contractile network in a steady-state LN that needs 
to expand during an inflammatory response to allow for LN swelling and 
accommodate lymphocyte influx. FRCs accomplish this task by stretching during 
the early phase of an immune response, followed by subsequent proliferation if the 
immune response is prolonged. In steady state podoplanin expression on FRCs 
promotes FRC contractility and tension throughout the FRC network. During an 
inflammatory response the accumulation of CLEC2-expressing DCs causes 
increased binding of podoplanin on FRCs to CLEC2 on DCs, leading to the 
inhibition of podoplanin-mediated contractility in FRCs (Acton et al., 2014; Astarita 
et al., 2015). Importantly, in mice that lack CLEC2 expression on DCs, LN 
expansion is severely impaired, while administration of soluble CLEC2 facilitates 
LN expansion in response to inflammation (Acton et al., 2014; Astarita et al., 2015). 
In addition to this well-documented role for DCs in FRC stretching, DCs have also 
been linked to the regulation of FRC proliferation, as DC depletion in CD11c-DTR 
mice abrogated inflammation-induced FRC proliferation (Chyou et al., 2011; Yang 
et al., 2014). However, although these changes in LN swelling mediated by DCs 
are likely to have an impact on T cell and B cell response, these implications have 
not been formally addressed yet.  
1.2 Mouse models to study dendritic cells 
Transgenic mouse models have proven to be indispensable tools to study all 
aspects of DC biology. These models have allowed for the identification of DC 
subsets and delineation of DC ontogeny, and have provided a wealth of information 
on DC function, to name but a few. Among the models most frequently used are 
mice that express Cre recombinase in DCs, knockout mice for transcription factors 
involved in DC development, mice in which DCs can be inducibly depleted and 
mice in which DCs are labelled with fluorescent proteins.  
Chapter 1 Introduction 
59 
 
1.2.1 Introduction to Cre-loxP system 
The Cre recombinase-loxP system was first discovered in a bacteriophage in 1981, 
used some years later to recombine DNA in a mammalian cell line, and has since 
been used extensively for genome manipulation in many organisms (Sternberg and 
Hamilton, 1981; Sauer and Henderson, 1988). The system relies on the Cre 
recombinase enzyme that recognises specific 34-base pair sequences called loxP 
sites that consist of a 8-base pair spacer and two 13-base pair palindromic 
sequences (Sternberg and Hamilton, 1981). When two such sites are recognised, 
recombination of the DNA takes place, the outcome of which depends on the 
orientation of the loxP sites. A stretch of DNA within the genome that is flanked by 
two loxP sites in the same orientation will be circularised, leading to the loss of the 
loxP-flanked DNA fragment from the genome and one intact loxP site ending up in 
the circular DNA fragment and one intact loxP site remaining in the genome. Two 
loxP sites oriented in opposite directions promote a Cre-mediated inversion of the 
flanked DNA fragment without the loss of any DNA from the genome, while 
preserving both loxP sites. Finally, when two loxP sites are located on different 
chromosomes the action of Cre recombinase will lead to chromosomal 
translocation.  
In transgenic mice the gene encoding Cre recombinase can be expressed under 
the control of a generic promoter that allows for widespread Cre-mediated loxP 
recombination, or under the control of tissue specific, cell specific or otherwise 
restricted promoters to achieve loxP recombination only in cells or tissues of 
interest. Additionally, a split-Cre system has been developed consisting of two 
inactive Cre fragments that form a functional Cre recombinase when expressed in 
the same cell (Hirrlinger, Scheller, et al., 2009; P. Wang et al., 2012). The two split-
Cre fragments can be expressed by two different promoters, allowing for more 
precise targeting of Cre activity to the desired cells (Hirrlinger, Scheller, et al., 
2009; P. Wang et al., 2012). Furthermore, various modified Cre recombinases have 
been generated that are non-functional unless a certain compound is introduced to 
activate the recombinase activity. One major group consists of Cre recombinase 
fused to a mutated from of the hormone-binding domains of the estrogen receptor 
(ER). CreER, or the improved CreERT2, is normally sequestered in the cytoplasm 
where it is inactive. Upon binding of the ligand 4OH-tamoxifen to the mutated ER 
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domain, the CreER or CreERT2 enzyme translocates to the nucleus where 
recombination of loxP sites can take place. Analogous to the split-Cre system, a 
split-CreERT2 system has also been developed that allows for a more targeted 
expression of functional CreERT2 (Hirrlinger, Requardt, et al., 2009). As 4OH-
tamoxifen has poor bioavailability, the prodrug tamoxifen is normally used for in 
vivo studies and can be administered systemically via oral or parental routes, but is 
also amenable to local topical application. 
1.2.2 DTR-based mouse models to constitutively or inducibly deplete 
dendritic cells 
Our knowledge of DC biology has greatly benefited from the introduction of	  mouse 
models that allow for specific depletion of DCs. Most such models make use of the 
diphtheria toxin receptor (DTR) system. DTR is a membrane-anchored protein that 
is also called heparin-binding EGF-like growth factor (HB-EGF) and is targeted by 
diphtheria toxin (DT), a toxin produced by Corynebacterium diphtheriae 
(Higashiyama et al., 2008). Fragment B of the toxin binds the receptor, which 
results in receptor-mediated endocytosis of the toxin and subsequent translocation 
of the A fragment (DTA) into the cytosol. DTA inactivates the polypeptide chain 
elongation factor 2, which leads to the inhibition of protein synthesis and cell death 
(Saito et al., 2001). Mice are naturally resistant to DT intoxication due to a low 
binding affinity of DT for murine HB-EGF, which is about 105 times lower than the 
affinity of DT for simian or human HB-EGF (Saito et al., 2001). Therefore, 
expression of primate DTR on murine cells by transgenesis renders these cells 
highly susceptible to DT intoxication and cell death, while not affecting the rest of 
the mouse.  
 
The first DTR model to inducibly deplete DCs used a minimal CD11c promoter to 
drive a DTR-GFP fusion protein (Jung et al., 2002). In these mice cDCs, pDCs and 
LCs express DTR and are ablated upon a single DT injection (Jung et al., 2002). 
However, longer term DC depletion is not possible, as CD11-DTR mice die upon 
multiple DT injections, probably because of aberrant DTR expression on epithelial 
cells of the gut (Zaft et al., 2005). Long-term DC depletion can only be achieved in 
radiation chimeras in which WT mice are reconstituted with CD11c-DTR BM. 
Chapter 1 Introduction 
61 
 
Radioresistant cells such as LCs remain of host origin in irradiation chimeras and 
are therefore not depleted upon DT injection, which can be exploited, but may also 
be a limitation of this experimental setup. To circumvent the necessity to generate 
irradiation chimeras for longer-term DC depletion, another mouse model was 
developed that used a bacterial artificial chromosome approach to express DTR, a 
fragment of the OVA protein and GFP regulated by the CD11c locus control region 
(Hochweller et al., 2008). Unlike CD11c-DTR mice, these CD11c-DOG mice do not 
die upon repeated DT injections. However one major limitation of both CD11c-DTR 
and CD11c-DOG mice is that CD11c expression is not constrained to DCs, but is 
also found on some macrophages, plasmablasts, activated T cells, NK cells and 
Ly6clow monocytes, and many of these cell populations are depleted in both 
CD11c-DTR and CD11c-DOG mice upon DT injection (Jung et al., 2002; Probst, 
Tschannen, et al., 2005; Hochweller et al., 2008). Therefore, results obtained in 
these mice are difficult to firmly attribute to DCs, as other immune cell populations 
are also affected. Furthermore, both CD11c-DTR and CD11c-DOG mice exhibit 
neutrophilia and monocytosis upon DT injection, which may confound results 
obtained, especially when bacterial or viral infections are examined (Hochweller et 
al., 2008; Tittel et al., 2012; van Blijswijk, Schraml and Reis e Sousa, 2013). For 
example, one study observed improved bacterial clearance in DC-depleted CD11c-
DTR and CD11c-DOG mice in a bacterial pyelonephritis model, which turned out to 
be caused by neutrophilia and not by DC depletion per se (Tittel et al., 2012). 
CD11c-DTR and CD11c-DOG mice display an early wave of neutrophilia that is 
manifest 24h after DT injection and a late wave beginning at 72h after DT injection. 
The early neutrophilia is due to the release of neutrophils from the bone marrow in 
response to chemokines CXCL1 and CXCL2 and is mouse model dependent (Tittel 
et al., 2012). Indeed, the more recently generated CD11c-LuciDTR mice that 
express DTR, GFP, luciferase and Cre recombinase under control of the CD11c 
locus control region do not show the early neutrophilia (Tittel et al., 2012). In 
contrast, the late neutrophilia is a consequence of increased granulopoiesis, likely 
caused by increased levels of Flt3l and is present in all mice in which DCs are 
depleted (Tittel et al., 2012). 
DTR expression is not restricted to cDCs when expressed under control of the 
CD11c locus control region or minimal promoter. Therefore, mice were generated 
that use the expression pattern of the transcription factor Zbtb46 to drive DTR 
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expression on cDCs (Meredith, Liu, Darrasse-Jeze, et al., 2012). Within the 
immune system Zbtb46 expression is restricted to cDCs, some activated 
monocytes and monocytes cultured in vitro with GM-CSF and IL-4, but is absent 
from pDCs and LCs, and hence DTR expression in these zDC-DTR mice is fairly 
restricted to cDCs, though monocytes may also express DTR (Meredith, Liu, 
Darrasse-Jeze, et al., 2012; Satpathy, KC, et al., 2012). However, outside of the 
immune system Zbtbt46 is also expressed in committed erythroid progenitors and 
endothelial cells, leading to death of zDC-DTR mice upon DT injection (Satpathy, 
KC, et al., 2012). Consequently, zDC-DTR mice can only be used as radiation 
chimeras generated by reconstitution of wild type mice with zDC-DTR bone marrow. 
In a different approach a loxP-flanked stop-cassette followed by the gene encoding 
simian DTR was inserted into the first intron of the Itgax locus (encoding CD11c) 
(Okuyama et al., 2010). In these CD11c-iDTR mice DTR is only expressed from the 
CD11c locus control region when the loxP-flanked stop-cassette is excised by Cre 
recombinase. Therefore, depending on the Cre transgenic line used, only a subset 
of CD11c-expressing cells will express DTR and will be sensitive to DT-mediated 
depletion. To demonstrate proof-of-principle, CD11c-iDTR mice were crossed with 
CAG-Cre mice, which ubiquitously express Cre recombinase (Okuyama et al., 
2010). In this cross all CD11c-expressing cells in the spleen were depleted upon 
DT injection, demonstrating the feasibility of this approach (Okuyama et al., 2010). 
 
In addition to transgenic mice that aim for the depletion of all DCs, several mouse 
models have been generated to only deplete certain DCs subsets. The expression 
pattern of langerin has been used to try and generate mice to specifically and 
inducibly deplete LCs. Two groups independently generated mice to inducibly 
deplete langerin+ cells by placing DTR and GFP expression under the control of the 
langerin promoter, either via a knock-in approach or insertion into the 3’ 
untranslated region of the langerin locus (Bennett et al., 2005; Kissenpfennig et al., 
2005). Initially it was thought that langerin is exclusively expressed on LCs, and 
that therefore only LCs would be depleted in Langerin-DTR mice. Although LCs are 
efficiently depleted in these mice upon DT administration, more recent studies have 
shown that the CD103+ dermal DCs also express langerin, as well as some CD8α+ 
DCs in the spleen and LNs, and these DCs are also depleted in Langerin-DTR 
mice injected with DT (Poulin et al., 2007; Bursch et al., 2007; Henri et al., 2010). 
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As LCs remain depleted for much longer than the langerin+ DCs after a single dose 
of DT (around 2 weeks versus 5 days), clever timing of experiments can allow for 
specific assessment of the effect of LC depletion (Kissenpfennig et al., 2005; 
Bursch et al., 2007). Alternatively, radiation chimeras can be generated in which 
Langerin-DTR mice are reconstituted with WT BM, taking advantage of the 
radioresistance of LCs (Kautz-Neu et al., 2011). Apart from the Langerin-DTR mice, 
transgenic mice were developed that express DTR under control of the human 
langerin regulatory elements, the huLangerin-DTR mice (Bobr et al., 2010). 
Interestingly, in these mice the human langerin regulatory elements only drive DTR 
expression in LCs and not in CD103+ dermal DCs, and consequently only LCs are 
depleted in huLangerin-DTR mice injected with DT (Bursch et al., 2007; Bobr et al., 
2010). 
In addition to these inducible depletion systems, huLangerin-DTA mice were 
generated that constitutively lack LCs due to the expression of DTA (and 
immediate cell death) under control of the human langerin regulatory elements 
(Kaplan et al., 2005). As with huLangerin-DTR mice, dermal CD103+ DCs are 
unaffected in huLangerin-DTA mice (Bursch et al., 2007). Interestingly, murine 
intestinal DCs do not express langerin, while human intestinal DCs do (Welty et al., 
2013). In huLangerin-DTA mice DTA is also expressed in CD103+ CD11b+ DCs in 
the intestine and these cells are indeed absent from these mice (Welty et al., 2013).  
 
Inducible depletion of pDCs can be achieved by using the promoter of human blood 
dendritic cell antigen 2 (BDCA-2, CLEC4C), which is exclusively expressed on 
pDCs in humans, or by exploiting the expression pattern of SiglecH in the mouse 
(Swiecki et al., 2010; Takagi et al., 2011; Swiecki et al., 2014). Although BDCA-2 is 
not present in the mouse, transgenic huBDCA-2-DTR mice exclusively express 
DTR on pDCs (Swiecki et al., 2010) and DT treatment of BDCA-2-DTR mice leads 
to efficient and specific mouse pDC depletion (Swiecki et al., 2010). Two transgenic 
mice have been generated to express DTR from the SiglecH locus control region 
(Takagi et al., 2011; Swiecki et al., 2014). In the first model DTR and GFP 
transgenes were inserted into the 3’ untranslated region of the Siglech gene, while 
the second one made use of a bacterial artificial chromosome approach (Takagi et 
al., 2011; Swiecki et al., 2014). SiglecH is highly expressed on pDCs, but is also 
found on a fraction of CDPs and preDCs, cDCs and certain macrophages (Zhang 
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et al., 2006; Blasius, 2006; Swiecki et al., 2010; Satpathy, KC, et al., 2012; Swiecki 
et al., 2014). It was initially reported that DT administration to SiglecH-DTR mice 
selectively depleted pDCs without affecting other immune cells, but a subsequent 
study showed that also other SiglecH-expressing cells are eliminated (Takagi et al., 
2011; Swiecki et al., 2014). Furthermore, although the insertion of the transgene 
into the 3’ untranslated region was intended not to interfere with SiglecH 
expression, homozygous mice turned out to be deficient in SiglecH expression, 
altering the phenotype and function of pDCs in SiglecH-DTR mice (Takagi et al., 
2011; Swiecki et al., 2014). 
 
A few different approaches have been taken to inducibly deplete CD8α-like DCs in 
the mouse. The Clec9a-DTR model uses a bacterial artificial chromosome to 
express DTR under the control of the Clec9a locus (Piva et al., 2012). DNGR-1, the 
product of the Clec9a locus, is expressed on CD8α+ DCs in the spleen and these 
cells are depleted in Clec9a-DTR mice upon DT treatment (Piva et al., 2012). 
Given that DNGR-1 is also expressed on CD8α-like DCs in other tissues, these 
cells are expected to be depleted in Clec9a-DTR mice as well, although this 
remains to be demonstrated. pDCs express low levels of DNGR-1 and are partially 
reduced by DT treatment in Clec9a-DTR mice (Piva et al., 2012). Moreover, more 
recent research has shown that DNGR-1 is expressed on CDP and preDC 
populations, which suggest that these precursor populations may also be affected 
by DT injection of Clec9a-DTR mice (Schraml et al., 2013). If CDPs and preDCs 
are reduced by DT treatment, this may result in quantitative and qualitative 
differences in other cDC populations that do not express DNGR-1. 
Another C-type lectin receptor whose expression is relatively restricted to CD8α-
like DCs is CD205 (DEC-205), although LCs, dermal DCs and thymic epithelial 
cells also express CD205 (Jiang et al., 1995; Kissenpfennig et al., 2005). CD205-
DTR mice were generated by inserting a DTR transgene fused to GFP into the 3’ 
untranslated region of the CD205 gene (Fukaya et al., 2012). As CD205-DTR mice 
die upon DT injection, irradiated WT mice reconstituted with CD205-DTR BM have 
to be used for depletion studies (Fukaya et al., 2012). In these irradiation 
chimaeras DT injection depletes CD205+ DCs, but not LCs and thymic epithelial 
cells, which are radioresistant (Fukaya et al., 2012). 
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Finally, XCR1-DTR mice have been developed that harbour a Dtr and Venus gene 
knocked into the Xcr1 locus, replacing the entire Xcr1 coding region (Yamazaki et 
al., 2013). XCR1 is selectively expressed on CD8α-like DCs and DT injection of 
XCR1-DTR mice depletes CD8α+ DCs in spleen and LNs and CD103+ migDCs in 
LNs, but does not affect other leukocyte populations (other tissues were not 
analysed) (Yamazaki et al., 2013). 
 
Unfortunately at present no transgenic mouse exists that allows for inducible 
depletion of CD11b+ DCs. The reason is probably that CD11b+ DCs are a more 
heterogeneous group of DCs than CD8α-like DCs or pDCs and that it has proven to 
be difficult to find a marker that is selectively expressed on CD11b+ DCs. CD11b-
DTR mice exist that use the CD11b promoter to express both DTR and GFP 
(Duffield et al., 2005). However, CD11b+ DC depletion has not been assessed in 
these mice and more importantly, CD11b is also expressed on many other myeloid 
cells such as monocytes, macrophages and granulocytes, rendering these mice not 
useful to study CD11b+ DC biology. In theory, a more specific way to inducibly 
deplete CD11b+ DCs is by crossing the CD11c-iDTR mice that harbour a loxP-
flanked stop-cassette followed by the gene encoding simian DTR with CD11b-Cre 
mice (Ferron and Vacher, 2005; Boillée et al., 2006; Okuyama et al., 2010). This 
cross should only induce DTR expression on CD11c+ cells that have expressed 
CD11b at some point during their life, which is true for CD11b+ DCs, but also for 
certain macrophages and monocytes. It therefore remains to be seen which cell 
populations would be depleted in these mice. Both CD11c-iDTR and CD11b-Cre 
mice are available, but such cross has not been published yet.  
 
In summary, many DTR- and DTA-based mouse strains are available to inducibly 
or constitutively deplete all DCs or DC subsets in vivo. However, although these 
mouse models are useful tools to study DC biology, other cell populations than the 
one intended may be affected, which complicates the interpretation of experiments. 
Furthermore, at least the CD11c-based DTR models have been shown to suffer 
from neutrophilia and monocytosis upon DT injection, which must be taken into 
account when interpreting results. Unfortunately, the induction of neutrophilia and 
monocytosis has not been formally examined in other models. Moreover, some 
DTR-based models such as zDC-DTR mice and CD205-DTR mice die upon DT 
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injection and may only be used as irradiation chimaeras. Finally, mouse models 
have been developed to deplete LCs, pDCs and CD8α-like DCs, but no model 
exists to inducibly deplete CD11b+ DCs, hampering the study of this subset. 
1.2.3 Fluorescence-based models to track dendritic cells 
Besides mouse models to deplete DCs, another powerful tool to study DC biology 
in vivo is to use mice that harbour fluorescently labelled DCs. Many DTR-based 
mouse models express a fluorescent protein (usually GFP) in addition to the DTR 
transgene, like CD11c-DTR and langerin-DTR mice (Jung et al., 2002; Bennett et 
al., 2005; Kissenpfennig et al., 2005). The fluorescent protein expression is not only 
useful to track DT-mediated ablation and subsequent recovery of the DTR-
expressing DC population in these mice, but can also be used to visualise the 
labelled cells in the absence of DT treatment. In addition to the mouse models that 
combine DTR expression with fluorescent protein expression, transgenic mice have 
also been developed that exclusively express fluorescent proteins. For example, in 
CD11c-YFP mice YFP-Venus expression is controlled by the CD11c promoter and 
cells with high CD11c expression are high YFPbright, while in cells with lower CD11c 
expression YFP is dimmer (Lindquist et al., 2004). CD11c is also expressed on 
other cells than DCs, but in many tissues the majority of the CD11chi, and therefore 
YFPbright, cells are often DCs. CD11c-YFP mice are therefore very useful for 
microscopy-based approaches. Confocal microscopy on tissue sections from 
CD11c-YFP mice readily shows the localisation and dendritic morphology of DCs in 
for example LNs and spleen (Lindquist et al., 2004; Gerner, Torabi-Parizi and 
Germain, 2015). Moreover, the YFP signal in DCs is bright enough to allow for the 
detection of DCs by intravital microscopy and track their behaviour in vivo. In this 
respect CD11c-YFP mice have for example been used to visualise the uptake of 
beads, bacteria and malaria sporozoites by DCs in LNs, DC migration in the 
afferent lymphatics of mesLNs, or antigen sampling in the intestine (Chieppa et al., 
2006; Olga Schulz et al., 2009; McDole et al., 2012; Radtke et al., 2015; Gerner, 
Torabi-Parizi and Germain, 2015).  
Zbtb46-GFP mice harbour the gene encoding GFP in the endogenous Zbtb46 
locus, which allows for selective GFP expression in cDCs, some activated 
monocytes, committed erythroid progenitors and endothelial cells (Satpathy, KC, et 
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al., 2012; Meredith, Liu, Darrasse-Jeze, et al., 2012). In irradiation chimeras in 
which WT mice are reconstituted with Zbtb46-GFP BM, endothelial cells are of WT 
origin and not labelled, allowing for the visualisation of cDCs (and maybe activated 
monocytes, depending on the experimental setup). These irradiation chimeras 
have a more restricted fluorescent protein expression than the CD11c-YFP mice 
and can be a useful alternative to visualise cDCs in tissue sections or by intravital 
microscopy. 
 
Several mouse models exist to visualise specific DC subsets, analogous to the 
subset-specific DTR-based mouse models as discussed in 1.2.2. Langerin-GFP 
mice contain the gene encoding GFP in the 3’ untranslated region of the langerin 
locus, resulting in GFP expression in LCs, CD103+ dermal DCs and some CD8α+ 
DCs in the spleen and LNs (Kissenpfennig et al., 2005; Bursch et al., 2007). 
Additionally, both Langerin-DTR strains also express GFP in the same cell types 
(Kissenpfennig et al., 2005; Bennett et al., 2005; Bursch et al., 2007). All these 
mice can be used to visualise LCs in epidermal sheets and langerin+ cells in tissue 
sections (Kissenpfennig et al., 2005; Bennett et al., 2005; Bursch et al., 2007). 
CD205-DTR mice express GFP as well and may be used to visualise CD8α-like 
DCs, although some other cell types are also labelled (Fukaya et al., 2012). 
However, whether GFP expression in these mice is bright enough for microscopy 
experiments remains to be established. DNGR-1 (or CLEC9A) is expressed on 
CD8α-like DCs and at lower levels on pDCs. Clec9a-GFP mice express GFP under 
control of the Clec9a locus and both CD8α-like DCs and pDCs express GFP in 
these mice, although GFP levels are lower in pDCs (Sancho et al., 2009). XCR1 
expression is specific for CD8α-like DCs and both XCR1-DTR and XCR1-Venus 
mice express the fluorescent protein Venus from the endogenous Xcr1 locus 
(Yamazaki et al., 2013). Venus is selectively expressed in CD8α-like DCs in both 
lymphoid and non-lymphoid tissues and can be used to visualise these cells by 
confocal microscopy (Yamazaki et al., 2013). These mice will be a useful tool to 
study CD8α-like DCs by intravital microscopy or in tissue sections.  
 
In the above-mentioned mouse models fluorescent protein expression is directly 
driven by a DC-restricted promoter. Alternatively, mouse lines that express Cre 
recombinase in DCs crossed to fluorescent reporter mice can be used to visualise 
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DCs in vivo or in tissue sections. Using the Cre-loxP system to fluorescently label 
DCs has advantages over using direct fluorescent protein expression driven by a 
DC-restricted promoter. Firstly, a Cre mouse line regulated by a given promoter 
may label different cell populations than a mouse line expressing a fluorescent 
protein regulated by the same promoter, as the Cre-mediated excision of loxP sites 
is irreversible and inheritable by daughter cells. Secondly, the Cre-loxP system is 
more versatile, as many different fluorescent reporter mouse lines exist that 
express different fluorescent proteins. Finally, if a mouse line expressing an 
inducible Cre recombinase is available, not only spatial control but also temporal 
control over fluorescent protein expression can be achieved. 
CD11c-Cre mice will recombine loxP sites in any CD11c-expressing cell, and when 
these mice are crossed to a reporter mouse DCs are labelled, but also many 
macrophages and some other immune cells such as T cells and B cells (Caton, 
Smith-Raska and Reizis, 2007). As many macrophages are labelled in CD11c-Cre 
mice crossed to the ROSA26-LSL-YFP reporter line, these mice have been used to 
visualise alveolar macrophages by intravital microscopy (Westphalen et al., 2014). 
However, to visualise DCs, CD11c-Cre mice crossed to a fluorescent reporter line 
are less useful. Interestingly, CD11c-CreERT mice have been generated that 
express an inducible form of Cre recombinase under the control of the CD11c 
promoter (Probst et al., 2003). When these mice are crossed with a GFP reporter 
line and tamoxifen is administered, about 4-8% of DCs in lymphoid organs turn 
GFP+ (Probst et al., 2003). Although the recombination frequency is relatively low, 
it should label enough DCs for microscopy-based experiments. Furthermore, 
recombination only takes place during a relatively short time frame, which should 
limit the labelling of non-DCs.  
Another useful Cre mouse line are the Clec9a-Cre mice, which express Cre 
recombinase under control of the Clec9a locus (Schraml et al., 2013). In these 
mice Cre is expressed at the CDP and preDC stage, as well as in CD8α-like DCs 
and pDCs. As DC precursors express Cre and loxP excision is irreversible, all DCs 
are labelled in Clec9a-Cre mice crossed to the ROSA26-LSL-YFP reporter line and 
can be visualised by microscopy (Schraml et al., 2013). 
The only two transgenic mouse lines currently available to express Cre 
recombinase in a subset of DCs are the Langerin-Cre mice that have the gene 
encoding Cre recombinase knocked into the murine langerin locus and the 
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huLangerin-Cre mice that express Cre under control of the human langerin 
regulatory elements (Kaplan et al., 2007; Zahner et al., 2011). Langerin-Cre mice 
express Cre in LCs and other langerin+ DCs, and when crossed to a RFP reporter 
strain all these cells are RFP+ (Zahner et al., 2011). As the human langerin 
regulatory elements were used to generate huLangerin-Cre mice, Cre is only active 
in LCs and probably in intestinal CD103+ CD11b+ DCs (Bursch et al., 2007; Welty 
et al., 2013). When huLangerin-Cre mice are crossed to a GFP reporter mouse 
strain LCs are specifically GFP+ (Kaplan et al., 2007). 
 
In summary, multiple fluorescence-based mouse models to visualise DCs in vivo 
and in tissue sections are available. CD11c-YFP, Zbtbt46-GFP and Clec9a-Cre 
mice crossed to a reporter strain all label DCs with fluorescent proteins, but do not 
distinguish between subsets. Subset-specific labelling can be achieved with 
Langerin-GFP, XCR1-GFP, Clec9a-GFP and huLangerin-Cre mice crossed to a 
reporter strain, and with several of the DTR strains that express a fluorescent 
protein in addition to DTR. Unfortunately, only one mouse strain, the CD11c-
CreERT mouse, currently exists that expresses an inducible Cre recombinase and 
therefore allows for temporal control over labelling of DCs in vivo. It will be very 
useful for the study of DCs and DC subsets if other inducible Cre mice are 
developed.  
1.2.4 Transcription factor knockout mice to study DC function 
Besides mice that allow for constitutive or inducible depletion of DCs and mice in 
which DCs are fluorescently labelled, another group of mice to study DC biology is 
mice that lack a transcription factor. These mice can be full knockouts, affecting not 
only DCs but all cells in the body, but may also contain DC-specific deletions. In the 
latter case parts of the gene of interest are flanked by loxP sites and DC-specific 
Cre expression is used to generate a DC-specific knockout.  
 
A detailed overview of transcription factor expression and dependency is given in 
1.1.2.2. Although full knockout mice for various transcription factors have been 
instrumental to delineate transcription factor dependency of DCs, most are not 
useful to study other aspects of DC biology. The main reason is that transcription 
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factors are usually expressed in and important for many other cell types in addition 
to DCs. Full knockout mice lack the transcription factor of interest in all cells, which 
complicates the interpretation of results obtained in these mice. The main 
exception are Batf3-/- mice, which have a selective deficiency in CD8α-like DCs 
(Hildner et al., 2008; Edelson et al., 2010). Therefore, Batf3-/- mice are often used 
to study immune responses in the absence of CD8α-like DCs, for example in the 
context of Listeria monocytogenes, Toxoplasma gondii, influenza or West Nile virus 
infection, contact hypersensitivity and tumour rejection. However, Batf3 is not only 
expressed in CD8α-like DCs, but in all cDC subsets, Th1 cells and at lower levels 
in Th2 and Th17 cells, although these cells do not rely on Batf3 for their 
development and survival (Hildner et al., 2008). It is therefore conceivable that the 
function of DCs still present in Batf3-/- mice and Th1, Th2 and Th17 cells is altered 
due to the lack of Batf3 in these cells, which should be taken into account when 
interpreting results.  
 
The transcription factor E2-2 is essential for pDCs, but is also involved in 
development and E2-2-/- mice die at birth (Cisse et al., 2008). This lethal phenotype 
can be overcome by generating conditional knockout mice by crossing E2-2fl/fl mice 
with CD11c-Cre mice. These conditional E2-2 knockout mice show about a 3-fold 
reduction in pDC numbers and the remaining pDCs are functionally impaired, which 
may be sufficient to show a phenotype in certain experimental settings, but not in 
all (Cisse et al., 2008). 
 
IRF4-/- mice show impaired CD11b+ DC development. However, IRF4 is also 
important for the function and homeostasis of T cells and B cells, which makes it 
difficult to determine which cell type(s) is responsible for observed immune defects 
in these mice (Mittrücker et al., 1997; Suzuki et al., 2004). To circumvent the 
effects of IRF4 deficiency on lymphocytes, IRF4fl/fl mice were crossed with CD11c-
Cre mice to generate mice in which IRF4 deficiency is confined to DCs (Persson, 
Uronen-Hansson, et al., 2013; Schlitzer et al., 2013). Indeed, these conditional 
IRF4 knockout mice show a specific impairment in development and function of 
intestinal CD103+ CD11b+ DCs and CD11b+ DCs in the lung (Persson, Uronen-
Hansson, et al., 2013; Schlitzer et al., 2013). Similarly, mice that are deficient in 
Notch2 signalling in DCs, via conditional deletion of Notch2 or the downstream 
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transcription factor RBP-J by CD11c-Cre, have reduced CD11b+ DCs in the spleen 
(Caton, Smith-Raska and Reizis, 2007; Lewis et al., 2011). In the case of Notch2 it 
was shown that a specific subset of splenic CD11b+ DCs, the ESAMhi cells, were 
selectively missing (Lewis et al., 2011). CD103+ CD11b+ DCs in the intestine were 
also lost in mice that lacked Notch2 in DCs, while this subset was not investigated 
in the RBP-J conditional knockout mice (Caton, Smith-Raska and Reizis, 2007; 
Lewis et al., 2011). 
 
So, although deficiency in many transcription factors leads to a (partial) loss of DCs 
or impaired DC functionality, only a few of these models may be useful to study DC 
function beyond the direct effects of transcription factor loss. Of the models 
discussed here only Batf3-/- are widely used to study immune responses in the 
absence of CD8α-like DCs. 
1.2.5 Chemokine (receptor) knockout mice to study DC function 
Analogous to mice lacking transcription factors, mice that lack chemokines or 
chemokine receptors are also useful tools to study DC biology. The chemokine 
receptor CCR7 and its ligands CCL19 and CCL21 are essential for DC, T cell and 
B cell migration and positioning within tissues (Förster et al., 1999; Förster, 
Davalos-Misslitz and Rot, 2008). CCL19 and CCL21 are expressed on HEVs and 
by FRCs in the T cell zone of LNs. CCL21 is also expressed in lymphatic vessels, 
lymphoid and non-lymphoid organs (Förster, Davalos-Misslitz and Rot, 2008). Due 
to a gene duplication event mice have two genes encoding CCL21, CCL21-Leu 
and CCL21-Ser, that differ by one amino acid and show differential expression 
patterns (Förster, Davalos-Misslitz and Rot, 2008). Plt/plt mice have a spontaneous 
deletion in the gene loci encoding CCL19 and CCL21-Ser, without affecting 
CCL21-Leu. These mice still express CCL21-Leu in lymphatic vessels of non-
lymphoid tissues, but completely lack the expression of CCL19 and CCL21 in 
lymphoid organs (Vassileva et al., 1999; Luther et al., 2000; Nakano and Gunn, 
2001). 
Loss of CCR7 expression on T cells leads to homing defects of these T cells to LNs 
and to the white pulp in the spleen, and impairs migration within lymphoid organs 
(Förster et al., 1999; Worbs et al., 2007). A similar phenotype is observed in plt/plt 
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mice, which also show impaired T cell homing (Gunn et al., 1999). Migration of DCs 
from peripheral tissues to LNs is also crucially dependent on CCR7. Full knockout 
mice for CCR7 or mice that lack CCR7 on all cells except for T cells show impaired 
DC migration from peripheral tissues to LNs and harbour severely reduced DC 
numbers in their LNs (Ohl et al., 2004; Wendland et al., 2011). DC migration is also 
reduced in plt/plt mice, even though CCL21-Leu is still expressed on the lymphatics 
in peripheral tissues (Gunn et al., 1999). 
 
Migration of DCs from peripheral tissues to LNs is considered to be a defining 
property of DCs. As CCR7 is crucial for DC migration, CCR7 expression and 
CCR7-dependent migration to LNs are often used to help classify myeloid cells in 
peripheral tissues as DCs. However, LCs and certain monocyte-derived cells also 
express CCR7 and migrate towards LNs, and therefore CCR7-dependent migration 
is not a unique feature of DCs (Ohl et al., 2004; Zigmond et al., 2012; 
Tamoutounour et al., 2013). Besides the use of CCR7-/- mice to assess CCR7-
dependent migration of myeloid cells, these mice are also used to study the effects 
of antigen delivery by migDCs (and other migrating myeloid cells) on immune 
responses. A local inflammation or infection in peripheral tissues generally leads to 
antigen-specific T cell responses in the draining LNs and migDCs are in most 
cases crucial for the transportation of antigen to the LNs (Ohl et al., 2004; Plantinga 
et al., 2013). The accumulation of antigen in LNs is abolished in CCR7-/- mice, 
leading to impaired immune responses (Ohl et al., 2004; Tamoutounour et al., 
2012; Plantinga et al., 2013). However, a major limitation of using CCR7-/- mice for 
these studies is that not only DC migration is impaired, but also T cell homing and 
migration, which in itself impacts immune responses. One way to overcome this 
limitation is to adoptively transfer CCR7-/- T cells or DCs into a WT host (or suitable 
transgenic host). More recently a conditional proficient CCR7 transgenic mouse 
was developed (Wendland et al., 2011). In these mice the endogenous Ccr7 locus 
is disrupted by insertion of a loxP flanked neomycin gene, followed by a gene 
encoding the human CCR7 protein, which is not transcribed when the neomycin 
cassette is present. Effectively these mice are a full knockout for CCR7, but Cre-
mediated recombination can induce human CCR7 expression on specific cells. 
When these mice are crossed to a T cell-specific Cre mouse strain, such as CD4-
Cre that was used in the original paper describing these mice, T cells express 
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human CCR7 and regain full functionality (Wendland et al., 2011). However, CD4 is 
also expressed on certain DC subsets that consequently may also express human 
CCR7 when CD4-Cre mice are used. Nonetheless, such crosses will be very useful 
to dissect the contribution of CCR7-dependent antigen delivery to LNs on immune 
responses.  
 
Egress of Ly6chi monocytes from the bone marrow is critically dependent on the 
chemokine receptor CCR2 (Serbina and Pamer, 2006). CCR2-/- mice show 
accumulation of Ly6chi monocytes in the bone marrow and reduced frequencies of 
Ly6chi monocytes in the blood and of monocyte-derived cells in tissues, both under 
steady state conditions and during inflammation (Boring et al., 1997; Kuziel et al., 
1997; Serbina and Pamer, 2006). CCR2-/- mice have therefore proven to be a 
useful tool to show monocytic origin of myeloid cell populations in tissues and to 
study immune responses in the absence of inflammatory monocytes (Serbina, 
Salazar-Mather, et al., 2003; Ginhoux et al., 2007; Tamoutounour et al., 2012; 
2013; Satpathy et al., 2013). Interestingly, a recent study reported that a fraction of 
preDC-derived CD11b+ DCs in the intestine and mesLN express CCR2 and is 
reduced in CCR2-/- mice (C. L. Scott et al., 2015). These results highlight that 
caution is warranted when using CCR2-/- mice to address the origin and function of 
myeloid cells. 
1.2.6 Models to trace the dendritic cell lineage 
Tracing of daughter cells of progenitors is a powerful tool to establish lineage 
relationships and can be used to classify various mononuclear phagocytes into 
DCs, monocytes and macrophages (Guilliams et al., 2014; Schraml and Reis e 
Sousa, 2014; Poltorak and Schraml, 2015). One method to establish a precursor-
product relationship is to sort the precursors, adoptively transfer them into a 
congenic host and retrieve and analyse the donor-derived cells at a defined time 
point after transfer. However, this method is not always feasible, as precursors tend 
to be rare cell populations and enough cells need to be sorted in order to retrieve 
donor cells from the host. Furthermore, it is not always clear when to analyse the 
hosts and if the wrong time point is chosen, certain products of progenitors may be 
missed. Finally, these types of experiments may require sublethal irradiation of the 
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host to ensure engraftment of donor cells and always involve intravenous injection 
of precursors, which may lead to results that are not reflective of the physiological 
behaviour of precursors.  
 
Alternatively, a genetic approach based on the Cre-loxP system can be taken to 
fate map precursors in vivo. In this case a transgenic mouse line expressing a 
constitutive or inducible Cre in the precursor of interest is crossed to a fluorescent 
reporter strain. Cre-mediated expression of the fluorescent protein is induced in the 
precursor and is inherited by all daughter cells. Analysis of the labelled cells then 
identifies precursor-derived cells.  
The only mouse model available to trace the dendritic cell lineage are Clec9a-Cre 
mice that express Cre recombinase in CDPs and preDCs (Schraml et al., 2013). 
When Clec9a-Cre mice are crossed to a ROSA26-LSL-YFP reporter line, DCs are 
labelled with YFP both in steady state and during inflammation (Schraml et al., 
2013). However, Clec9a-Cre mice are not perfect as lineage tracers, as CD8α-like 
DCs and pDCs also express DNGR-1 (or CLEC9A) and therefore will express YFP 
irrespective of precursor origin. Furthermore, the labelling penetrance is not 
complete, so some CDP- and preDC-derived cells do not express YFP (Schraml et 
al., 2013). Identification of genes whose expression is restricted to CDPs and/or 
preDCs should aid in the generation of Cre mouse lines that will overcome these 
limitations. Furthermore, the development of mice that express an inducible version 
of Cre recombinase specifically in CDPs and/or preDCs will allow for temporal 
control over the lineage tracing of DCs.  
1.3 Aims and objectives 
DCs comprise a heterogeneous group of innate immune cells, unified by a shared 
developmental origin, overlapping surface marker expression, morphology and 
functions. Many different subsets of DCs have been identified over the years, which 
can be stratified into pDCs and cDCs, the latter of which consists of the CD8α-like 
subgroup of DCs and CD11b-expressing DCs. Alternatively, cDCs can be 
separated into DCs resident in lymphoid tissues (resDCs) and DCs that populated 
peripheral tissues from where they migrate to LNs (migDCs). 
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The field of DC biology has greatly benefited from transgenic mouse models to 
genetically manipulate DCs. Examples are mice that lack transcription factors, 
growth factors or chemokines essential for DC development or function, mice in 
which DCs can be inducibly depleted, or mice that have their DCs labelled with 
fluorescent proteins. However, although these models have greatly contributed to 
our understanding of DC biology, there are still many open questions that await 
novel mouse models to be answered. 
 
In this thesis novel mouse models are presented to study DCs in vivo. All these 
mice target DC precursors via genetic editing of the Clec9a locus, thereby 
manipulating the DC lineage. Chapter 3 discusses the validation of a novel mouse 
model to inducibly deplete DCs in vivo via expression of DTR on DCs, and general 
limitations of this type of model to study DC biology. In Chapter 4 the generation 
and validation of a transgenic mouse engineered to constitutively lack DCs is 
presented. Finally, Chapter 5 discusses how DC precursors seed tissues by 
making use of novel mouse models and advanced microscopy techniques.  
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Chapter 2. Materials & Methods 
2.1 Mice 
2.1.1 Mouse strains used 
Clec9a-Cre (Schraml et al., 2013), ROSA26-LSL-iDTR (Buch et al., 2005), CD11c-
Cre (Caton, Smith-Raska and Reizis, 2007), CD11c-DTR (Jung et al., 2002), 
CD11c-DOG (Hochweller et al., 2008), Langerin-DTR (Kissenpfennig et al., 2005), 
CD19-Cre (Rickert, Roes and Rajewsky, 1997), DEREG (Lahl et al., 2007), 
ROSA26-YFP (Srinivas et al., 2001), ROSA26-mTmG (Muzumdar et al., 2007), 
ROSA26-dTomato (Madisen et al., 2010), ROSA26-confetti (Snippert et al., 2010), 
C57BL/6J and B6.SJL mice were bred at Cancer Research UK in specific 
pathogen-free conditions. All transgenic mouse lines were on a C57BL/6J 
background and were maintained by Neil Rogers. CD11c-DTR mice (Jung et al., 
2002) on a C57BL/6J background were a kind gift from Giovanna Lombardi, 
Langerin-DTR mice (Kissenpfennig et al., 2005) on a C57BL/6J background were a 
kind gift from Clare Bennett and ROSA26-CreERT2 mice (Ventura et al., 2007) on 
a C57BL/6J background were a kind gift from Dinis Calado. All were bred at 
Cancer Research UK in specific pathogen-free conditions. 
Six to Twenty week old mice were used in all experiments, unless otherwise 
specified. All animal experiments were performed in accordance with national and 
institutional guidelines for animal care and were approved by the London Research 
Institute Animal Ethics Committee and by the UK Home Office.  
2.1.2 Mouse generation 
Clec9a-DTA and Clec9a-CreERT2 mice were generated using a modified version 
of the targeting vector pFloxRI-C9a-EGFP that was used to generate Clec9a-GFP 
mice (Sancho et al., 2009). The DTA gene was amplified by PCR from a pMC1DT-
A vector provided by Axel Behrens using the primers 
AAAGTCGACATGGACCCTGATGATGTTGTTGATTCT and 
AAAGGATCCTTAGAGCTTTAAATCTCTGTAGGTA (bold nucleotides indicate SalI 
and BamHI restriction sites, underlined nucleotide indicates silent mutation to 
remove BamHI site) using the expand high fidelity PCR system (Roche). Both the 
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pFloxRI-C9a-EGFP vector and the DTA PCR product were digested with SalI and 
BamHI (NEB) and purified on agarose gel. The DTA gene was ligated into the cut 
vector using T4 ligase (NEB). The resulting pFloxRI-C9a-DTA vector was 
sequenced to confirm correct cloning, linearized using NotI (NEB) digestion and 
transfected into C57BL/6-derived embryonic stem (ES) cells (PRXB6N, 
Primogenix) by electroporation. Cells were selected in medium containing G418 
and gancyclovir and clones were picked after selection. Clones were screened for 
successful targeting by PCR with the PCR primers 
TCTGAGAGCTCCCTGGCGAAT and TCTCTTAGCCCTATTTCCACCACA using 
LA taq DNA polymerase (TaKaRa). Clones positive by PCR were additionally 
screened by Southern blot for correct targeting. Correctly targeted ES cell clones 
were injected into blastocyst donors, which were transferred back into pseudo-
pregnant females. Chimeric males were mated with C57BL/6J females. Germline 
transmission of correctly targeted clones was confirmed by PCR with the PCR 
primers AAAAGTTCCACTTTCTGGATGATGA and 
AGATCGCCTGACACGATTTCCTG for the targeted allele and 
AAAAGTTCCACTTTCTGGATGATGA and TCACTTACTCCTCCATGCTGACG for 
the WT allele using GoTAQ Flexi DNA polymerase system (Promega). 
 
The CreERT2 gene was amplified from a pCre-ERT2 vector (Indra et al., 1999) 
provided by Taija Makinen using the primers 
AAAGTCGACATGTCCAATTTACTGACCGTACACC and 
AAAGTTAACTCAAGCTGTGGCAGGGAAACC (bold nucleotides indicate SalI and 
HpaI restriction sites) with the expand high fidelity PCR system (Roche). The 
pFloxRI-C9a-EGFP vector was cut with BamHI (NEB), treated with large klenow 
fragment DNA polymerase I (NEB) to generate a blunt end and then cut with SalI 
(NEB). The CreERT2 PCR product was first cut with SalI (NEB) and subsequently 
with HPAI (NEB). The CreERT2 gene was ligated into the cut vector using T4 
ligase (NEB), using the SalI site and blunt end ligation. The resulting pFloxRI-C9a-
CreERT2 vector was sequenced to confirm correct cloning, linearized using NotI 
(NEB) digestion and transfected into C57BL/6-derived ES cells (PRXB6N, 
Primogenix) by electroporation. Cells were selected in medium containing G418 
and gancyclovir and clones were picked after selection. Clones were screened for 
successful targeting by PCR with the PCR primers 
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TCTGAGAGCTCCCTGGCGAAT and TCTCTTAGCCCTATTTCCACCACA using 
LA taq DNA polymerase (TaKaRa). Clones positive by PCR were additionally 
screened by southern blot for correct targeting. Correctly targeted ES cell clones 
were injected into blastocyst donors, which were transferred back into pseudo-
pregnant females. Chimeric males were mated with C57BL/6J females. Germline 
transmission of correctly targeted clones was confirmed by PCR with the PCR 
primers AAAAGTTCCACTTTCTGGATGATGA and CCCAGAAATGCCAGATTACG 
for the targeted allele and AAAAGTTCCACTTTCTGGATGATGA and 
TCACTTACTCCTCCATGCTGACG for the WT allele using GoTAQ Flexi DNA 
polymerase system (Promega). 
 
The neomycin cassette was removed by crossing Clec9a-DTA or Clec9a-CreERT2 
mice with PGK-Cre mice (Lallemand et al., 1998).  
2.1.3 DT treatment 
To deplete DCs in Clec9a+/CreROSAiDTR mice, mice were injected i.p. with 12ng/g 
body weight diphtheria toxin (Sigma Aldrich) in PBS and analysed 24 hours later. 
2.1.4 Tamoxifen treatment 
Tamoxifen diet (TAM400) was purchased from Harlan. Mice were changed from 
normal diet to TAM400 diet ad libitum for six days before analysis.  
Tamoxifen was purchased from Sigma Aldrich (T5648) and always protected from 
light. For oral gavage, tamoxifen was dissolved in 100% EtOH at 2g/ml and diluted 
50 times with peanut oil (Sigma Aldrich) to a final concentration of 40mg/ml. Mice 
were gavaged with 100µl of 40mg/ml tamoxifen for four consecutive days. 
Tamoxifen was dissolved in peanut oil at 80mg/ml for s.c. injections and 20mg/ml 
for i.p. injections by rotating the suspension at 56°C in a hybridisation oven, 
protected from light, until the tamoxifen was dissolved. Aliquots were kept at 4°C 
for the duration of the experiment and warmed to 37°C before injection. For s.c. 
injections mice were injected with 100µl on day 1, 3 and 5 (8mg tamoxifen per 
injection). For i.p. injections mice were injected daily with 5µl/g body weight (100µg 
tamoxifen/g body weight) for five consecutive days.  
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2.1.5 Influenza Infection 
Mice were anaesthetised via an i.p. injection of ketamine/xylasine. Mice were 
infected i.n. with 1x104 pfu influenza A HK31 (ATCC, strain A/Hong Kong/8/68) in 
PBS. Mice were monitored daily for weight loss and signs of infection. Mice were 
sacrificed at day 9 post infection. 
2.1.6 CFA/OVA immunisation 
CFA/OVA emulsion was prepared by sonicating equal volumes of 2mg/ml EndoFit 
Ovalbumin (Invivogen) in PBS with Complete Freund’s Adjuvant (Sigma Aldrich) 
until an emulsion was formed. The emulsion was tested by floating a drop on PBS 
and only used when the emulsion did not dissolve into the PBS. Mice were 
immunised s.c. draining to the inguinal lymph node with 50µl CFA/OVA emulsion 
(50µg OVA per injection). Mice were sacrificed at day 12 post infection. 
2.1.7 Mixed BM chimeras 
BM was isolated from femur, tibia and ilium. Bones were flushed with ice-cold 5% 
foetal calf serum in PBS, centrifuged for 4min/1400rpm/4°C and resuspended in 
2ml PBS. Cell suspensions were counted and adjusted to 1x107 cells/ml. For mixed 
BM chimeras BM from both donors was combined in a 1:1 ratio.  
Hosts were treated with 0.043% HCl (Sigma Aldrich) in their drinking water ad 
libitum, starting 7 days before irradiation and continuing up to 10 weeks after 
irradiation. Host mice were irradiated twice with 6.6 Gray, separated by 4 hours. 
Hosts were injected i.v. 24 hours after the last irradiation with 2x106 total BM donor 
cells.  
Peripheral blood was collected via tail vein bleed into heparinised tubes to assess 
reconstitution after a minimum of eight weeks after BM transfer.  
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2.2 Flow cytometry 
2.2.1 Cell isolation 
Inguinal lymph nodes were used for analysis of skin draining lymph nodes. Spleens, 
lymph nodes, thymus and Peyer’s patches were cut into small pieces and digested 
with Collagenase IV (200U/ml, Worthington) and DNase I (0.2mg/ml, Roche) in 
RPMI for 30 min at 37°C. Digested tissues were strained through a 70µm cell 
strainer (BD Bioscience) and washed with FACS buffer (3% foetal calf serum, 5mM 
EDTA, 0.02% sodium azide in PBS). For spleens, red blood cells were lysed with 
Red Blood Cell Lysis Buffer (2 min at RT; Sigma). For flow cytometry analysis cells 
were resuspended in FACS buffer. 
 
For small intestines (SI) Peyer’s patches and connective tissue were removed. 
Connective tissue was removed from colons. SI or colons were cut open 
longitudinally and rinsed with PBS. The tissue was cut in 0.5cm long pieces and 
incubated in 20ml of RMPI with 25mM HEPES, L-glutamine, Penicillin/Streptomycin, 
50µM β-mercaptoethanol, 5mM EDTA (all Gibco), 3% foetal calf serum and 
0.145mg/ml DL-dithiothreitol (Sigma) for 20min at 37°C with shaking. SI or colons 
were subsequently vortexed for 30s and strained through a fine mesh kitchen 
strainer. Pieces were washed three times in 10ml of RMPI with 25mM HEPES, L-
glutamine, Penicillin/Streptomycin, 50µM β-mercaptoethanol and 2mM EDTA (all 
Gibco), while vortexing in between each washing step to remove intraepithelial 
lymphocytes. SI or colon pieces were digested with Collagenase IV (200U/ml, 
Worthington) and DNase I (0.2mg/ml, Roche) in 10 ml RPMI medium for one hour 
at 37°C. Digested tissues were strained through a 70µm cell strainer (BD) and 
washed with FACS buffer. 
For the analysis of dermis and epidermis both ears were collected and split into 
dorsal and ventral halves. Split ears were then incubated for 1 hour at 37°C, while 
floating dermis-down on 2U/ml Dispase II (Roche) in PBS. Epidermis and dermis 
were subsequently separated and digested separately with Collagenase IV 
(200U/ml; Worthington) and DNase I (0.2mg/ml, Roche) in RPMI for 1 hour at 37°C. 
Digested tissues were strained through a 70µm cell strainer (BD) and washed with 
FACS buffer.  
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For the SI, colon, dermis and epidermis leukocytes were enriched by Percoll 
gradient centrifugation (GE Healthcare). 9 Parts Percoll were combined with 1 part 
10x PBS to obtain 100% Percoll. Cells were resuspended in 70% Percoll in PBS or 
HBSS, overlaid with 37% and 30% Percoll and centrifuged at room temperature for 
30min at 2000rpm without braking. Cells were collected at the 70/37% interface. 
2.2.2 Counting of cell suspensions 
10µl of a sample was combined with 5000 nominal 10µm latex beads (Beckman 
Coulter) and 5ng/ml propidium iodide in FACS buffer, in a total volume of 100µl. 
This sample was analysed on a BD FACS Calibur (BD Biosciences) and the cell 
number was calculated with the formula: cells acquired/beads acquired*50.  
 
2.2.3 MACS enrichment 
Single cell suspensions from one spleen were resuspended in 180µl MACS buffer 
(5% foetal calf serum, 2mM EDTA in PBS, degassed) and 20µl CD11c microbeads 
(Miltenyi Biotec) was added. Samples were incubated for 15min at 4°C, washed by 
adding 10ml MACS buffer and resuspended in 500µl MACS buffer.  
LS MACS columns (Miltenyi Biotec) were prepared by attaching them to the MACS 
magnet and rinsing with 3ml MACS buffer, after which the cell suspension was 
applied. The column was washed three times with 3ml MACS buffer. Columns were 
removed from the MACS magnet and CD11c+ cells were eluted with 5ml MACS 
buffer. 
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2.2.4 Antibodies for Flow Cytometry 
Target Fluorophore Clone Company Final 
concentration 
CD3ε APC 145-2C11 BD Bioscience 2µg/ml 
CD3ε FITC 145-2C11 BD Bioscience 5µg/ml 
CD3ε PE 145-2C11 BD Bioscience 2µg/ml 
CD4 FITC RM4-5 BD Bioscience 2.5µg/ml 
CD4 Pacific Blue RM4-5 Biolegend 1.25µg/ml 
CD8α eFluor 605nc 53-6.7 eBioscience 1:20 
CD8α BV605 53-6.7 Biolegend 10µg/ml 
CD8α FITC 53-6.7 BD Bioscience 5µg/ml 
CD8α Pacific Blue 53-6.7 Biolegend 1.25µg/ml 
CD11b AF700 M1/70 eBioscience 1µg/ml 
CD11b APC 
eFluor780 
M1/70 eBioscience 1µg/ml 
CD11b eFluor450 M1/70 eBioscience 1µg/ml 
CD11b eFluor 605nc M1/70 eBioscience 1:20 
CD11c  APC 
eFluor780 
N418 eBioscience 1µg/ml 
CD11c FITC HL3 BD Bioscience 2.5µg/ml 
CD11c PercpCy5.5 N418 Biolegend 1µg/ml 
CD16/32 
(Fc block) 
 2.4G2 BD Bioscience 2.5µg/ml 
CD19 PeCy7 1D3 eBioscience 1µg/ml 
CD19 V450 1D3 BD Bioscience 0.5µg/ml 
CD24 BV605 M1/69 BD Bioscience 10µg/ml 
CD24 eFluor 605nc M1/69 eBioscience 1:20 
CD24 FITC M1/69 BD Bioscience 5µg/ml 
CD45.1 eFluor 605nc A20 eBioscience 1:20 
CD45.1 FITC A20 BD Bioscience 2.5µg/ml 
CD45.1 PeCy7 A20 eBioscience 2µg/ml 
CD45.1 PercpCy5.5 A20 eBioscience 1µg/ml 
CD45.2 FITC 104 BD Bioscience 2.5µg/ml 
CD45.2 PeCy7 104 Biolegend 1µg/ml 
CD45R (B220) eFluor450 RA3-6B2 eBioscience 2µg/ml 
CD45R (B220) FITC RA3-6B2 BD Bioscience 1.25µg/ml 
CD45R (B220) PE RA3-6B2 BD Bioscience 0.5µg/ml 
CD64 AF647 X5-4/7.1 Biolegend 2µg/ml 
CD64 PE X5-4/7.1 Biolegend 1µg/ml 
CD103 APC 2E7 eBioscience 2µg/ml 
CD103 PE 2E7 eBioscience 1µg/ml 
CD103 PercpCy5.5 2E7 Biolegend 4µg/ml 
CD115 AF488 AFS98 eBioscience 1.67µg/ml 
CD115 Percp 
eFluor710 
AFS98 eBioscience 1µg/ml 
CD117 PeCy7 2B8 Biolegend 1µg/ml 
CD135 APC A2F10 Biolegend 2µg/ml 
CD172α APC P84 BD Bioscience 2µg/ml 
CD197 (CCR7) PE 4B12 eBioscience 4µg/ml 
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CD205 APC NLDC-145 Biolegend 1µg/ml 
CD207 
(Langerin) 
AF488 929F3.01 Dendritics 2.5µg/ml 
CD207 
(Langerin) 
AF647 929F3.01 Dendritics 2.5µg/ml 
CD326 (Ep-
CAM) 
AF647 G8.8 Biolegend 1.25µg/ml 
CD326 (Ep-
CAM) 
Percp 
eFluor710 
G8.8 eBioscience 1µg/ml 
DNGR-1 
(CLEC9A) 
PE 1F6 Biolegend 5µg/ml 
F4/80 AF647 C1:A3-1 Biolegend 2.5µg/ml 
hHB-EGF 
(DTR) 
biotinylated polyclonal R&D 2µg/ml 
I-A/I-E (MHCII) APC eFluor-
780 
M5/114.15.2 eBioscience 0.4µg/ml 
I-A/I-E (MHCII) AF647 M5/114.15.2 Biolegend 0.5µg/ml 
I-A/I-E (MHCII) AF700 M5/114.15.2 eBioscience 1µg/ml 
IRF8 APC V3GYWCH eBioscience 2µg/ml 
Ly6c/Ly6g  
(Gr-1) 
FITC RB-8C5 BD Bioscience 0.5µg/ml 
Ly6c/Ly6g  
(Gr-1) 
PercpCy5.5 RB-8C5 Biolegend 2µg/ml 
Ly6g AF700 RB-8C5 eBioscience 0.67µg/ml 
NK1.1 APC PK136 eBioscience 2µg/ml 
NK1.1 Pacific Blue PK136 Biolegend 2.5µg/ml 
SiglecH AF647 440c eBioscience 4µg/ml 
SiglecH PE 440c eBioscience 2µg/ml 
TER-119 Pacific Blue TER-119 Biolegend 5µg/ml 
Rat IgG1 
isotype control 
PE  BD Bioscience  
Table 2 Antibodies used for flow cytometry 
Abbreviations: AF (Alexa Fluor), APC (Allophycocyanin), BV (Brilliant Violet), Cy 
(Cyanide), FITC (Fluorescein isothiocyanate), nc (Nanocrystal), PE 
(Phycoerythrin), PerCp (Peridinin-chlorophyll-protein) 
Final concentrations are given in µg/ml when available. Otherwise the dilution is 
stated. 
 
When staining for precursors in the BM, the following lineage cocktail was used: 
CD45R (B220) eFluor450, CD4 Pacific Blue, CD8α Pacific Blue, CD11b eFluor450, 
NK1.1 Pacific Blue, Ter119 Pacific Blue and CD19 V450.  
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2.2.5 Flow Cytometry analysis 
For extracellular staining up to 4 million cells were blocked with anti-CD16/32 in 
FACS buffer (3% foetal calf serum, 5mM EDTA, 0.02% sodium azide in PBS) for 
10min at 4°C and then stained for 20min at 4°C with the staining cocktail in FACS 
buffer in the presence of anti-CD16/32. Samples were washed three times with 
FACS buffer. For biotinylated antibodies, the extracellular antibody staining was 
followed by a 20min staining with streptavidin-PE diluted 1:1200 in FACS buffer 
(BD Biosciences), after which samples were washed three times with FACS buffer. 
 
Peripheral blood samples were fixed and red blood cells lysed with BD FACS lysing 
solution (BD Biosciences) for 5-10min at RT after extracellular staining. 
 
PE-SIINFEKL and PE-SSLENFRAYV (both Proimmune) pentamers were used for 
CFA/OVA immunisation and influenza infection, respectively. One million cells were 
stained with 7.5µl pentamer in 25µl FACS buffer (without sodium azide) for 15min 
at RT. Samples were washed three times with FACS buffer, after which the 
extracellular staining protocol was followed.  
Dapi was used to exclude dead cells, except for when cells were fixed and/or 
stained intracellularly with anti-CD207 or anti-IRF8. In the latter case dead cells 
were excluded by live/dead fixable violet dye (Invitrogen). For intracellular staining, 
cells were stained for surface markers, followed by staining with the fixable 
live/dead dye. fFxation and intracellular staining were performed with FIX&PERM 
(ADG) according to the manufacturer’s protocol. 
Samples were collected on a LSR Fortessa flow cytometer (BD Biosciences) and 
analysed using FlowJo 9 software (TreeStar Inc.). Gating strategies to identify DCs 
in lymphoid organs, non-lymphoid tissues and DC progenitors in the BM are shown 
in Figure 2.1, Figure 2.2 and Figure 2.3 respectively.  
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Figure 2.1 Flow cytometry gating strategy to identify DCs in lymphoid organs 
The gating strategies to identify DCs in spleen (A), thymus (B), sdLN (C) and 
mesLN (D) are shown. Numbers indicate gate frequencies. 
 
Chapter 2 Materials and Methods 
 
86 
 
ep
id
er
m
is
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
CD64-
Live CD45+
0 102 103 104 105
0
102
103
104
105
MHCII+
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
MHCII
C
D
11
c
C
D
11
c
CD64
E
pC
A
M
CD103
CD64- CD64+
CD103+
dn
LC
LC
de
rm
is
CD64-A
29.4
99.6
98.7
35.8
29.267.8
5.1
87.0
6.9
B
sm
al
l i
nt
es
tin
e
P
P
C
D
10
3
CD11b
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
CD11c+MHCII+ CD64-
CD64- CD64+
CD103+ CD103+
CD11b+
CD11b+
0 102 103 104 105
0
102
103
104
105
Live CD45+
DC
MHCII
C
D
11
c
C
D
11
c
CD64
27.5 41.0
57.9
9.5
6.5
81.0
0.79
 
Figure 2.2 Flow cytometry gating strategy to identify DCs in non-lymphoid 
tissues 
The gating strategies to identify DCs in epidermis and dermis (A) and Peyer’s 
patches (PP) and small intestine (B) are shown. Numbers indicate gate 
frequencies. 
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Figure 2.3 Flow cytometry gating strategy to identify DC progenitors in the BM 
The gating strategy to identify DC progenitors the BM is shown. Numbers indicate 
gate frequencies and ‘lin’ denotes lineage cocktail (CD45R (B220), CD4, CD8α, 
CD11b, NK1.1, Ter119 and CD19). 
 
2.3 Microscopy 
2.3.1 Antibodies used for microscopy 
Target Fluorophore Clone Company Final 
concentration 
CD3ε FITC 145-2C11 BD 
Bioscience 
4µg/ml 
CD11b AF594 M1/70 eBioscience 10µg/ml 
CD31 AF647 MEC13.3 Biolegend 0.8µg/ml 
CD45R (B220) eFluor450 RA3-6B2 eBioscience 2µg/ml 
CD324 (E-
cadherin) 
AF594 DECMA-1 Biolegend 1µg/ml 
CD326 (EpCAM) BV421 G8.8 Biolegend 0.5µg/ml 
CCL21 
 
Goat anti-rabbit 
 - 
 
AF555 
Polyclonal 
rabbit 
polyclonal 
Peprotech 
 
Invitrogen 
1:100 
 
10µg/ml 
ER-TR7 AF488 Sc-73355 Santa Cruz 0.25µg/ml 
I-A/I-E (MHCII) AF647 M5/114.15.2 Biolegend 2µg/ml 
I-A/I-E (MHCII) AF700 M5/114.15.2 eBioscience 2µg/ml 
IRF8 APC V3GYWCH eBioscience 1µg/ml 
MECA79 AF488 MECA-79 eBioscience 10µg/ml 
Table 3 Antibodies used for microscopy	  
Abbreviations: AF (Alexa Fluor), APC (Allophycocyanin), BV (Brilliant Violet) 
Final concentrations are given in µg/ml when available. Otherwise the dilution is 
stated. 
 
Chapter 2 Materials and Methods 
 
88 
 
2.3.2 Confocal microscopy 
Inguinal lymph nodes were frozen in OCT (Tissue-TEK) and 10µm sections were 
cut on a cryostat. Sections were air dried, fixed for 10min in 2% paraformaldehyde 
(Electron Microscopy Sciences) and washed in PBS. Blocking was performed for 
30min at room temperature in 10% goat serum (Sigma) in PBS. Sections were 
stained for 1 hour at room temperature with the indicated antibodies in blocking 
buffer. Slides were washed in PBS and mounted in Fluoromount-G (Southern 
Biotech). Images were acquired on a LSM710 upright confocal microscope (Zeiss) 
using a 10x dry objective and analysed with Bitplane Imaris software. Images are 
maximum intensity projections of tile scans and z-stacks. 
 
2.3.3 Fixation with PLP and staining of sections for histo-cytometry 
Desired tissues were dissected and SI and colons were flushed with ice-cold PBS. 
To preserve fluorescence, tissues were treated according to the PLP protocol 
(Bajénoff, Granjeaud and Guerder, 2003; Gerner et al., 2012). All tissues except SI 
and colons were fixed overnight at 4°C in 1% paraformaldehyde (Electron 
Microscopy Sciences), 75mM L-lysine (Sigma) and 2.12mg/ml NaIO4 (Sigma) in 
0.1M P-buffer (phosphate buffer, pH7.4). SI and colon were fixed for 2-3 hours at 
4°C in the paraformaldehyde-containing buffer, after which they were cut open 
longitudinally and rolled into Swiss rolls. Rolls were secured with a pin and placed 
back in the paraformaldehyde-containing buffer to fix overnight at 4°C. 
Tissues were washed in 0.1M P-buffer, transferred to 30% w/v sucrose (Fisher 
Scientific) in 0.1M P-buffer and incubated overnight at 4°C. SI and colon rolls were 
transferred into OCT (Tissue-TEK) and incubated overnight at room temperature 
with gentle shaking. Tissues were frozen in OCT and cut on a cryostat.  
Tissue sections were rehydrated for 10min in 0.1M Tris pH7.4 and either mounted 
in Vectashield hard set (Vector labs) or stained with antibodies. For staining, slides 
were blocked for 30min at RT in 1% foetal calf serum, 0.3% Triton X-100 (Sigma) 
and 1% mouse serum (Sigma) in 0.1M Tris pH7.4. Primary antibodies were diluted 
in the blocking buffer and sections were incubated 16-48h at 4°C in a humidified 
chamber. Sections were washed in 0.1M Tris pH7.4 and mounted in Mowiol (5g 
Mowiol (Merck), 12ml H2O, 12g glycerol and 24ml of 200mM Tris pH8.5). 
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2.3.4 Histo-cytometry 
The histo-cytometry protocol presented here was developed in collaboration with 
Ronald Germain and Michael Gerner (National Institutes of Health). Stained and 
mounted tissue sections were analysed on a LSM880 invert confocal microscope 
with a 25x oil objective (Zeiss). Lasers 405nm, 458nm, 514nm, 561nm and 633nm 
were used to excite the flourophores with a 458/514/561/633 dichroic and a plate 
for the 405nm laser (to attenuate the laser power reaching the sample). Lambda 
mode scanning (detecting 410-687nm) was used to detect BV421, CFP, GFP, YFP, 
RFP, AF594 and AF647 or APC. AF700 was detected in a separate channel 
collecting 686-735nm. For all images tile scans and z-stacks were acquired and for 
the z-stack the optimal step size for a pinhole of 1 airy unit was chosen. Images 
were taken at 1024x1024 voxel density with a line averaging of 8. The fluorophores 
were unmixed into separate channels using the unmixing algorithm of the Zen 
software (Zeiss). Single-stained slides were used to obtain the reference spectra of 
the different fluorophores. Images are maximum intensity projections of tile scans 
and z-stacks. 
Images were analysed using Bitplane Imaris software, as previously described 
(Gerner et al., 2012). 3D volumetric surface objects were created on the confetti 
channels using the surface rendering module in Imaris. Surface parameters 
(intensities of separate channels and location) were exported to Excel (Microsoft) 
as comma-separated files, which could then be imported into FlowJo 10 (TreeStar 
Inc.) to perform gating. 
2.4 Miscellaneous 
2.4.1 IFNγ  ELISA 
5x105 Cells/well were plated in round-bottom 96-well tissue culture plates in 200µl 
R10 medium with 10µg/ml CD4 peptides or 5µg/ml CD8 peptides (Table 4). 
Cultures were incubated overnight in a 37°C 5% CO2 incubator. The next day 
cultures were centrifuged 1400rpm/4°C/4min and supernatants were transferred to 
a new 96-well tissue culture plate. Supernatants were frozen at -20°C until analysis.  
IFNγ was detected using the BD OptEIA Set Mouse IFNγ (BD Biosciences). NUNC 
immuno Maxisorb 96-well plates (Thermo Scientific) were coated with the capture 
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antibody diluted 1:250 in 100µl coating buffer (0.1 M Sodium Carbonate, 7.13g/l 
NaHCO , 1.59g/l NaCO ; pH9.5) overnight at 4°C. Plates were washed 5 times with 
ELISA wash (0.05% Tween20 in PBS) and blocked in 10% foetal calf serum in PBS 
for 1 hour at room temperature. Plates were subsequently washed 5 times with 
ELISA wash, after which 50µl supernatant or 5µl supernatant in 45µl R10 
medium was added. A standard curve of recombinant IFNγ was also included. 
Samples were incubated for 2 hours at room temperature. Plates were washed 5 
times with ELISA wash and 100µl detection antibody diluted 1:250 and streptavidin-
horse radish peroxidase diluted 1:250 in 10% foetal calf serum in PBS was added 
to each well. Plates were incubated for 1 hour at room temperature. Plates were 
subsequently washed 10 times with ELISA wash and 50µl tetramethylbenzidine 
/hydrogen peroxide substrate solution (BD Biosciences) was added to each well. 
Plates were incubated for 30min at room temperature in the dark. 50µl Stop 
solution was added to each well and absorbance was read at 450nm on a 
Molecular Devices microplate reader. 
 
Name CD4/CD8 Peptide sequence 
HA211-225 CD4 YVQASGRVTVSTRRS 
NP276-290 CD4 LPACVYGPAVASGYD 
PA224-233 CD8 SSLENFRAYV 
NP366-374 CD8 ASNENMETM 
PB1703-711 CD8 SSYRRVPGI 
NS2114-121 CD8 RTFSFQLI 
Table 4 Peptides used for restimulation  
Peptides were generated by the LRI Peptide Chemistry Core Facility. 
 
2.4.2 Flt3L BMDC culture 
Both femurs and tibiae from one mouse were collected and flushed with R10 
medium (10% foetal calf serum, L-glutamine, Penicillin/Streptomycin in RPMI). Red 
blood cells were lysed with Red Blood Cell Lysis Buffer for 1min on ice (Sigma 
Aldrich). 20ml R10 was added and cells were centrifuged 1400rpm/4°C/4min. The 
pellet was resuspended in 24ml R10 with 150ng/ml Flt3L (R&D Systems) and cells 
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were seeded in a 6-well plate with 4ml cell suspension/well or in 96-well flat bottom 
plates with 250µl/well. Cells were incubated for 9 days at 37°C and 10% CO2. 
For 4OH-tamoxifen (Sigma Aldrich, H7904) treatment, the 4OH-tamoxifen was 
dissolved in 100% ethanol at 10mg/ml (25.8mM). 1µM 4OH-tamoxifen diluted in 
medium was added to cells in a 96-well plate at day 0 and cells were analysed at 
day 9. 
2.4.3 Transwell Assay 
The transwell assay was performed in 24-well plates with 5.0µm Pore 
Polycarbonate Membrane Inserts (Corning) with RPMI medium containing 0.5% 
BSA and 10mM Hepes. Recombinant CCL21 (R&D) was diluted in this medium to 
the appropriate concentration and 600µl was placed in each well. Single cell 
suspensions from pooled brachial, axillary and inguinal LNs were prepared, 
counted and resuspended in RPMI medium containing 0.5% BSA and 10mM 
Hepes, to a final concentration of 1*107 cells/ml. Inserts were placed in the wells 
and 100µl of the cell suspension was placed in the insert. Plates were incubated for 
3-4h at 37°C and 10% CO2, after which cells from the well and insert were 
collected, stained for CD11c and MHCII and analysed by flow cytometry. The 
frequency of migrated cells was calculated by dividing cells in the well by cells in 
well plus insert. 
2.4.4 Southern Blot 
Genomic DNA was isolated by incubating about 5mm of tail in 700µl tail buffer 
(50mM Tris pH8.0, 100mM EDTA, 100mM NaCl ,1% SDS and 0.34mg/ml 
Proteinase K (Qiagen)) overnight at 55°C. Non-dissolved material was removed by 
centrifugation at 13000rpm for 10s. 300µl 5M NaCl was added to the supernatant 
and samples were centrifuged at 13000rpm for 10min. 800µl Supernatant was 
collected and 530µl isopropanol was added. Samples were centrifuged at 
13000rpm for 10min and supernatant was discarded. 1ml 70% EtOH was added 
and samples were centrifuged at 13000rpm for 5min. Supernatant was discarded 
and the pellet was air-dried. The DNA was dissolved in 200µl H2O and quantified 
on a Nanodrop (Thermo Scientific). 
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10µg of DNA per Southern Blot was digested overnight at 37°C with BamHI 
enzyme (NEB) and DNA was cleaned via phenol-chloroform extraction. 
 
The digoxigenin (DIG) labelling system (Roche) was used for the southern blot 
analysis. Southern blot probes against the ‘5 homology arm and Neo cassette were 
DIG-labelled with the PCR DIG probe synthesis kit. Both probes were amplified 
from a pcDNA plasmid containing the 5’ probe sequence. The primers to amplify 
the 5’ probe are AAGTCTGACTTAGAAACCTCATT and 
AGCCTGGGCTTACAGCAT, and for the neo probe 
GATTGAACAAGATGGATTGCACGC and AATATCACGGGTAGCCAACG. 
 
BamHI-digested DNA was run on a 0.8% agarose gel at 60V. The gel was briefly 
stained with ethidium bromide (Sigma) to check the loading. The gel was next 
incubated in hydrolysis buffer (0.25M HCl) for about 2 hours, then in denaturation 
buffer (1.5M NaOH, 0.5M NaCl) for 30min and finally in neutralisation buffer (1.5M 
NaCl, 0.5M Tris pH7.2, 10mM EDTA), all at room temperature. DNA was 
transferred to a nylon membrane overnight at room temperature in a Schleicher 
and Schuell transfer turboblotter. DNA was UV-cross-linked (1200 µJoules x100) to 
the membrane. 
The membrane was prehybridised with DIG easy hyb solution (Roche) for 30min at 
42°C in a hybridisation oven. DIG-labelled probes were denatured by boiling for 
5min followed by rapid cooling on ice. The denatured probe was diluted in DIG 
easy hyb solution (2µl probe per 1ml) and the membrane was incubated in this 
solution overnight at 42°C. 
The membrane was washed twice for 5min at room temperature with wash buffer I 
(2x SSC 0.1% SDS,), twice with wash buffer II ( 0.2x SSC, 0.1% SDS) for 15min at 
68°C and once with wash buffer III (0.1M maleic acid pH7.5, 0.15M NaCl and 0.3% 
Tween 20 v/v) for 3min at room temperature. 
The membrane was equilibrated by incubating for 2min in detection buffer (0.1M 
Tris pH9.5, 0.1M NaCl). The membrane was then transferred to a hybridisation bag 
and 10 drops of CSPD (Roche) were added before the bag was sealed. The 
membrane was incubated for 5min at room temperature and transferred to a new 
hybridisation bag, incubated for 10min at 37°C and exposed to a film. 
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2.4.5 Semi-quantitative RT-PCR 
Cells were pelleted, resuspended in 1mL TRIzol (Invitrogen) and incubated for 
5min at room temperature. 400µl Chloroform was added (Fisher Scientific), 
samples were vortexed for 15s and incubated for 2min at RT. Samples were 
centrifuged for 12500rpm/4°C/10min and the aqueous phase was transferred to a 
new tube. 800µl 100% isopropanol (Fisher Scientific) was added and samples were 
incubated for 15min at room temperature. Samples were centrifuged for 
12500rpm/4°C/15min and the supernatant was removed. Samples were washed 
with 70% ethanol (Fisher Scientific) and centrifuged for 12500rpm/4°C/5min. 
Supernatant was removed and the RNA pellet was air-dried, before being 
resuspended in 20µl H2O. Samples were incubated at 55°C for 10-15min to 
dissolve the RNA and quantified by Nanodrop (Thermo Scientific). 
Any residual DNA was removed by DNA-free DNase Treatment and Removal Kit 
(Ambion). RNA was diluted to 10µg/44µl and 5µl buffer from the kit and 1µl DNase I 
were added. Samples were incubated for 30min at 37°C, after which 1µl DNase I 
was added and the samples were incubated for another 30min at 37°C. 10µl 
Inactivation buffer from the kit was added and the samples were incubated for 3min 
at room temperature while vortexing regularly. Samples were centrifuged for 
10000rpm/4°C/5min and the supernatant containing the RNA was transferred to a 
new tube.  
cDNA was generated using SuperScript II reverse transcriptase (Invitrogen). 7µl of 
DNA-free RNA was combined with 1µl oligo(dT) 12-18 primer (Invitrogen) and 1.5µl 
dNTPs PCR nucleotide mix (Promega) and incubated for 5min at 65°C followed by 
5min on ice. 4µl 5x FS buffer, 2µl dithiothreitol, 1µl reverse transcriptase (all from 
kit) and 3.5µl H2O were added. The sample was incubated for 10min at 25°C, 1h at 
42°C and 15min at 70°C.  
For the semi-quantitative RT-PCR, a neat, 10x diluted and 100x diluted sample 
were amplified with the indicated PCR primers using GoTaq Green Master Mix 
(Promega). PCR reactions were run in a total volume of 20µl and PCR primer 
concentrations of 0.125µM. The PCR programme was set to run for 3min at 95°C, 
perform 35 cycles of (30s at 95°C, 30s at 60°C, 40s at 72°C) and 10min at 72°C. 
8µl Of the PCR product was run on a 2% agarose gel along with 5µl of 1kb plus 
DNA ladder (Invitrogen). 
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Target Forward primer Reverse primer Product 
hprt TGAAGAGCTACTGTAAT
GATCAGTCAAC 
AGCAAGCTTGCAACCTTAAC
CA 
186bp 
dta CGTACCACGGGACTAA
ACCTGGT 
TGCGAGAACCTTCGTCAGTC
C 
224bp 
Creert2 GGTGCGCCTGCTGGAA
GATG 
TCCACAAAGCCTGGCACCCT
CT 
297bp 
Table 5 Primers used for semi-quantitative RT-PCR 
2.4.6 Statistical analyses 
Statistical analyses were performed in Prism 6 (Graphpad). Results are shown as 
mean ± standard deviation. Unpaired student t tests were performed to calculate p-
values, unless otherwise stated. 
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Chapter 3. A Novel Mouse Model to Inducibly 
Deplete Dendritic Cells 
3.1 Introduction 
Mouse models to deplete DCs have proven useful tools to elucidate DC function in 
vivo. The first such model exploited CD11c expression to drive expression of 
simian DTR fused to GFP in DCs (Jung et al., 2002). CD11c is commonly used as 
marker for DCs, but is also expressed by some macrophages, plasmablasts, Ly-
6Clow monocytes, activated T cells and NK cells, resulting in DTR expression and 
DT-mediated depletion of these cell types (Jung et al., 2002; Probst, Tschannen, et 
al., 2005; Hochweller et al., 2008). More recently, improved models have been 
developed in which DTR expresison is more highly restricted to DCs (CD11c-DOG 
and zDC-DTR mice) (Hochweller et al., 2008; Meredith, Liu, Darrasse-Jeze, et al., 
2012) or is expressed selectively in specific DC subsets (Langerin-DTR, BDCA2-
DTR, SiglecH-DTR, CD205-DTR and Clec9a-DTR mice) (Bennett et al., 2005; 
Kissenpfennig et al., 2005; Swiecki et al., 2010; Takagi et al., 2011; Fukaya et al., 
2012; Piva et al., 2012). All these models allow for successful DT-mediated 
ablation of the target DC populations and have been instrumental in advancing DC 
research, despite suffering from limitations, predominantly due to misexpression of 
DTR, or side effects such as neutrophilia following DT-mediated DC ablation (Tittel 
et al., 2012; van Blijswijk, Schraml and Reis e Sousa, 2013; Jiao et al., 2014). 
Nevertheless, no immune abnormalities have been reported in any models 
expressing DTR on DCs in the absence of DT treatment, despite the fact that DTR, 
being an EGF family member, might potentially be able to engage murine EGF 
receptors. 
 
DNGR-1 (also known as CLEC9A) is specifically expressed on CDPs and preDCs 
and as a consequence, mice expressing Cre recombinase under the control of the 
Clec9a locus can be used to fate map those precursors in vivo when crossed to a 
ROSA26-YFP reporter line (Schraml et al., 2013). In Clec9a+/CreROSAYFP mice YFP 
expression is largely restricted to DCs, even under inflammatory conditions. 
Clec9a+/CreROSAYFP mice can therefore be used to genetically trace the DC lineage 
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in vivo. Unfortunately, penetrance of YFP labelling is not complete in heterozygous 
Clec9a-Cre mice, possibly due to the rapid cycling of DC precursors. Therefore, 
only roughly half of the CD11b+ DCs are labelled in Clec9a+/CreROSAYFP mice. 
Labelling of CD8α-like DCs is nearly complete, as these DC subsets also express 
DNGR-1, and consequently Cre, as differentiated cells.  
To generate DT-sensitive DCs in vivo, Clec9a-Cre mice (Schraml et al., 2013) were 
crossed to a ROSA26-iDTR strain (Buch et al., 2005) to generate 
Clec9a+/CreROSAiDTR mice that express DTR on DCs . All mice used for 
experiments were heterozygous for Cre recombinase and, therefore, DNGR-1 
sufficient, unless otherwise stated. No differences were observed between mice 
harbouring either one or two copies of DTR and therefore both were combined in 
experiments shown in this chapter. 
3.2 DT injection efficiently depletes DCs but no other cells in 
spleens of Clec9a+/CreROSAiDTR mice 
Clec9a+/CreROSAiDTR mice were first validated for DTR expression specifically on 
DCs and efficient depletion of DCs upon DT injection. Flow cytometry analysis 
using an antibody that recognises DTR revealed that in the spleen of 
Clec9a+/CreROSAiDTR animals 93±1% of CD8α+ DCs and 59±5% of CD11b+ DCs 
expressed DTR (Figure 3.1A). The fact that circa 40% of CD11b+ splenic DCs were 
negative for DTR expression is in line with the previously observed incomplete 
penetrance of Cre activity in heterozygous Clec9a-Cre mice crossed to ROSA26-
LSL-YFP mice (Schraml et al., 2013). In line with the observed DTR expression, 
virtually all splenic CD8α+ DCs and most CD11b+ DCs were depleted 24 hours 
post-treatment when Clec9a+/CreROSAiDTR mice were injected i.p. with one dose of 
DT (Figure 3.1B,C). In contrast, DT treatment did not have any effect on CD8α+ 
DCs or CD11b+ DCs in Clec9a+/+ROSAiDTR control mice (Figure 3.1C). 
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Figure 3.1 Efficient DC depletion in spleens of DT-injected Clec9a+/CreROSAiDTR 
mice 
(A) CD8α+ DCs (CD11c+ MHCII+ CD8α+) and CD11b+ DCs (CD11c+ MHCII+ 
CD11b+) in spleen were stained with a polyclonal anti-DTR antibody and analysed 
by flow cytometry. Each plot is representative of at least 6 mice per group. (B-C) 
Mice were injected i.p. with DT or PBS and sacrificed 24h later. (B) Representative 
plots of spleen for PBS and DT treated Clec9a+/CreROSAiDTR mice (gated on live, 
autofluorescence- cells). Frequency of gated population is shown. (C) Frequency of 
CD8α+ DCs and CD11b+ DCs in spleen of PBS- and DT-treated control and 
Clec9a+/CreROSAiDTR mice is shown. A one-way ANOVA with a Tukey’s multiple 
comparisons post-test was performed to calculate p-values. Ns: non significant, 
****: p≤0.0001. This experiment was performed twice with 4-7 mice per group. One 
representative experiment is shown. 
 
One of the limitations that many of the current mouse models to inducibly deplete 
DCs suffer from, is the emergence of neutrophilia and monocytosis upon DT 
injection. In light of these observations, Clec9a+/CreROSAiDTR mice were assessed 
for increased neutrophil and monocyte frequencies upon DT injection. As expected, 
neutrophils and monocytes did not express DTR in Clec9a+/CreROSAiDTR mice 
(Figure 3.2A). Notably, DC depletion was not accompanied by neutrophilia and 
monocytosis 24 hours after DT administration (Figure 3.2B), in contrast to depletion 
in other models such as CD11c-DOG mice and CD11c-DTR mice. 
Clec9a+/CreROSAiDTR mice were not tested for the presence of a ‘late’ (72h after DT 
injection and onwards) wave of neutrophilia and monocytosis and therefore at 
present it is unknown if Clec9a+/CreROSAiDTR mice exhibit increased granulopoiesis 
upon DC depletion. 
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Figure 3.2 Clec9a+/CreROSAiDTR mice do not show neutrophilia or monocytosis 
upon DT injection 
(A) Monocytes (CD11b+ Ly6c+ Ly6g-) and neutrophils (CD11b+ Ly6g+) in spleen 
were stained with a polyclonal anti-DTR antibody and analysed by flow cytometry. 
Each plot is representative of at least 6 mice per group. (B) Mice were injected i.p. 
with DT or PBS and sacrificed 24h later. Frequency of monocytes (mono) and 
neutrophils (neutro) in spleen of PBS- and DT-treated control and 
Clec9a+/CreROSAiDTR mice is shown. A one-way ANOVA with a Tukey’s multiple 
comparisons post-test was performed to calculate p-values. Ns: non significant. 
This experiment was performed twice with 4-7 mice per group. One representative 
experiment is shown. 
 
To interrogate if deletion is restricted to DCs in Clec9a+/CreROSAiDTR mice, other 
immune cell populations in the spleens of these mice were examined. As shown in 
Figure 3.3A, B cells, T cells, NK cells, NKT cells and red pulp macrophages did not 
express DTR in Clec9a+/CreROSAiDTR mice and these cell populations were not 
affected 24 hour after DT injection of Clec9a+/CreROSAiDTR mice (Figure 3.3B). 
 
In summary, when Clec9a+/CreROSAiDTR mice were injected with DT, virtually all 
splenic CD8α+ DCs and most CD11b+ DCs were depleted 24 hours post-treatment 
while other immune cell populations in the spleen were spared. Notably, DT-
mediated DC depletion in this strain was not accompanied by neutrophilia and 
monocytosis, at least at this time point, in contrast to depletion in other models 
such as CD11c-DOG mice and CD11c-DTR mice. Therefore, Clec9a+/CreROSAiDTR 
mice can be used to successfully and specifically deplete DCs in the spleen using 
DT with minimal side effects caused by DT treatment. 
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Figure 3.3 Other immune cells are not affected in the spleen of DT-injected 
Clec9a+/CreROSAiDTR mice 
(A) B cells (MHCII+ CD11c-), T cells (CD3+ NK1.1- MHCII-), NK cells (CD3- NK1.1+ 
MHCII-), NKT cells (CD3+ NK1.1+ MHCII-) and red pulp macrophages (F4/80+ 
autofluorescent) in spleen were stained with a polyclonal anti-DTR antibody and 
analysed by flow cytometry. Each plot is representative of at least 6 mice per 
group. (B) Mice were injected with DT or PBS and sacrificed 24h later. B cells, T 
cells, NK cells, NKT cells and red pulp macrophages in spleen of PBS- and DT-
treated control and Clec9a+/CreROSAiDTR mice were identified by flow cytometry. 
Frequencies of cell populations are shown. A one-way ANOVA with a Tukey’s 
multiple comparisons post-test was performed to calculate p-values. Ns: non 
significant. This experiment was performed twice with 4-7 mice per group. One 
representative experiment is shown. 
 
3.3 LNs of Clec9a+/CreROSAiDTR mice show hypocellularity and 
reduced frequencies of DCs 
As expected, DTR was also expressed by both resDCs and migDCs in sdLNs of 
Clec9a+/CreROSAiDTR mice, but not by LCs (Figure 3.4A), which do not originate 
from DC precursors and were also not labelled in Clec9a+/CreROSAYFP mice 
(Schraml et al., 2013). The incomplete penetrance of DTR expression was also in 
line with previous findings in Clec9a+/CreROSAYFP mice (Schraml et al., 2013).  
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In accordance with DTR expression on resDCs, these cells were depleted in sdLNs 
upon DT injection (Figure 3.4B). However, when analysing sdLNs, it was noticed 
that both resDCs and migDCs were present at reduced frequency in PBS-treated 
Clec9a+/CreROSAiDTR mice compared to PBS-treated genetic control mice (Figure 
3.4B). 
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Figure 3.4 sdLNs of PBS-injected Clec9a+/CreROSAiDTR mice show a reduction in 
DCs 
(A) resDCs (CD11c+ MHCIIint), migDCs (CD11c+ MHCIIhi) and LC (CD11c+ MHCIIhi 
CD207+ CD103-) in sdLNs were stained with polyclonal anti-DTR antibody and 
analysed by flow cytometry. Each plot is representative of at least 6 mice per 
group. (B) Mice were injected with DT or PBS and sacrificed 24h later. ResDCs 
and migDCs in sdLNs of PBS- and DT-treated control and Clec9a+/CreROSAiDTR 
mice were identified by flow cytometry and DC subsets as percentage of live 
leukocytes are plotted. A one-way ANOVA with a Tukey’s multiple comparisons 
post-test was performed to calculate p-values. Ns: non significant, *: p≤0.05, **: 
p≤0.01, ***: p≤0.001. This experiment was performed twice with 4-7 mice per 
group. One representative experiment is shown. 
 
To follow-up on this unexpected observation, LNs, spleens and thymi of untreated 
Clec9a+/CreROSAiDTR mice were analysed in greater detail. Untreated 
Clec9a+/CreROSAiDTR mice indeed displayed a marked reduction in frequency of 
both resDCs and migDCs in sdLNs when compared to Cre-negative controls 
(Figure 3.5AB), confirming above-mentioned findings in PBS-treated 
Clec9a+/CreROSAiDTR and control mice. Both CD8α+ and CD11b+ resDC subsets 
and all migDC subsets (LC, CD103+ migDCs and DN migDCs) were reduced in 
frequency in Clec9a+/CreROSAiDTR mice (Figure 3.5B). A particularly intriguing 
observation was the reduced frequency of LCs, as these cells do not come from a 
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DC precursor and did not express DTR (Figure 3.4A). This result suggests that 
DTR does not merely act in a cell autonomous manner, but also exerts effects on 
DTR-negative cells.  
A similar decrease in frequency of resDCs and migDC as in sdLNs of 
Clec9a+/CreROSAiDTR mice was observed in mesLNs (Figure 3.5C). In the mesLNs 
both CD8α+ and CD11b+ resDC subsets and all migDC subsets were reduced. In 
contrast, CD8α+ and CD11b+ DC frequency in the spleen and DC frequency in the 
thymus were identical between Clec9a+/CreROSAiDTR mice and Cre-negative 
controls (Figure 3.5D). Together, these observations suggest that only lymphoid 
organs with an afferent lymph supply and, consequently, possessing migDCs are 
affected. 
 
As migDCs in LNs originate from non-lymphoid tissues, the next question to ask 
was if DC frequency is also reduced in skin and small intestine, from where DCs 
migrate to sdLNs and mesLNs, respectively. Interestingly, LC frequency in the 
epidermis and LC, CD103+ DC and DN DC frequencies in the dermis were identical 
in Clec9a+/CreROSAiDTR mice when compared to Cre-negative controls (Figure 3.6A), 
even though their migratory counterparts in sdLNs were reduced. A similar 
observation was made in the small intestine and Peyer’s patches, were the 
frequency of CD64+ cells, CD103+ CD11b- DCs, CD103+ CD11b+ DCs and CD103- 
CD11b+ DCs or total DCs, respectively, was similar between Clec9a+/CreROSAiDTR 
and control mice (Figure 3.6B). 
As Clec9a+/CreROSAiDTR mice only seem to show reduced DC frequencies in LNs, 
but not other lymphoid organs or non-lymphoid tissues, it is unlikely that 
Clec9a+/CreROSAiDTR mice have a defect at the level of DC precursors or their ability 
to seed tissues. 
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Figure 3.5 LNs but not spleen or thymus of Clec9a+/CreROSAiDTR mice display 
reduced DC frequencies 
(A) Representative plots of sdLNs of control and Clec9a+/CreROSAiDTR mice, gated 
on live cells. (B) Total resDCs (CD11c+ MHCIIint), CD8α+ resDCs (CD11c+ MHCIIint 
CD8α+) and CD11b+ resDCs (CD11c+ MHCIIint CD11b+) (left panel), and total 
migDCs (CD11c+ MHCIIhi), LCs (CD11c+ MHCIIhi CD207+ CD103-), CD103+ 
migDCs (CD11c+ MHCIIhi CD207+ CD103+) and double negative (DN) migDCs 
(CD11c+ MHCIIhi CD207- CD103-) (right panel) in sdLNs of control and 
Clec9a+/CreROSAiDTR mice were identified by flow cytometry and DC subsets as 
percentage of live leukocytes are plotted. (C) Total resDCs (CD11c+ MHCIIint), 
CD8α+ resDCs (CD11c+ MHCIIint CD8α+) and CD11b+ resDCs (CD11c+ MHCIIint 
CD11b+) (left panel), and total migDCs (CD11c+ MHCIIhi), CD103+ migDCs 
(CD11c+ MHCIIhi CD11b- CD103+), CD103+ CD11b+ migDCs (CD11c+ MHCIIhi 
CD11b+ CD103+) and CD11b+ migDCs (CD11c+ MHCIIhi CD11b+ CD103-) (right 
panel) in mesLNs of control and Clec9a+/CreROSAiDTR mice were identified by flow 
cytometry and DC subsets as percentage of live leukocytes are plotted. (D) CD8α+ 
DCs (CD11c+ MHCII+ CD8α+) and CD11b+ DCs (CD11c+ MHCII+ CD11b+) in spleen 
and DCs in thymus (CD11c+ MHCII+) were identified by flow cytometry and DC 
subsets as percentage of live leukocytes are plotted. Each dot represents one 
mouse. Ns: non significant, *: p≤0.05, **: p≤0.01, ***: p≤0.001, ****: p≤0.0001. Data 
are pooled from at least two independent experiments. 
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Figure 3.6 Epidermis, dermis, small intestine and Peyer's patches of 
Clec9a+/CreROSAiDTR mice do not have reduced frequencies of DCs 
(A) LCs (MHCII+ CD64- EpCAMhi), CD103+ DCs (MHCII+ CD64- CD103+) and 
double negative DCs (DN DCs, MHCII+ CD64- CD103- EpCAM-) in epidermis and 
dermis of control and Clec9a+/CreROSAiDTR mice were identified by flow cytometry 
and DC subsets as percentage of live CD45+ cells are plotted. (B) CD64+ cells 
(CD11c+ MHCII+ CD64+), CD103+ CD11b- DCs (CD11c+ MHCII+ CD64- CD103+ 
CD11b-), CD103+ CD11b+ DCs (CD11c+ MHCII+ CD64- CD103+ CD11b+) and 
CD103- CD11b+ DCs (CD11c+ MHCII+ CD64- CD103- CD11b+) in the small intestine 
and DCs (CD11c+ MHCII+) in the Peyer’s Patches (PP) of control and 
Clec9a+/CreROSAiDTR mice were identified by flow cytometry and DC subsets as 
percentage of live CD45+ cells (small intestine) or of live leukocytes (PP) are 
plotted. Each dot represents one mouse. Ns: non significant. Data are pooled from 
at least two independent experiments. 
 
In addition to lower DC frequency, and equally unexpected, untreated 
Clec9a+/CreROSAiDTR mice also had a marked reduction in the cellularity of sdLNs 
and mesLNs (Figure 3.7) when compared to their genetic controls. This 
hypocellularity accentuated the dearth of LN DCs and was not seen in the spleen 
and thymus, which displayed normal cellularity (Figure 3.7). All immune cell 
populations were reduced in number in the LNs of Clec9a+/CreROSAiDTR mice, 
contributing to the overall hypocellularity, although the loss of T cells was most 
acute, leading to an increase in the ratio of B to T cells (Figure 3.8A). However, 
despite hypocellularity and increased B/T cell ratio, the overall LN architecture 
appeared intact (Figure 3.8B). 
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Figure 3.7 LNs, but not spleen or thymus, are hypocellular in Clec9a+/CreROSAiDTR 
mice 
Single-cell suspensions of sdLNs, mesLNs, spleen and thymus from control and 
Clec9a+/CreROSAiDTR mice were counted and the number of total leukocytes is 
plotted. Each dot represents one mouse. Ns: non significant, **: p≤0.01, ****: 
p≤0.0001. Data are pooled from at least two independent experiments. 
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Figure 3.8 LNs of Clec9a+/CreROSAiDTR mice show an altered T/B cell ratio, but 
maintain LN organisation 
(A) T cells (CD3+ MHCII-) and B cells (MHCII+ CD11c-) in mesLNs of control and 
Clec9a+/CreROSAiDTR mice were identified by flow cytometry and T cells and B cells 
as percentage of live leukocytes are plotted. (B) Frozen sections of sdLNs from 
control and Clec9a+/creROSAiDTR mice were stained with anti-CD3 and anti-B220 
antibodies and imaged by confocal microscopy. Scale bar: 300µm. Images are 
representative of 3 mice per group. 
 
To determine the influence of age on the observed phenotype, DC frequency and 
cellularity in spleen and sdLNs of one year old Clec9a+/CreROSAiDTR mice and Cre-
negative controls were assessed. In line with the findings in younger mice, there 
was no difference in splenic DC frequency or spleen cellularity between 
Clec9a+/CreROSAiDTR and Cre-negative control mice (Figure 3.9AB). However, the 
frequency of migDCs in sdLNs of old Clec9a+/CreROSAiDTR mice was again reduced 
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compared with control mice (Figure 3.9A). Furthermore, cellularity was reduced in 
sdLNs of old Clec9a+/CreROSAiDTR mice (Figure 3.9B). No difference in resDC 
frequency was observed in this experiment, which may be due to the small number 
of mice analysed.  
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Figure 3.9 Reduced migDC frequency in LNs and LN hypocellularity is 
maintained in old Clec9a+/CreROSAiDTR mice 
(A) CD8α+ DCs (CD11c+ MHCII+ CD8α+) and CD11b+ DCs (CD11c+ MHCII+ 
CD11b+) in spleen and resDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) in 
sdLNs of one year old control and Clec9a+/CreROSAiDTR mice were identified by flow 
cytometry and DC subsets as percentage of live leukocytes are plotted. (B) Single-
cell suspensions of spleen and sdLNs from one year old control and 
Clec9a+/CreROSAiDTR mice were counted and the number of total leukocytes is 
plotted. Each dot represents one mouse. Ns: non significant, *: p≤0.05, ***: 
p≤0.001. Data are from one experiment. 
 
3.4 In mixed bone marrow chimeras the phenotype of 
Clec9a+/CreROSAiDTR BM is dominant over WT BM 
DTR expression could be toxic to DCs, acting in a cell-autonomous fashion to 
decrease survival or migration. Alternatively, expression of DTR on DCs might act 
in a non-cell-autonomous manner to broadly influence the environment and all DCs 
within it. To distinguish these possibilities, mixed BM chimeras were generated with 
a 1:1 mixture of CD45.1+ WT BM and CD45.2+ Clec9a+/+ROSAiDTR (Cre-negative) 
or Clec9a+/CreROSAiDTR (Cre-positive) BM. Full chimerism was confirmed by 
measuring the ratio of CD45.1 to CD45.2 in blood neutrophils (Figure 3.10A). 
Frequencies of resDCs and migDCs within the total CD45.1+ or CD45.2+ population 
in both sdLNs and mesLNs were first compared. Among CD45.2+ cells, both resDC 
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and migDC frequencies were reduced in sdLNs and mesLNs of mice receiving Cre-
positive BM compared to animals receiving control Cre-negative BM (Figure 
3.10BC). These data indicated that the paucity of DCs in Clec9a+/CreROSAiDTR mice 
could not be rescued by the presence of WT cells.  
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CD45.2+ C57BL/6J hosts were lethally irradiated and reconstituted with a 1:1 mixture of CD45.1+ WT and CD45.2+ Clec9a+/+ROSAiDTR or 
Clec9a+/CreROSAiDTR BM. Mice were analyzed 7 months after BM transfer. 
(B) Single cell suspensions of sdLNs were analyzed by flow cytometry. CD45.1+ and CD45.2+ cells were identified and within these fractions resDCs (CD11c+ 
MHCIIint) and migDCs (CD11c+ MHCIIhi) were gated. Frequencies of resDCs and migDCs within the CD45.2+ or CD45.1+ fraction are plotted. Each dot represents 
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Figure 3.10 In mixed BM chimeras the phenotype conferred by 
Clec9a+/CreROSAiDTR BM is dominant 
CD45.2+ C57BL/6J hosts were lethally irradiated and reconstituted with a 1:1 
mixture of CD45.1+ WT and CD45.2+ Clec9a+/+ROSAiDTR or Clec9a+/CreROSAiDTR 
BM. Mice were analysed 7 months after BM transfer.  
(A) Peripheral blood was analysed by flow cytometry. Neutrophils (neutro; CD11b+ 
Gr1+) were identified and the frequency of CD45.2+ neutrophils is plotted. (B) 
Single cell suspensions of sdLNs were analysed by flow cytometry. CD45.1+ and 
CD45.2+ cells were identified and within these fractions resDCs (CD11c+ MHCIIint) 
and migDCs (CD11c+ MHCIIhi) were gated. Frequencies of resDCs and migDCs 
within the CD45.2+ or CD45.1+ fraction are plotted. (C) Same analysis as in (B), but 
then for mesLNs. Each dot represents one mouse. Ns: non significant, *: p≤0.05, 
**: p≤0.01, ****: p≤0.0001. Data are representative of two independent 
experiments. 
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Even more intriguingly, the WT compartment in chimeras receiving Cre-positive BM 
was similarly affected. As shown in Figure 3.10BC, in the CD45.1+ WT 
compartment the frequencies of migDCs in both sdLNs and mesLNs, and resDCs 
in sdLNs were reduced in chimeras receiving Cre-positive BM, but not in chimeras 
receiving Cre-negative control BM. Therefore, DTR does not appear to merely 
affect in a cell autonomous manner those DCs that express it. Rather, 
Clec9a+/CreROSAiDTR BM-derived cells have a dominant effect that reduces the 
frequency of DCs derived from WT BM. These observations are reminiscent of the 
reduced frequency of LCs in Clec9a+/CreROSAiDTR mice (Figure 3.5B), as in both 
cases DCs that do not express DTR are reduced in frequency. 
The dominance of Clec9a+/CreROSAiDTR BM was also reflected in the size of sdLNs 
and mesLNs, but not spleen, which was reduced in chimeras receiving Cre-positive 
BM when compared with control chimeras (Figure 3.11). In summary, the 
hypocellularity and relative reduction of DCs in LNs of Clec9a+/CreROSAiDTR mice 
are replicated in mixed chimeras containing Clec9a+/CreROSAiDTR BM. 
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Figure 3.11 LNs of mixed BM chimeras reconstituted with Clec9a+/CreROSAiDTR 
and WT BM show hypocellularity 
CD45.2+ C57BL/6J hosts were lethally irradiated and reconstituted with a 1:1 
mixture of CD45.1+ WT and CD45.2+ Cl c9a+/+ROSAiDTR or Clec9a+/CreROSAiDTR 
BM. Mice were analysed 7 mo ths after BM transfer. Total leukocyte numbers of 
spleen, sdLNs and mesLNs are plotted. Each dot r presents one mo se. Ns: non 
significant, **: p≤0.01. Data are representative of two indep nde t experime ts.
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3.5 Other mice that express DTR on DCs also show LN 
hypocellularity and reduced DC frequencies 
The LN hypocellularity and reduced frequencies of DC subsets in LNs could be the 
result of targeting the Clec9a locus, targeting the ROSA26-locus, or expressing 
DTR on DCs. Arguing against the first two possibilities, the original reporter mice in 
which the Clec9a-Cre strain was crossed to ROSA26-YFP mice, all had normal 
size LNs and unaltered LN composition (Figure 3.12). Nevertheless, to determine 
whether the phenotype was exclusive to the use of the Clec9a-Cre strain, CD11c-
Cre mice (Caton, Smith-Raska and Reizis, 2007) were crossed to ROSA26-iDTR 
mice. CD11c-Cre+veROSAiDTR mice expressed DTR on a high proportion of DCs in 
sdLNs (Figure 3.13A). These mice also showed hypocellularity of sdLNs and 
mesLNs (Figure 3.13BC), and reduced frequencies of migDCs in sdLNs and 
mesLNs compared with littermate controls (Figure 3.13BC). ResDC frequency was 
reduced in mesLNs of CD11c-Cre+veROSAiDTR mice (Figure 3.13C) and there was a 
trend for reduced frequencies of resDCs in sdLNs, albeit not reaching statistically 
significance (Figure 3.13B). Thus, CD11c-Cre+veROSAiDTR mice largely phenocopy 
Clec9a+/CreROSAiDTR mice and also show LN hypocellularity and a reduced 
frequency of DCs. 
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Figure 3.12 Clec9a+/creROSAYFP mice do not show hypocellularity or reduced DC 
frequency of LNs 
SdLNs of Clec9a+/creROSAYFP mice were analysed for total cellularity (left panel) 
and frequency of resDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) (right 
panel). Each dot represents one mouse. Ns: non significant. Data are from one 
experiment. 
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Figure 3.13 CD11c-Cre+veROSAiDTR mice show LN hypocellularity and reduced DC 
frequency in LNs 
(A) ResDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) in sdLNs from 
CD11c-Cre+veROSAiDTR mice were stained with a polyclonal anti-DTR antibody and 
analysed by flow cytometry. Data are representative of at least six mice per group. 
(B-C) SdLNs (B) and mesLNs (C) of CD11c-Cre+veROSAiDTR mice were analysed 
for total cellularity (left panel) and frequency of resDCs (CD11c+ MHCIIint) and 
migDCs (CD11c+ MHCIIhi) (right panel). Each dot represents one mouse. Data are 
pooled from at least two independent experiments. Ns: non significant, *: p≤0.05, 
**: p≤0.01 ***: p≤0.001, ****: p≤0.0001. 
 
Next, the original CD11c-DTR mice (Jung et al., 2002) were analysed, which have 
been widely used to study DC functions in vivo for over ten years. These mice 
expressed DTR on most DCs in sdLNs, although especially some of the resDCs 
did not stain positive with the polyclonal DTR antibody (Figure 3.14A). Similar to 
Clec9a+/CreROSAiDTR mice, CD11c-DTR mice showed reduced frequencies of 
resDCs and migDCs in sdLNs and mesLNs and hypocellularity of the same organs 
(Figure 3.14BC). As CD11c-DTR mice do not express DTR from the ROSA26-
locus, this finding excludes the possibility that the ROSA26-iDTR strain is 
responsible for the observed phenotype. Together, these results indicate that 
paucity of LN DCs and hypocellularity of LNs is a feature common to 
Clec9a+/CreROSAiDTR, CD11c-Cre+veROSAiDTR and CD11c-DTR mice.  
 
Chapter 3 Results 
 
110 
 
A
0 102 103 104 105
0
20
40
60
80
100
0 102 103 104 105
0
20
40
60
80
100
%
 o
f m
ax
DTR
resDC migDC
Control
CD11c-DTR
Littermate control
CD11c-DTR
0.0
1.5x107
1.0x107
5.0x106
To
ta
l L
eu
ko
cy
te
s
****
0.0
0.5
1.0
1.5
%
 o
f l
iv
e 
ce
lls
res
DC
mi
gD
C
***
***
sdLN
0.0
0.2
0.4
0.6
0.8
1.0
****
****
res
DC
mi
gD
C
%
 o
f l
iv
e 
ce
lls
3x107
2x107
1x107
0.0
****
To
ta
l L
eu
ko
cy
te
s
Littermate control
CD11c-DTR
mesLN
B
C
 
Figure 3.14 CD11c-DTR mice show LN hypocellularity and reduced DC frequency 
in LNs 
(A) ResDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) in sdLNs from 
CD11c-DTR mice were stained with a polyclonal anti-DTR antibody and analysed 
by flow cytometry. Data are representative of at least six mice per group. (B-C) 
SdLNs (B) and mesLNs (C) of CD11c-DTR mice were analysed for total cellularity 
(left panel) and frequency of resDCs (CD11c+ MHCIIint) and migDCs (CD11c+ 
MHCIIhi) (right panel). Each dot represents one mouse. Data are pooled from at 
least two independent experiments. ***: p≤0.001, ****: p≤0.0001. 
 
The above-mentioned strains all allow for expression of DTR on multiple DC 
subtypes. To test if expression of DTR on a subset of DCs is sufficient to induce 
the observed phenotype, Langerin-DTR mice (Kissenpfennig et al., 2005) were 
analysed. In Langerin-DTR mice, DTR expression is under control of the CD207 
locus, which is active in LCs, CD103+ dermal DCs and some CD8α+ resDCs. As 
observed for the other mouse strains, Langerin-DTR mice displayed reduced 
frequencies of migDCs in sdLNs and hypocellularity of the same organ compared 
with littermate controls (Figure 3.15B). This phenotype was not observed in 
mesLNs, unlike in the other strains tested (Figure 3.15D). Further investigation 
revealed that the difference in phenotype between sdLNs and mesLNs in Langerin-
DTR mice correlated with levels of DTR expression: very little DTR expression was 
observed on resDCs and migDCs from mesLNs (Figure 3.15C) while DTR was 
Chapter 3 Results 
 
111 
 
expressed on both resDCs and migDCs subsets in sdLNs, although both 
expression levels and the frequency of cells stained positive were very low (Figure 
3.15A). In sum, analysis of Langerin-DTR mice suggests that even low DTR 
expression on a subset of DCs is sufficient to induce reduced migDCs 
accumulation in LNs and LN hypocellularity. Moreover, the effects of DTR appear 
to be local and not systemic, as in Langerin-DTR mice the affected LNs are only 
those in which DTR expression is found on DCs. 
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Figure 3.15 Langerin-DTR mice show hypocellularity and reduced DC frequency 
only in sdLNs 
(A,C) ResDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) in sdLNs (A) or 
mesLNs (C) from Langerin-DTR mice were stained with a polyclonal anti-DTR 
antibody and analysed by flow cytometry. Data are representative of at least six 
mice per group. (B,D) SdLNs (B) and mesLNs (D) of Langerin-DTR mice were 
analysed for total cellularity (left panel) and frequency of resDCs (CD11c+ MHCIIint) 
and migDCs (CD11c+ MHCIIhi) (right panel). Each dot represents one mouse. Data 
are pooled from at least two independent experiments. Ns: non significant, **: 
p≤0.01 ***: p≤0.001. 
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Finally, CD11c-DOG mice were tested. Like CD11c-DTR mice, these mice also 
exploit CD11c expression to express DTR on DCs. However, CD11c-DOG mice 
utilise the CD11c locus control region instead of a minimal promoter to drive DTR 
expression (Jung et al., 2002; Hochweller et al., 2008). Surprisingly, no difference 
was found in sdLN and mesLN cellularity or DC frequencies in sdLNs and mesLNs 
between CD11c-DOG mice and controls (Figure 3.16BD). However, resDCs in 
sdLNs and mesLNs of CD11c-DOG mice expressed DTR at very low levels (Figure 
3.16AC). Moreover, DTR expression on migDCs in sdLNs and mesLNs of CD11c-
DOG mice was undetectable by antibody staining (Figure 3.16AC). These results 
suggest that low DTR expression on resDCs alone may not be not sufficient to 
confer the phenotype of LN hypocellularity and reduced frequencies of DCs in LNs. 
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Figure 3.16 CD11c-DOG mice do not show LN hypocellularity or reduced 
frequency of LN DCs 
(A,C) ResDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) in sdLNs (A) or 
mesLNs (C) from CD11c-DOG mice were stained with a polyclonal anti-DTR 
antibody and analysed by flow cytometry. Data are representative of at least six 
mice per group. (B,D) SdLNs (B) and mesLNs (D) of CD11c-DOG mice were 
analysed for total cellularity (left panel) and frequency of resDCs (CD11c+ MHCIIint) 
and migDCs (CD11c+ MHCIIhi) (right panel). Each dot represents one mouse. Data 
are pooled from at least two independent experiments. Ns: non significant, *: 
p≤0.05. 
Chapter 3 Results 
 
113 
 
In sum, CD11c-Cre+veROSAiDTR and CD11c-DTR mice showed a similar phenotype 
of LN hypocellularity and reduced frequencies of DCs in LNs as 
Clec9a+/CreROSAiDTR mice, while Langerin-DTR mice only show this phenotype in 
the LNs were DTR expression could be observed by antibody staining. In contrast, 
CD11c-DOG mice did not show any aberrations in LNs, but also failed to show 
DTR expression on migDCs and had very low DTR expression on resDCs. 
3.6 Mice that express DTR on B cells or Tregs do not show a 
profound LN hypocellularity or reduced DC frequencies 
To address whether DTR expression on other immune cells than DCs leads to a 
similar LN phenotype, CD19-Cre mice (Rickert, Roes and Rajewsky, 1997) were 
crossed to ROSA26-iDTR mice, to drive expression of DTR on B cells. Notably, 
frequencies of B cells and resDCs were not decreased in sdLNs and mesLNs of 
CD19+/CreROSAiDTR mice compared with controls (Figure 3.17AB). MigDC 
frequencies were unaltered in sdLNs, but slightly decreased in mesLNs (Figure 
3.17AB), although this decrease was much smaller than that observed in the DC-
restricted DTR models tested here. CD8α + DCs in the spleen of 
CD19+/CreROSAiDTR mice were unaltered, while CD11b+ DC frequency was 
increased in spleens of CD19+/CreROSAiDTR mice (Figure 3.17C) compared with 
controls. Furthermore, CD19+/CreROSAiDTR mice displayed only a mild reduction in 
cellularity of sdLNs, but not of the mesLNs or spleen (Figure 3.17A-C).  
DEREG mice, in which DTR is expressed on Tregs (Lahl et al., 2007), were also 
analysed. DEREG mice displayed a mild decrease in the frequency of migDCs in 
both sdLNs and mesLNs compared with controls, while resDCs in LNs and DCs in 
the spleen were unaltered (Figure 3.18A-C). However, in contrast to mice 
expressing DTR on DCs, DEREG mice did not show signs of LN hypocellularity 
(Figure 3.18AB).  
 
Chapter 3 Results 
 
114 
 
To
ta
l L
eu
ko
cy
te
s
1.0x108
5.0x107
1.5x108
0.0
ns
0
1
2
3
CD
8_

  D
C
CD
11
b+  
DC
%
 o
f l
iv
e 
ce
lls
ns
***
spleen
CD19+/+ ROSAiDTR
CD19+/Cre ROSAiDTR
To
ta
l L
eu
ko
cy
te
s
1.5x107
2.0x107
1.0x107
0.0
5.0x106
2.5x107 ns
%
 o
f l
iv
e 
ce
lls
0.0
0.5
1.0
1.5
25
50
res
DC
 
mi
gD
C
B 
ce
ll
ns
**
*
mesLN
0.0
1.25x107
1.0x107
5.0x106
2.5x106
7.5x106
To
ta
l L
eu
ko
cy
te
s
*
res
DC
 
mi
gD
C
B 
ce
ll
0.0
0.5
1.0
1.5
25
50
%
 o
f l
iv
e 
ce
lls
ns
ns
ns
sdLNA B
C
 
Figure 3.17 Expression of DTR on B cells does not lead to overall LN 
hypocellularity and reduced frequencies of LN DCs 
Left panels: single-cell suspensions of sdLNs (A), mesLNs (B) and spleen (C) from 
control and CD19+/CreROSAiDTR mice were counted and the number of total 
leukocytes is plotted. Right panels: resDCs (CD11c+ MHCIIint) and migDCs 
(CD11c+ MHCIIhi) in sdLNs (A) and mesLNs (B) and CD8α+ DCs (CD11c+ MHCII+ 
CD8α+), CD11b+ DCs (CD11c+ MHCII+ CD11b+) and B cells in spleen (C) of control 
and CD19+/CreROSAiDTR mice were identified by flow cytometry and DC subsets or 
B cells as percentage of live leukocytes are plotted. Each dot represents one 
mouse. Data are pooled from at least two independent experiments. Ns: non 
significant, *: p≤0.05, **: p≤0.01 ***: p≤0.001. 
 
In summary, neither CD19+/CreROSAiDTR mice nor DEREG mice fully recapitulate 
the phenotype of dramatic hypocellularity of LNs and reduced frequencies of 
resDCs and migDCs in LNs. However, LNs of CD19+/CreROSAiDTR and DEREG 
mice are not identical to those in the respective controls, perhaps because of 
effects of DTR expression on B cells or Tregs or because of an unknown cause 
(e.g., haploinsufficiency of CD19 or aberrations due to BAC integration). Overall, 
these results suggest that expression of DTR on a large fraction of LN cells is not 
necessarily detrimental but that its expression specifically on DCs has unexpected 
consequences. 
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Figure 3.18 Expression of DTR on Tregs does not lead to overall LN 
hypocellularity and reduced frequencies of LN DCs 
Left panels: single-cell suspensions of sdLNs (A), mesLNs (B) and spleen (C) from 
control and DEREG mice were counted and the number of total leukocytes is 
plotted. Right panels: resDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) in 
sdLNs (A) and mesLNs (B) and CD8α+ DCs (CD11c+ MHCII+ CD8α+) and CD11b+ 
DCs (CD11c+ MHCII+ CD11b+) in spleen (C) of control and DEREG mice were 
identified by flow cytometry and DC subsets as percentage of live leukocytes are 
plotted. Each dot represents one mouse. Data are pooled from at least two 
independent experiments. Ns: non significant, **: p≤0.01, ***: p≤0.001. 
 
3.7 Clec9a+/CreROSAiDTR mice can mount normal immune 
responses upon immunisation or infection 
Above-mentioned experiments investigated the unperturbed immune system of 
mice expressing DTR on DCs or other immune cells, and revealed that DTR 
expression specifically on DCs results in LN hypocellularity and reduced 
frequencies of DCs in LNs. As LNs are key sites for initiation and progression of 
local immune responses and DCs play a crucial role in these processes, 
Clec9aCre/CreROSAiDTR mice were next immunised with CFA/OVA or infected with 
influenza to study their ability to mount an immune response. Due to the limited 
availability of mice, homozygous Clec9aCre/CreROSAiDTR (and therefore DNGR-1 
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deficient) mice had to be used for these experiments, age and sex-matched with 
either control mice from the ROSA26-iDTR colony (CFA/OVA immunisation) or with 
Clec9a+/+ROSAiDTR mice from the same colony (influenza infection). 
CFA/OVA immunisation led to expansion of draining LNs in both 
Clec9aCre/CreROSAiDTR and control mice (Figure 3.19A). Surprisingly, the difference 
in LN size between naïve Clec9aCre/CreROSAiDTR and control mice was lost upon 
immunisation (Figure 3.19A). In contrast, the difference in frequency of cells that 
fall in the resDC or migDC gates between Clec9aCre/CreROSAiDTR and control mice 
was maintained upon immunisation (Figure 3.19B). At 12 days post immunisation 
OVA-specific pentamer+ CD8α+ CD44+ T cells were present in draining sdLNs of 
Clec9aCre/CreROSAiDTR mice, although their numbers were lower than in draining 
sdLNs of control mice (Figure 3.20A). Likewise, in spleens of immunised control 
mice pentamer+ CD8α+ CD44+ T cells could be found, despite at a very low level, 
while in spleens of Clec9aCre/CreROSAiDTR mice no specific pentamer stain could be 
detected (Figure 3.20B). Altogether, these results indicate that 
Clec9aCre/CreROSAiDTR mice can mount a CD8+ T cell response, but that this 
response may be smaller than in control mice.  
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Figure 3.19 sdLNs expand normally in CFA/OVA immunised Clec9aCre/CreROSAiDTR 
mice 
ROSA26-iDTR control (‘Cre negative’) and Clec9aCre/CreROSAiDTR (‘Cre positive’) 
mice were immunised s.c. in one flank with CFA/OVA (50µg OVA protein per 
mouse), draining to inguinal sdLN. Both draining and non-draining sdLNs and 
spleens were collected at day 12 post-immunisation, as well as LNs and spleens 
from non-immunised naïve mice. (A) Single cell suspensions from sdLNs were 
counted and the number of total leukocytes is plotted. (B) ResDCs (CD11c+ 
MHCIIint) and migDCs (CD11c+ MHCIIhi) in sdLNs were identified by flow cytometry 
and DC subsets as percentage of live leukocytes are plotted. (C) Single cell 
suspensions from spleens were counted and the number of total leukocytes is 
plotted. (D) CD8α+ DCs (CD11c+ MHCII+ CD8α+) and CD11b+ DCs (CD11c+ 
MHCII+ CD11b+) in spleen were identified by flow cytometry and DC subsets as 
percentage of live leukocytes are plotted. Each dot represents one mouse. Data 
are from one experiment. Ns: non significant, *: p≤0.05, **: p≤0.01. 
 
 
 
Chapter 3 Results 
 
118 
 
0
2000
4000
6000
8000
10000
C
D
8_


 C
D
44
+  p
en
ta
m
er
+  
T 
ce
lls
nd d nd d
Cre
negative
Cre
positive
na
iv
e
C
re
 n
eg
at
iv
e
na
iv
e
C
re
 p
os
iti
ve
**
0
10000
20000
30000
40000
C
D
8_


 C
D
44
+  p
en
ta
m
er
+  
T 
ce
lls
Cr
e n
eg
ati
ve
Cr
e p
os
itiv
e
Cr
e n
eg
ati
ve
Cr
e p
os
itiv
e
CFA/OVA naive
**
sdLN spleen
one way anova with Tukey’s multiple comparrison test
A B
 
Figure 3.20 Clec9aCre/CreROSAiDTR mice can mount a CD8+ T cell response upon 
CFA/OVA immunisation 
ROSA26-iDTR control (‘Cre negative’) and Clec9aCre/CreROSAiDTR (‘Cre positive’) 
mice were immunised s.c. in one flank with CFA/OVA (50µg OVA protein per 
mouse), draining to inguinal sdLN. Both draining and non-draining sdLNs and 
spleens were collected at day 12 post-immunisation, as well as LNs and spleens 
from non-immunised naïve mice. Single cell suspensions from sdLNs (A) and 
spleens (B) were generated and CD8α+ CD44+ T cells (CD3+ MHCII- CD8α+ CD4- 
CD44+) were identified by flow cytometry, total pentamer+ CD8α+ CD44+ T cells are 
plotted. Each dot represents one mouse. Data are from one experiment. **: p≤0.01. 
 
The influenza infection induced an influenza-specific CD8+ T cell response in both 
Clec9aCre/CreROSAiDTR and control mice, as exemplified by the presence of 
pentamer+ CD8α+ CD44+ T cells in both medLNs and spleens (Figure 3.22AB) and 
IFNγ production by restimulated single cell suspensions from medLNs and spleens 
of infected mice (Figure 3.22CD). However, while the number of pentamer+ CD8α+ 
CD44+ T cells was similar in medLNs of Clec9aCre/CreROSAiDTR and control mice, 
there was a trend for reduced pentamer+ CD8α+ CD44+ T cells in spleens of 
Clec9aCre/CreROSAiDTR mice compared with controls (Figure 3.22AB). However, no 
difference in IFNγ production could be observed between cultures from spleens 
from Clec9aCre/CreROSAiDTR and control mice when restimulated with CD8+ T cell 
epitope peptides (Figure 3.22D).  
To assess CD4+ T cell priming upon influenza infection, single cell suspensions 
from medLNs and spleens of infected mice were restimulated with peptides 
representing CD4+ T cell epitopes and IFNγ production was assessed. As shown in 
Figure 3.22CD, cultures from medLNs and spleens of infected 
Clec9aCre/CreROSAiDTR mice may have produced more IFNγ upon restimulation.  
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Figure 3.21 MedLNs expand normally in influenza X-31 infected 
Clec9aCre/CreROSAiDTR mice 
Clec9a+/+ROSAiDTR control (‘Cre negative’) and Clec9aCre/CreROSAiDTR (‘Cre 
positive’) mice were infected i.n. with 1x104 pfu influenza X-31. MedLNs and 
spleens were collected at day 9 post infection, along with medLNs and spleens of 
naïve mice. (A) Single cell suspensions from spleens were counted and the 
number of total leukocytes is plotted. (B) CD8α+ DCs (CD11c+ MHCII+ CD8α+) and 
CD11b+ DCs (CD11c+ MHCII+ CD11b+) in spleen were identified by flow cytometry 
and DC subsets as percentage of live leukocytes are plotted. (C) Single cell 
suspensions from medLNs were counted and the number of total leukocytes is 
plotted. (D) ResDCs (CD11c+ MHCIIint) and migDCs (CD11c+ MHCIIhi) in LNs were 
identified by flow cytometry and DC subsets as percentage of live leukocytes are 
plotted. Each dot represents one mouse. Data are from one experiment. Ns: non 
significant, **: p≤0.01. 
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Figure 3.22 Clec9aCre/CreROSAiDTR and control mice mount similar CD8+ and CD4+ 
T cell responses upon influenza X-31 infection 
Clec9a+/+ROSAiDTR control (‘Cre negative’) and Clec9aCre/CreROSAiDTR (‘Cre 
positive’) mice were infected i.n. with 1x104 pfu influenza X-31. MedLNs and 
spleens were collected at day 9 post infection, along with medLNs and spleens of 
non-infected naïve mice. Single cell suspensions from medLNs (A) and spleens (B) 
were generated, CD8α+ CD44+ T cells (CD3+ MHCII- CD8α+ CD4- CD44+) were 
identified by flow cytometry and total pentamer+ CD8α+ CD44+ T cells are plotted. 
Single cell suspensions (5x105 cells/well) from medLNs (C) and spleens (D) were 
restimulated overnight with the indicated peptides, after which IFNγ concentrations 
in the supernatants were determined by ELISA. Peptide names were shortened to 
their starting amino acid for brevity. Full peptide names and sequences are found in 
Table 4. Dashed line denotes detection limit of the ELISA. Only samples that 
reached the detection limit are shown with a bar. IFNγ from restimulated cultures 
from spleens of naïve mice (2 Cre negative and 3 Cre positive) or of naïve medLNs 
(one pooled sample for Cre negative and one pooled sample for Cre positive) were 
below detection limit and were not included in the graph for clarity. Each dot or bar 
represents one mouse. Data are from one experiment. Ns: non significant 
 
Both upon immunisation with CFA/OVA and infection with influenza, draining LNs 
were able to increase in size to a similar extend as in control mice, indicating that 
LNs in Clec9a+/CreROSAiDTR mice can expand normally in an inflammatory setting. 
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However, both experiments also showed that cells that fall in the resDC or migDC 
gates were still reduced in frequencies in draining LNs of immunised or infected 
Clec9aCre/CreROSAiDTR mice compared with controls. Both CFA/OVA immunisation 
and influenza infection induced antigen-specific CD8+ T cells in 
Clec9aCre/CreROSAiDTR mice. However, in the case of CFA/OVA immunisation the 
total numbers of pentamer+ CD8+ T cells in draining LNs was lower in 
Clec9aCre/CreROSAiDTR mice compared with controls, while in the influenza setting 
no such difference was observed. Interestingly, both experiments revealed a trend 
for reduced pentamer+ CD8+ T cells in spleens of immunised or infected mice. 
Altogether, these results may indicate that although CD8+ T cells can be efficiently 
primed in Clec9aCre/CreROSAiDTR mice, the resulting antigen-specific CD8+ T cells 
may not be fully functional. 
In general, the results presented here should be interpreted with some caution, as 
both the CFA/OVA immunisation and the influenza X-31 infection were only 
performed once with mouse cohorts that were not perfectly matched. Furthermore, 
Clec9aCre/CreROSAiDTR mice are deficient for DNGR-1, in addition to expressing 
DTR on DCs. Therefore the differences observed here may also be attributable to 
DNGR-1 deficiency instead of to DTR expression. 
3.8 What is the mechanism by which DTR expression confers 
LN abnormalities? 
The results presented thus far indicate that DTR expression on DCs confers LN 
hypocellularity and reduced DC frequencies in LNs. As only tissues with an afferent 
lymph supply seem to be affected and the paucity of migDCs in LNs may reflect an 
impairment in their migration from peripheral sites, the migratory ability of DTR-
expressing DCs was assessed. To this extent, a transwell assay was performed 
with leukocytes isolated from sdLNs of Clec9a+/CreROSAiDTR and control mice. 
Interestingly, both resDCs and migDCs from Clec9a+/CreROSAiDTR mice were 
impaired in their migration towards the chemokine CCL21 in this in vitro assay 
(Figure 3.23). Therefore, CCR7 expression was assessed by flow cytometry on DC 
subpopulations in sdLNs. Both CD8α+ resDCs and CD11b+ resDCs from 
Clec9a+/CreROSAiDTR and control mice did not express detectable levels of CCR7, 
while all migDC populations and LCs in sdLNs expressed CCR7 (Figure 3.24). 
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However, there was no difference in CCR7 expression levels between 
Clec9a+/CreROSAiDTR and control mice (Figure 3.24) and therefore CCR7 
expression could not explain the impaired migration of sdLN DCs from 
Clec9a+/CreROSAiDTR mice in the transwell assay, nor provide an explanation for the 
observed reduction in DC frequency in LNs of Clec9a+/CreROSAiDTR mice. 
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Figure 3.23 DCs from sdLNs of Clec9a+/CreROSAiDTR mice show impaired 
migration towards the chemokine CCL21 
DCs were isolated from sdLNs of Clec9a+/CreROSAiDTR and control mice and 
exposed to the indicated concentrations CCL21 in a transwell assay. After 4h, cells 
from wells and inserts were collected and resDCs (CD11c+ MHCIIint) and migDCs 
(CD11c+ MHCIIhi) were identified by flow cytometry and the frequency of migrated 
cells was calculated. **: p≤0.01, ***: p≤0.001. This experiment was performed once 
with experimental duplicates for each concentration. 
 
Flt3l is essential for DC homeostasis and mice lacking Flt3l or its receptor Flt3 (also 
called CD135) show a severe reduction in DCs (McKenna et al., 2000; Waskow et 
al., 2008). Hence, Flt3 expression was determined on sdLN DCs. Virtually all 
resDCs and migDCs isolated from sdLNs expressed Flt3, as did LCs. Expression 
levels varied per subset, but were similar between Clec9a+/CreROSAiDTR and control 
mice for any given subset (Figure 3.24).  
 
In sum, DTR-expressing DCs are impaired in their migration in an in vitro transwell 
assay, which may explain why DCs are reduced in LNs of mice that express DTR 
on DCs. However, DTR-expressing DCs express normal levels of the chemokine 
receptor CCR7 and the receptor tyrosine kinase Flt3, which can therefore not 
explain why DC migration and/or survival is impaired in a DTR background. 
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Figure 3.24 DC subsets in sdLNs of Clec9a+/CreROSAiDTR mice do not show 
differential CCR7 or CD135 (Flt3) expression compared with controls 
CD8α+ resDCs (CD11c+ MHCIIint CD8α+), CD11b+ resDCs (CD11c+ MHCIIint 
CD11b+), LCs (CD11c+ MHCIIhi CD207+ CD103-), CD103+ migDCs (CD11c+ 
MHCIIhi CD207+ CD103+) and double negative (DN) migDCs (CD11c+ MHCIIhi 
CD207- CD103-) in sdLNs of control and Clec9a+/CreROSAiDTR mice were identified 
by flow cytometry and the levels of CCR7 and CD135 are shown for each subset. 
Grey shading represents isotype control. This experiment was performed once and 
each plot is representative of three mice.  
 
Naïve lymphocytes enter LNs via HEVs and DCs have been shown to be essential 
for maintaining HEV function (Moussion and Girard, 2011). Therefore, the reduced 
LN size observed in mice that express DTR on DCs may be secondary to the 
reduction in DC frequency in LNs of these mice. To test this hypothesis, LN 
cryosections were stained with an antibody against the pan-endothelial marker 
CD31 and with the HEV-specific antibody MECA79 that recognises sulphated 
carbohydrate ligands for L-selectin, the homing receptor expressed by 
lymphocytes. However, neither the distribution and size of HEVs, nor the intensity 
of the MECA79 staining differed markedly between LNs from Clec9a+/CreROSAiDTR 
and control mice (Figure 3.25A), suggesting that a difference in HEV function 
cannot explain the LN hypocellularity in mice that express DTR on DCs. 
HEVs express abundant amounts of CCL21 (Gunn et al., 1998; J. J. Campbell et 
al., 1998), while the most important source of CCL21 in T cell zones are FRCs 
(Link et al., 2007). In addition, FRCs form an elaborate network that supports 
leukocyte trafficking in the T cell zone (M. J. Miller et al., 2002; Bajénoff et al., 
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2006). As DCs are important for maintaining FRC function (Acton et al., 2014; 
Astarita et al., 2015), a paucity of DCs could lead to LN hypocellularity via 
malfunctioning FRCs and/or reduced CCL21 production. The FRC network and 
CCL21 expression were therefore examined in LN sections from 
Clec9a+/CreROSAiDTR and control mice. Interestingly, staining with the ER-TR7 
antibody, which recognises an extracellular protein produced by FRCs, revealed a 
differential distribution of this FRC extracellular matrix protein in LN sections of 
Clec9a+/CreROSAiDTR and control mice (Figure 3.25B). LNs from 
Clec9a+/CreROSAiDTR mice showed a less pronounced ER-TR7 staining around 
HEVs (visualised by anti-CD31 staining), while the network was more prominent in 
the T cell zone, compared with LN sections from control mice (Figure 3.25B). 
Furthermore, anti-CCL21 staining showed a reduction in this chemokine in LN 
sections from Clec9a+/CreROSAiDTR mice (Figure 3.25B). Together these results 
indicate that the FRC network may be disrupted in LNs of Clec9a+/CreROSAiDTR 
mice.  
 
In sum, DCs in Clec9a+/CreROSAiDTR mice may be impaired in their migration to 
LNs, leading to reduced frequencies of DCs in LNs, which in turn may impact on 
the FRC network in LNs and causing LN hypocellularity. However, the experiments 
presented here are not sufficient to fully confirm these conclusions. Firstly, it is still 
unclear why Clec9a+/CreROSAiDTR mice may be impaired in their migration and 
moreover, migration was only assessed in vitro and not in an in vivo setting. 
Moreover, the experiments presented here do not address the fundamental 
question of how DTR expression modulates the DC function and/or the DC 
microenvironment. 
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Figure 3.25 Clec9a+/creROSAiDTR mice appear to have normal HEVs, but may have 
an altered FRC network 
Frozen sections of sdLNs from control and Clec9a+/creROSAiDTR mice were stained 
with anti-CD31 and anti-MECA79 antibodies (A) or with anti-CD31, ER-TR7 and 
anti-CCL21 antibodies (B) and imaged by confocal microscopy. Scale bar: 200µm. 
Images are representative of 3 mice per group. 
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3.9 Discussion 
Mouse models to inducibly deplete DCs are useful tools to elucidate the role of 
DCs in immune functions. Many of these models rely on transgenic DTR 
expression driven by promoters more or less restricted to DCs. Despite the fact that 
the first such model, the CD11c-DTR mouse (Jung et al., 2002), was generated 
over ten years ago and has since been used extensively (van Blijswijk, Schraml 
and Reis e Sousa, 2013), mice in which simian or human DTR is forcibly expressed 
on DCs have not been reported to display immune abnormalities. Unexpectedly, 
the results presented in this chapter show that these models display reduced LN 
cellularity and a profound decrease in the relative frequency of DCs in LNs in the 
absence of DT treatment. 
Five different mouse models were tested in which DTR is forcibly expressed in DCs 
(Clec9a+/CreROSAiDTR, CD11c-Cre+veROSAiDTR, CD11c-DTR, Langerin-DTR and 
CD11c-DOG mice). Although this list includes widely used models for DC depletion, 
it is not exhaustive. In particular, the recently described zDC-DTR mice (Meredith, 
Liu, Darrasse-Jeze, et al., 2012) were not investigated. Furthermore, the data 
presented here do not allow assessing whether it is necessary and/or sufficient for 
DTR to be expressed by a particular subset of DCs to confer the LN phenotype. In 
this regard, Clec9a-DTR mice (Piva et al., 2012), XCR1-DTR mice (Yamazaki et 
al., 2013), SiglecH-DTR and BDCA2-DTR mice (Swiecki et al., 2010) may be used 
to address the consequences of expressing DTR on CD8α-like cDCs or pDCs. In 
addition, it will be interesting to assess LN cellularity and phagocyte frequency in 
mice in which DTR is forcibly expressed on monocytes or macrophages, as these 
mononuclear phagocytes are found in similar niches and may perform similar 
functions as DCs. 
The mechanistic basis for these findings is not fully elucidated, although the data 
presented here may provide some clues. As DC frequencies were unaltered in the 
spleen and non-lymphoid tissues in the mouse models examined here, and 
because in Langerin-DTR mice the sdLNs, but not mesLNs were affected, a defect 
at the level of DC precursors or their ability to seed tissues is unlikely. Rather, only 
tissues with an afferent lymph supply seem to be affected and the paucity of 
migDCs in LNs likely reflects an impairment in their migration from peripheral sites, 
or a reduced lifespan once in the LN. Reduced lifespan might also explain the 
Chapter 3 Results 
 
127 
 
decrease in LN resDC frequencies. Furthermore, the alteration in LN composition 
and function in mice that express DTR on DCs is not imprinted during mouse 
development, as it can be conferred to adult mice by transplantation of BM from 
affected mice and, remarkably, acts dominantly over WT BM. It is therefore 
tempting to speculate that DCs expressing DTR modulate the LN 
microenvironment, either via a soluble factor or cell-cell contact, to make it 
unfavourable for DC immigration. This factor could be DTR itself, either shed from, 
or expressed on the DC surface, or another factor made by DCs or other cells, 
upon engagement of DTR on DCs and EGF receptors on adjacent cells. Within the 
LN, either the lack of DCs or, again, a modulation of the microenvironment by DTR-
expressing DCs, may impair the homing to, or retention in the LN of lymphocytes, 
resulting in LN hypocellularity. In this regard, it is notable that paucity of DCs has 
been shown to cause shutdown of HEVs (Moussion and Girard, 2011). 
Furthermore, when DC migration to LNs is impaired due to a lack of CCR7, LNs 
also show a reduced number of HEVs, reduced LN size and T cell lymphopenia in 
LNs (Wendland et al., 2011).  
A few of these possibilities were tested here. DCs isolated from LNs from 
Clec9a+/CreROSAiDTR mice were less able to migrate to the chemokine CCL21 in an 
in vitro transwell assay, and while HEVs looked normal, the FRC network was 
altered in LN sections from Clec9a+/CreROSAiDTR mice. However, none of these 
results can fully explain the phenotype observed and none address the 
fundamental question of how DTR expression on DCs exerts its biological effects. It 
may be that the phenotype observed is a consequence of a complex interaction 
with the external environment. In this regard, it will be of interest to analyse the 
same strains across multiple animal facilities or after rederivation into a gnotobiotic 
environment. 
Whatever the underlying mechanism, these findings indicate a need for caution 
when interpreting results obtained with DTR-based mouse models to inducibly 
deplete DCs, as the steady-state immune system in such mice clearly differs from 
that of controls. In this regard, it is important to note that small LN size has been 
shown to markedly impact immune responses and resistance to infection (van de 
Pavert et al., 2014). Although the CFA/OVA immunisation and influenza X-31 
infection experiments presented here did not show a marked impairment in immune 
response in mice expressing DTR on DCs, these experiments were not exhaustive 
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and mice expressing DTR on DCs may still show impaired immune responses in a 
different setting.  
Why the phenotype described here appears to have passed unnoticed or at least 
unreported is unclear, but may in part be due to the tendency to use PBS-injected 
DTR-expressing mice (rather than littermates not expressing DTR) as controls for 
mice receiving DT. Based on the findings presented here, both types of controls 
are warranted and some of the changes in immune responses observed upon DT-
mediated DC depletion might in fact be a composite caused by acute loss of DCs, 
superimposed on underlying LN defects. These findings also suggest that simian 
HB-EGF possesses biological activities in mice that cannot be ignored. As such, 
DTR expression on other cell types, including those outside the immune system, 
might alter their biology or, as shown here, that of their immediate environment. 
The latter may require shedding via the action of cell-specific metalloproteinases, 
explaining why expression on some cells (e.g., B cells or Tregs) is apparently 
innocuous while that is not the case for expression on DCs. Clearly, the use of DTR 
in mice has pitfalls that might impact on experimental approaches and need to be 
tempered with the great advantages awarded by the ability to ablate cells at will. 
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Chapter 4. A Novel Mouse Model to Constitutively 
Ablate Dendritic Cells 
4.1 Introduction 
DCs mediate both central and peripheral tolerance, which are crucial to avoid 
autoimmune reactions to develop. It was therefore hypothesised that constitutive 
ablation of DCs would lead to spontaneous autoimmunity. Both Ohmnacht et al. 
(Ohnmacht et al., 2009) and Birnberg et al. (Birnberg et al., 2008) have tested this 
hypothesis by crossing CD11c-Cre mice to two different strains of ROSA26-DTA 
mice, generating mice in which CD11c-expressing cells are ablated through 
expression of DTA. Remarkably, only the crosses generated by Ohmnacht et al. 
(Ohnmacht et al., 2009) developed spontaneous autoimmunity with increased Th1 
and Th17 cells and the generation of autoantibodies, while Birnberg et al. (Birnberg 
et al., 2008) reported unaffected T cell homeostasis under steady state conditions. 
Furthermore, CD11c is not only expressed on DCs, but also on other immune cells, 
such as activated T cells and Ly-6Clow monocytes (Jung et al., 2002; Probst, 
Tschannen, et al., 2005; Hochweller et al., 2008). Moreover, DCs also impact on 
processes beyond the regulation of T cell responses, such as the regulation of 
innate immune responses (Mashayekhi et al., 2011; Satpathy et al., 2013; Arora et 
al., 2014; Whitney et al., 2014) and stromal behaviour (Moussion and Girard, 2011; 
Acton et al., 2014).  
 
In an attempt to address these outstanding issues, transgenic mice were generated 
that express the DTA protein under direct control of the endogenous Clec9a locus, 
following a similar knock-in strategy as was used to generate Clec9a-GFP (Sancho 
et al., 2009) and Clec9a-Cre mice (Schraml et al., 2013). In these Clec9a-DTA 
mice, DTA should be expressed in the CDP and preDCs, killing these DC 
precursors. Therefore, Clec9a-DTA mice should not harbour any DCs from very 
early in development. By utilising the Clec9a locus to drive DTA expression, 
ablation should be restricted to the DC lineage without affecting other (immune) 
cells, as opposed to models that use CD11c expression to manipulate DCs.  
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4.2 Generation of Clec9a-DTA mice to constitutively ablate 
DCs 
The targeting construct to generate Clec9a-DTA mice was derived from the 
pFloxRI-C9a-EGFP vector that was used to generate Clec9a-GFP mice (Sancho et 
al., 2009). The egfp gene was replaced by the gene encoding DTA. Successful 
targeting by homologous recombination disrupts the Clec9a open reading frame 
abrogating DNGR-1 expression and leading to DTA expression under control of the 
endogenous Clec9a locus (Figure 4.1).  
 
1 2 3
NeoDTA
NeoDTA
BamHI
BamHI
13kb
8.9kb
BamHI
BamHI
5.4kb
genomic
 locus
targeting
vector
targeted
locus
2.2 kb PCR
BamHI
5’ homology arm 3’ hom. arm
Southern Blot probe loxP Exon Homology arm  
Figure 4.1 Targeting strategy to generate Clec9a-DTA mice 
The endogenous genomic Clec9a locus is shown at the top, with the targeting 
vector to generate Clec9a-DTA mice below. The targeted allele is also depicted 
(bottom). The PCR product (2.2kb) to screen correctly targeted ES cells is shown. 
BamHI restriction enzyme target sites, the locations of the Neo probe and 5’ probe 
and the size of the fragments detected by Southern blot screening are shown. 
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Figure 4.2 Generation of Clec9a-DTA mice 
(A) ES cell clones were screened by a PCR that spans the 3’ homology arm and 
results in a 2.2kb PCR product if the clone is correctly targeted (see Figure 4.1). 
384 clones were screened, from which a selection is shown here. The arrow 
denotes clone 2H3. The targeting vector was used as positive control (vector)  and 
a no-DNA sample (H2O) was used as negative control. The size of the ladder 
fragments is denoted on the right in kb. (B) ES cell clones positive by PCR (clones 
1D1, 2H3 and 4E5) were screened by Southern blot via digestion with BamHI and 
detection with neo and 5’ probes (see Figure 4.1). (C) Genomic DNA from Clec9a-
DTA 2H3 mice was screened by Southern blot as in (B). Genotype denotes 
homozygous (D/D), heterozygous (+/D) and WT (+/+) Clec9a-DTA 2H3 littermates. 
(D) A semi-quantitative RT-PCR was performed to assess DTA mRNA levels on 
CD11c MACS-enriched splenocytes from Clec9a+/+ (+/+) and Clec9a+/DTA mice 
(+/DTA). cDNA was used undiluted or diluted 10 or 100 times before the PCR 
reaction was performed with primers for dta or hprt as control. The targeting vector 
used to generate the mice was used as a positive control. The size of the ladder 
fragments is denoted on the right in kb. All experiments were performed once. 
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A total of 384 ES cell clones were first screened for correct targeting by PCR, 
which resulted in three positive clones (1D1, 2H3 and 4E5) (Figure 4.2A). These 
clones were subsequently analysed by Southern blot analysis, confirming correct 
targeting of clones 2H3 and 4E5, but revealing multiple insertions of the targeting 
vector for clone 1D1 (Figure 4.2B). The two correctly targeted clones 2H3 and 4E5 
were next used to generate chimeric mice and germline transmission was 
assessed by genotyping PCR of the offspring. Only clone 2H3 germline transmitted 
and established a colony of Clec9-DTA 2H3 mice, while clone 4E5 failed to 
transmit into the germline, despite numerous breeding attempts with different 
chimeric founders. For the remainder of this chapter ‘Clec9a-DTA mice’ will 
therefore refer to the colony established from the 2H3 ES cell clone.  
To further validate the Clec9a-DTA mice, genomic DNA was screened by Southern 
blot. The Southern blot analysis confirmed correct and unique targeting of the 
Clec9a locus in a heterozygous and a homozygous Clec9a-DTA mouse (Figure 
4.2C). The dta gene and proximal promoter were also sequenced from genomic 
DNA from a heterozygous Clec9a-DTA mouse to confirm that no mutations were 
introduced in the process of generating this mouse strain. Indeed, no mutations 
were found. In addition, the expression of dta mRNA was confirmed in CD11c-
enriched splenocytes by semi-quantitative RT-PCR (Figure 4.2D). 
In sum, out of 384 ES cell clones two clones were confirmed to be correctly 
targeted, one of which resulted in a Clec9a-DTA mouse colony. Correct targeting 
was reconfirmed in these mice by Southern blot analysis and dta mRNA expression 
could be detected in CD11c-enriched splenocytes from these mice.  
4.3 Characterisation of Clec9a-DTA mice 
The Clec9a-DTA mouse line bred well and Clec9a+/DTA and Clec9aDTA/DTA mice were 
born at the expected mendelian frequencies. These mice did not show any signs of 
illness and all survived into adulthood. Furthermore, adult Clec9a+/DTA and 
Clec9aDTA/DTA mice did not have monocytosis and neutrophilia in the spleen (Figure 
4.3A) and also did not have increased spleen or mesLN cellularity (Figure 4.3B). 
These results indicate that they do not develop a myeloproliferative disorder, as 
opposed to what was reported for CD11c-Cre mice crossed to ROSA26-DTA mice 
(Birnberg et al., 2008; Ohnmacht et al., 2009).  
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Figure 4.3 Clec9a+/DTA and Clec9aDTA/DTA mice do not show signs of 
myeloproliferative disorder 
(A) Total numbers of monocytes (mono, CD11b+ Gr-1int) and neutrophils (neutro, 
CD11b+ Gr-1hi) in spleens of 8-12 week old Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA 
mice is shown. (B) Single-cell suspensions of spleens and mesLNs from 8-12 week 
old Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice were counted and the number of 
total leukocytes is plotted. A one-way ANOVA with a Tukey’s multiple comparisons 
post-test was performed to calculate p-values. Each dot represents one mouse.  
Ns: non significant. Data are pooled from three independent experiments. 
 
To address if DCs are actually ablated in Clec9a-DTA mice, spleens and mesLNs 
of Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice were analysed for the presence of 
DC subsets. Surprisingly, total DC frequency in the spleen was increased in 
Clec9a+/DTA and Clec9aDTA/DTA mice compared with controls, which was entirely 
attributable to an increase of the CD11b+ DC subset (Figure 4.4A). On the contrary, 
CD8α+ DC frequency was reduced in spleens of both Clec9a+/DTA and Clec9aDTA/DTA 
mice (Figure 4.4A). Similarly, the frequencies of CD8α+ resDCs and CD103+ 
migDCs were reduced in mesLNs of Clec9a+/DTA and Clec9aDTA/DTA mice compared 
with controls, while the frequencies of CD11b+ resDCs, CD103+ CD11b+ migDCs 
and CD11b+ migDCs remained unchanged or were slightly increased in Clec9a+/DTA 
and Clec9aDTA/DTA mice (Figure 4.4B).  
Normal numbers of DCs can be identified in Clec9a-DTA mice, indicating that not 
all CDPs and preDCs were ablated. The precursor frequency in the bone marrow of 
Clec9a+/DTA and Clec9aDTA/DTA mice was therefore assessed. As shown in Figure 
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4.5, MDPs were unaltered in Clec9a+/DTA and Clec9aDTA/DTA mice, which is in line 
with earlier observations that MDPs do not express DNGR-1 (Schraml et al., 2013). 
Interestingly, CDPs and preDCs were unaffected in BM of Clec9a+/DTA and 
Clec9aDTA/DTA mice (Figure 4.5), indicating that the intended ablation of these 
precursor populations had failed.  
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Figure 4.4 Clec9a+/DTA and Clec9aDTA/DTA mice show a reduction in CD8α-like DCs, 
but have increased frequencies of CD11b+ DCs in spleen and mesLNs 
(A) Total DCs (CD11c+ MHCII+)), CD8α+ DCs (CD11c+ MHCII+ CD8α+) and CD11b+ 
DCs (CD11c+ MHCII+ CD11b+) in spleens of 8-12 week old Clec9a+/+, Clec9a+/DTA 
and Clec9aDTA/DTA mice were identified by flow cytometry and DC subsets as 
percentage of live leukocytes are plotted. (B) Total resDCs (CD11c+ MHCIIint), 
CD8α+ resDCs (CD11c+ MHCIIint CD8α+) and CD11b+ resDCs (CD11c+ MHCIIint 
CD11b+) (left panel), and total migDCs (CD11c+ MHCIIhi), CD103+ migDCs 
(CD11c+ MHCIIhi CD11b- CD103+), CD103+ CD11b+ migDCs (CD11c+ MHCIIhi 
CD11b+ CD103+) and CD11b+ migDCs (CD11c+ MHCIIhi CD11b+ CD103-) (right 
panel) in mesLNs of 8-12 week old Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice 
were identified by flow cytometry and DC subsets as percentage of live leukocytes 
are plotted. A one-way ANOVA with a Tukey’s multiple comparisons post-test was 
performed to calculate p-values. Each dot represents one mouse. Ns: non 
significant, *: p≤0.05, **: p≤0.01, ***: p≤0.001, ****: p≤0.0001. Data are pooled from 
at least two independent experiments. 
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Figure 4.5 MDPs, CDPs and preDCs are unaffected in BM of Clec9a+/DTA and 
Clec9aDTA/DTA mice 
MDPs (lin- MHCII- CD11c- CD115+ CD135+ CD117hi), CDPs (lin- MHCII- CD11c- 
CD115+ CD135+ CD117low) and preDCs (lin- MHCII- CD11clow) in BM of 8-12 week 
old Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice were identified by flow cytometry 
and MDPs, CDPs and preDCs as percentage of live leukocytes are plotted. A one-
way ANOVA with a Tukey’s multiple comparisons post-test was performed to 
calculate p-values. Each dot represents one mouse. Ns: non significant. Data are 
from one experiment or pooled from two independent experiments.  
 
To address if Clec9a-DTA mice develop any spontaneous autoimmunity with age, a 
cohort of Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice (5-10 per group) was aged 
for a year. However, none of the mice developed any signs of illness or died. In line 
with these results, one year old Clec9a+/DTA and Clec9aDTA/DTA mice had normal 
frequencies of CD11b+ DCs in the spleen, while the CD8α+ DC subset was reduced, 
but not absent (Figure 4.6A). MDP and CDP frequencies in the BM of old 
Clec9a+/DTA and Clec9aDTA/DTA mice were also similar to controls (Figure 4.6B) and 
the size of the spleens in Clec9a+/DTA and Clec9aDTA/DTA mice was normal (Figure 
4.6C). In sum, Clec9a-DTA mice do not develop any spontaneous illnesses with 
age and the DC compartment is similar between old and young Clec9a-DTA mice. 
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Figure 4.6 Old Clec9a+/DTA and Clec9aDTA/DTA mice show a similar phenotype as 
young mice 
(A) Total DCs (CD11c+ MHCII+)), CD8α+ DCs (CD11c+ MHCII+ CD8α+) and CD11b+ 
DCs (CD11c+ MHCII+ CD11b+) in spleens of one year old Clec9a+/+, Clec9a+/DTA 
and Clec9aDTA/DTA mice were identified by flow cytometry and DC subsets as 
percentage of live leukocytes are plotted. (B) MDPs (lin- MHCII- CD11c- CD115+ 
CD135+ CD117hi) and CDPs (lin- MHCII- CD11c- CD115+ CD135+ CD117low) in BM 
of one year old Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice were identified by 
flow cytometry and MDP and CDP as percentage of live leukocytes are plotted. (C) 
Single-cell suspensions of spleens from one year old Clec9a+/+, Clec9a+/DTA and 
Clec9aDTA/DTA mice were counted and the number of total leukocytes is plotted. 
Each dot represents one mouse. Ns: non significant, **: p≤0.01. Data are from one 
experiment. 
 
As CD8α+ DCs in spleen and CD8α+ resDCs and CD103+ migDCs in mesLN 
express DNGR-1 in a WT mouse and DTA expression is under control of the 
Clec9a locus, DNGR-1 levels were assessed on the surviving CD8α-like DCs in 
Clec9a+/DTA mice (Clec9aDTA/DTA mice are knock out for DNGR-1, as the dta 
transgene disrupts the Clec9a gene). Surprisingly, the remaining CD8α+ DCs in the 
spleen and CD8α+ resDCs and CD103+ migDCs in mesLNs of Clec9a+/DTA mice still 
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expressed DNGR-1 protein (Figure 4.7A). Furthermore, the CDP in BM also 
expressed DNGR-1 protein, while DNGR-1 expression was virtually absent on 
MDPs, even in Clec9a+/+ control mice (Figure 4.7B). The lower expression levels of 
DNGR-1 in Clec9a+/DTA mice compared with Clec9a+/+ control mice were expected, 
as Clec9a+/DTA mice only harbour one WT Clec9a allele, instead of two in Clec9a+/+ 
control mice and a similar pattern was observed in Clec9a+/Cre mice (Schraml et al., 
2013).  
These results indicate that even though the Clec9a locus is actively transcribed and 
translated from the WT allele in Clec9a+/DTA mice, generating DNGR-1 protein, the 
transgenic DTA allele is not, as transcription and translation of DTA results in 
immediate death of the cell. 
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Figure 4.7 Clec9a+/DTA mice still express DNGR-1 
(A) CD8α+ DCs (CD11c+ MHCII+ CD8α+) in the spleen and CD8α+ resDCs (CD11c+ 
MHCIIint CD8α+) and CD103+ migDCs (CD11c+ MHCIIhi CD11b- CD103+) in 
mesLNs from 8-12 week old Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice were 
stained with an anti-DNGR-1 antibody and analysed by flow cytometry. Data are 
representative of at least five mice per group. (B) MDPs (lin- MHCII- CD11c- 
CD115+ CD135+ CD117hi) and CDPs (lin- MHCII- CD11c- CD115+ CD135+ 
CD117low) in BM of 8-12 week old Clec9a+/+, Clec9a+/DTA and Clec9aDTA/DTA mice 
were stained with an anti-DNGR-1 antibody and analysed by flow cytometry. Data 
are representative of four mice per group. 
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4.4 Discussion 
Dendritic cells are key players in both innate and adaptive immune processes and 
can exert both immunostimulatory and immunomodulatory effects. So, to which 
side would the balance shift if DCs were taken out of the equation? On one hand a 
DC-less immune system could be largely immunodeficient, while on the other hand 
spontaneous autoimmunity could occur. In an attempt to answer this question, both 
Ohmnacht et al. (Ohnmacht et al., 2009) and Birnberg et al. (Birnberg et al., 2008) 
generated a DC-less mouse by crossing CD11c-Cre mice to two different strains of 
ROSA26-DTA mice. And although the results were mixed in terms of the 
development of autoimmunity, both groups reported that mice lacking DCs develop 
a myeloproliferative disorder, uncovering an unanticipated role for DCs in 
maintaining myeloid cell homeostasis. 
 
Here, Clec9a-DTA mice were generated to re-address the question what influence 
a constitutive lack of DCs has on the immune system, using a model in which 
deletion should only affect the DC lineage. The restricted deletion is of importance, 
as CD11c is not only expressed on DCs, but also on other immune cells such as 
activated T cells and Ly-6Clow monocytes (Jung et al., 2002; Probst, Tschannen, et 
al., 2005; Hochweller et al., 2008) and therefore these cells are likely to be affected 
in CD11c-Cre mice crossed to ROSA26-DTA mice. Especially the possible deletion 
of activated T cells is of importance here, as these cells are likely to play a role in 
autoimmune disorders. Differential deletion of activated T cells may explain why 
Ohmnacht et al. (Ohnmacht et al., 2009) observed spontaneous autoimmunity and 
Birnberg et al. (Birnberg et al., 2008) did not in similar mouse models.  
The generation of DTA transgenic mouse lines is risky, as any leakiness of the 
regulatory elements that control DTA expression will lead to aberrant DTA 
expression and immediate death of the cell. If this happens at the ES cell stage or 
early during development, these cells or embryos will die and do not give rise to a 
transgenic mouse line. This may explain why only one of the two confirmed ES cell 
clones transmitted to the germline, as aberrant DTA expression may have rendered 
the chimeras generated from clone 4E5 infertile. Mice generated from clone 2H3 
did not show the expected phenotype of a fully DC-less mouse. Instead, only DC 
subsets that express DNGR-1 as differentiated cells were reduced, while DNGR-1 
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negative DC subsets were unaffected, along with the CDP and preDC in the BM. 
Intriguingly, the surviving CD8α-like DCs in Clec9a+/DTA mice still expressed DNGR-
1 protein on the cell surface and CDPs also clearly stained positive for DNGR-1 by 
flow cytometry.  
An initial explanation for the observed phenotype of Clec9a-DTA mice could be that 
the dta gene is not functional in these mice. However, sequencing did not show any 
mutations in the gene itself or in the proximal promoter. In addition, Southern blot 
analysis confirmed correct integration in the genome. Moreover, CD8α-like DCs are 
reduced in Clec9a-DTA mice, indicating that DTA exerts some effects on the DC 
compartment in these mice. As any leakiness of the DTA construct will lead to 
immediate cell death, the whole process of generating Clec9a-DTA mice may have 
resulted in the selection of a hypomorph ES cell clone, giving rise to mice with 
reduced DTA expression. This event should occur either by epigenetic 
modifications of the locus, or by mutations in locus control regions outside of the 
proximal promoter that was sequenced. This hypothesis may explain why residual 
CD8α-like DCs still expressed DNGR-1 in Clec9a+/DTA mice, as the WT allele is 
unlikely to have been selected for an altered expression pattern. Furthermore, this 
hypothesis may also clarify why CDP and preDC frequencies were not affected, 
while CD8α-like DCs were reduced, as the Clec9a locus is likely to be regulated 
differently in DC precursors compared with differentiated CD8α-like DCs and 
(epi)genetic modifications of the Clec9a-dta allele may affect precursors and 
differentiated DCs differently.  
 
As Clec9a-DTA mice still harbour plenty of DCs, they are not useful to address the 
original research proposal of studying a DC-less immune system. Furthermore, 
although CD8α-like DCs are reduced in both Clec9a+/DTA and Clec9aDTA/DTA mice, 
they are not completely absent. This feature renders this mouse strain not useful to 
study the immune system in the absence of CD8α-like DCs and use them as an 
alternative for Batf3-/- mice.  
In summary, Clec9a-DTA mice were successfully generated, but did not show the 
intended phenotype of a DC-less mouse. These mice are therefore unlikely to be 
useful for future experiments.  
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Chapter 5. Fate Mapping of Single Dendritic Cell 
Precursors in the Small Intestine 
5.1 Introduction 
At a population level the progeny of CDPs and preDCs can be traced either by 
performing adoptive transfer studies, or by using lineage tracer mice. Both CDPs 
and preDCs express DNGR-1 and therefore mice expressing Cre recombinase 
under the control of the Clec9a locus can be used to trace the cDC lineage in vivo, 
when crossed to a fluorescent reporter line (Schraml et al., 2013). Both in adoptive 
transfer studies and in lineage tracer mice, DC precursor output is investigated at 
the population level and does not take into account cell-to-cell variations. Therefore, 
it is currently not known what is the clonal burst size of individual preDCs upon 
arrival in tissues, and if this changes under inflammatory conditions.  
Assessment of the behaviour of single precursors has been complicated by their 
scarceness and lack of unique markers. Here, a novel system is proposed to study 
how individual DC precursors seed peripheral tissues, both in steady state and 
during inflammation. To trace DC precursor progeny, the multicolour fluorescent 
reporter line ROSA26-confetti was used (Snippert et al., 2010). As shown in Figure 
5.1, ROSA26-confetti mice contain a strong promoter that allows for constitutive 
and ubiquitous gene expression, a loxP-flanked neomycin cassette that acts as 
STOP cassette preventing expression of downstream genes and the Brainbow-2.1 
cassette that contains genes encoding nuclear GFP, cytoplasmic YFP, cytoplasmic 
RFP and membrane-bound CFP (Livet et al., 2007; Snippert et al., 2010). 
Expression of Cre results in the stochastic recombination of loxP sites, which will 
either remove the floxed region when the loxP sites are oriented in the same 
direction, or induces inversion of the region when the loxP sites are oriented in 
opposite directions. The outcome of Cre-mediated recombination of the ROSA26-
confetti locus is the stochastic and heritable expression of one of the four 
fluorescent proteins. When Clec9a-Cre mice are crossed with ROSA26-confetti 
mice, Cre recombinase activity at the CDP and preDC stage is predicted to 
stochastically label these precursors with one of the four fluorescent proteins 
(Snippert et al., 2010; Schraml et al., 2013). The offspring of these precursors can 
Chapter 5. Results 
 
141 
 
then be visualised in tissues by confocal microscopy. Ideally, this labelling should 
be done using temporal control of Cre activity, so that DC precursors are ‘pulse-
labelled’, and their offspring can be ‘chased’ in the tissues. To achieve temporal 
control over precursor labelling, mice were generated that express an inducible 
form of Cre (CreERT2) under control of the Clec9a locus. In this chapter, the 
generation of such mice is reported, as well as the failure to use them to inducibly 
label DCs when crossed to fluorescent reporter mice. The remainder of the chapter 
therefore reports on the alternative strategy of using Clec9a-Cre mice crossed to 
ROSA26-confetti mice for DC fate mapping studies. 
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Figure 5.1 Schematic representation of ROSA26-confetti mice 
Schematic overview of the ROSA26-confetti locus. LoxP sites in forward or reverse 
orientation, the Neo-containing STOP cassette and the genes encoding nuclear 
GFP (nGFP), cytoplasmic YFP (YFP), cytoplasmic RFP (RFP) and membrane-
bound CFP (mCFP) are shown. A flipped font indicates that the gene is oriented in 
the opposite direction and will not be transcribed.  
 
5.2 Generation of Clec9a-CreERT2 mice to allow for temporal 
control over Cre recombination 
Clec9a-Cre mice have proven useful to trace the DC lineage, as Cre recombinase 
is expressed in CDPs and preDCs in these mice, in addition to pDCs and CD8α-
like DCs (Schraml et al., 2013). However, in these mice the Cre recombinase is 
always active and continuously labels DC precursors. To trace the fate of single 
precursors, an inducible Cre system that allows for temporal control over DC 
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precursor labelling would be ideal. CreERT2 is a fusion protein of mutated 
hormone-binding domains of the oestrogen receptor and Cre, and is only functional 
when bound to 4OH-tamoxifen. Clec9a-CreERT2 mice were generated in a similar 
way to Clec9a-DTA (see Chapter 4) and to Clec9a-Cre mice (Schraml et al., 2013) 
by using the pFloxRI-C9a-EGFP vector that was originally used to generate 
Clec9a-GFP mice (Sancho et al., 2009). The egfp gene was replaced by the gene 
encoding CreERT2, generating the pFloxRI-C9a-CreERT2 targeting vector. This 
vector was used to replace exons one and two of the endogenous Clec9a locus 
with the gene encoding CreERT2 and a floxed Neo cassette, as depicted in Figure 
5.2. 
 
1 2 3
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BamHI
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BamHI
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Southern Blot probe loxP Exon Homology arm
 
Figure 5.2 Targeting strategy to generate Clec9a-CreERT2 mice 
The endogenous genomic Clec9a locus is shown at the top, with the targeting 
vector to generate Clec9a-CreERT2 mice below. The targeted allele is also 
depicted (bottom). The PCR product (2.2kb) to screen correctly targeted ES cells is 
shown. BamHI restriction enzyme target sites, the locations of the Neo probe and 
5’ probe and the size of the fragments detected by Southern blot screening are 
shown. 
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Figure 5.3 Generation of Clec9a-CreERT2 mice 
(A) ES cell clones were screened by a PCR that spans the 3’ homology arm and 
results in a 2.2kb PCR product if the clone is correctly targeted (see Figure 5.2). 
384 clones were screened, from which examples are shown here. The arrows 
denote clones 1B8 and 2H10. The targeting vector to generate the mice was used 
as positive control (vector) and a no-DNA sample (H2O) was used as negative 
control. The size of the ladder fragments is denoted on the right in kb. (B) ES cell 
clones positive by PCR were screened by Southern blot via digestion with BamHI 
and detection with neo and 5’ probes (see Figure 5.2). Southern blots of two clones 
(clones 1B8 and 2H10) are shown. (C) Genomic DNA from two founder Clec9a-
CreERT2 mice was screened by Southern blot as in (B). Mice originating from ES 
cell clone 1B8 are denoted as ‘1’ and mice originating from ES cell clone 2H10 as 
‘2’ Genotype are homozygous (C/C), heterozygous (+/C) and WT (wt) Clec9a-
CreERT2 mice. In some mice the Neo cassette was crossed out. (D) A semi-
quantitative RT-PCR was performed to assess CreERT2 mRNA levels on Flt3l BM-
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derived DCs from Clec9a+/+ (+/+) and Clec9a+/CreERT2 2H10 mice (+/C). cDNA was 
used undiluted or diluted 10 or 100 times before the PCR reaction was performed 
with primers for creert2 or hprt as control. The targeting vector was used as a 
positive control. The size of the ladder fragments is denoted on the right in kb. All 
experiments were performed once. 
 
C57BL/6-derived ES cells were transfected with the linearized pFloxRI-C9a-
CreERT2 targeting vector and selected for neomycin resistance. A total of 384 
clones were initially screened by PCR for correct targeting and clones positive by 
PCR were additionally subjected to Southern blot analyses (Figure 5.3AB). Out of 
the 384 clones initially screened, six were correctly targeted and two of these, 
clones 1B8 and 2H10, were used to generate chimeric mice (Figure 5.3AB). Both 
clones transmitted to the germline and colonies of Clec9a-CreERT2 1B8 and 
Clec9a-CreERT2 2H10 mice were established. The floxed Neo cassette was 
removed by crossing these mice to PGK-Cre mice (Lallemand et al., 1998). To 
reconfirm correct targeting and removal of the Neo cassette, Southern blot analysis 
was performed on genomic DNA from Clec9a-CreERT2 1B8 and Clec9a-CreERT2 
2H10 mice that either retained the Neo cassette or had the Neo cassette crossed 
out. As shown in Figure 5.3C, all mice tested showed correct targeting and 
predicted presence or absence of the Neo cassette. The Creert2 gene and 
proximal promoter were also sequenced from genomic DNA of a heterozygous 
Clec9a-CreERT2 2H10 mouse to confirm the absence of mutations. As a final 
validation step, Creert2 mRNA levels were measured via semi-quantitative PCR in 
Flt3l BMDCs. Indeed, Creert2 mRNA was detected in BMDCs from heterozygous 
Clec9a-CreERT2 2H10 mice, but not in control BMDCs (Figure 5.3D). 
 
In summary, two different Clec9a-CreERT2 founder lines, 1B8 and 2H10, were 
successfully generated. Correct targeting was confirmed by Southern blot and 
Creert2 mRNA could be detected in Flt3l BM-derived DCs from Clec9a-CreERT2 
2H10 mice. 
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5.3 Characterisation of Clec9a-CreERT2 mice 
Both Clec9a-CreERT2 1B8 and Clec9a-CreERT2 2H10 mice were initially crossed 
to the ROSA26-YFP reporter line (Srinivas et al., 2001) to assess the efficiency of 
tamoxifen-induced CreERT2 activity. In a first experiment Clec9a+/CreERT2 
1B8ROSA+/YFP and Clec9a+/CreERT2 2H10ROSA+/YFP mice were fed a tamoxifen-
containing diet for six days. A ROSA26-CreERT2 mouse (that expresses CreERT2 
in all cells) (Ventura et al., 2007) crossed to the ROSA26-YFP reporter line 
(Srinivas et al., 2001) was included as a positive control. Unfortunately, the 
tamoxifen-containing diet proved to be very inefficient in inducing Cre-mediated 
recombination, even in the ROSACreERT2/YFP mice (Figure 5.4A). Similarly, oral 
gavage of tamoxifen failed to induce any YFP labelling in ROSACreERT2/YFP mice 
(Figure 5.4B). The absence of YFP expression in splenic DCs from Clec9a+/CreERT2 
1B8ROSA+/YFP and Clec9a+/CreERT2 2H10ROSA+/YFP mice in these experiments was 
therefore not interpretable (Figure 5.4).  
 
ROSA26-based fluorescent reporter lines differ in the efficiency of reporter 
expression, even when crossed to the same Cre driver (J. Liu et al., 2013). It has 
been shown that ROSA26-mTmG mice, which express membrane-bound Tomato 
before recombination and membrane-bound GFP after recombination, and 
ROSA26-dTomato mice are much more efficient in recombining the loxP sites than 
ROSA26-YFP mice (Srinivas et al., 2001; Muzumdar et al., 2007; Madisen et al., 
2010; J. Liu et al., 2013). Clec9a-CreERT2 1B8 and Clec9a-CreERT2 2H10 were 
therefore crossed to ROSA26-mTmG mice and to ROSA26-dTomato mice. These 
mice, along with ROSACreERT2/mTmG mice as positive control, were injected i.p. with 
tamoxifen to induce recombination. Even though tamoxifen injection induced robust 
GFP expression in splenic DCs of ROSACreERT2/mTmG mice, this treatment regime did 
not induce any recombination in Clec9a-CreERT2 1B8 and Clec9a-CreERT2 2H10 
mice crossed to either ROSA26-mTmG mice or ROSA26-dTomato mice (Figure 
5.5A). Subcutaneous injection of tamoxifen into Clec9a+/CreERT2 1B8ROSA+/mTmG mice 
also failed to induce recombination, despite the fact that the same treatment 
induced robust GFP expression in ROSACreERT2/mTmG mice (Figure 5.5B). 
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Figure 5.4 Tamoxifen-containing diet or oral gavage of tamoxifen does not 
induce labelling of DCs in the spleen of Clec9a+/CreERT2ROSA+/YFP mice 
(A) Mice were fed a tamoxifen-containing diet (TAM400) for six days. Spleens were 
analysed on day 6. Total DCs were identified as live, autofluorescent-negative 
CD11c+ MHCII+ cells and YFP expression was assessed in this population. (B) 
Mice were gavaged with 4mg tamoxifen for four days and analysed four days after 
the last gavage. Total DCs were identified as live, autofluorescent-negative CD11c+ 
MHCII+ cells and YFP expression was assessed in this population. These 
experiments were performed once with one mouse per group. 1B8 and 2H10 
denote the different founder lines. 
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Figure 5.5 I.p. or s.c. injection of tamoxifen does not induce labelling of DCs in 
the spleen of Clec9a+/CreERT2ROSA+/mTmG mice 
(A) Mice were injected i.p. on five consecutive days with 100µg tamoxifen per g 
body weight and analysed on day 6. Total DCs were identified as live, 
autofluorescent-negative CD11c+ MHCII+ cells and GFP (for ROSA26-mTmG 
crosses) or Tomato (for ROSA26-dTomato crosses) expression was assessed in 
this population. This experiment was performed twice with one mouse per group for 
ROSA26-mTmG crosses, once for ROSA26-dTomato crosses and once with 
Clec9a+/CreERT2 1B8ROSA+/YFP and Clec9a+/CreERT2 2H10ROSA+/YFP mice that still 
harboured the Neo cassette, with similar outcomes. (B) Mice were injected s.c. with 
8mg tamoxifen on day 1, 3 and 5 and analysed on day 6. Total DCs were identified 
as live, autofluorescent-negative CD11c+ MHCII+ cells and GFP expression was 
assessed in this population. This experiment was performed once with one mouse 
per group. 1B8 and 2H10 denote the different founder lines and ΔNeo refers to a 
crossed-out Neo cassette 
 
As tamoxifen is a prodrug that needs to be metabolised in the liver and in vivo 
administration might lead to poor bioavailability, CreERT2 activity was next tested 
in an in vitro setting. To this end Flt3l BM-derived DCs were generated from 
Clec9a+/CreERT2 1B8ROSA+/mTmG and Clec9a+/CreERT2 2H10ROSA+/mTmG mice in the 
presence of 4OH-tamoxifen. This setup generated a high degree of recombination 
in control Flt3l BMDC cultures generated from ROSACreERT2/mTmG mice. However, no 
GFP expression was observed in Clec9a+/CreERT2 1B8ROSA+/mTmG and Clec9a+/CreERT2 
2H10ROSA+/mTmG cultures, despite the fact that these cells express mRNA for 
Creert2 (Figure 5.3D, Figure 5.6). 
 
In sum, even though two Clec9a-CreERT2 founder lines were successfully 
generated, neither of them showed any sign of recombinase activity when crossed 
to various reporter lines, when tamoxifen was administered via oral or parental 
routes in vivo, or when Flt3l BMDC cultures were treated with 4OH-tamoxifen. 
Therefore, regrettably and for reasons that are unclear, the conclusion can only be 
that the Clec9a-CreERT2 1B8 and Clec9a-CreERT2 2H10 mice do not permit 
induction of Cre activity and labelling of DCs.  
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Figure 5.6 Treatment of Flt3l BMDC cultures from Clec9a+/CreERT2ROSA+/mTmG BM 
with 4OH-tamoxifen does not induce labelling of DCs 
Flt3l BMDCs were generated, 1µM 4OH-tamoxifen was added to the cultures on 
day 0 and the in vitro cultures were analysed on day 9. GFP expression was 
assessed in total live cells. This experiment was performed twice with BM cultures 
from one mouse per group. The same experiment was performed twice with Flt3l 
BMDCs generated from Clec9a+/CreERT2 2H10ROSA+/YFP mice (with Neo) and once 
with Flt3l BMDCs generated from Clec9a+/CreERT2 1B8ROSA+/YFP mice (with Neo), 
with similar outcomes. 1B8 and 2H10 denote the different founder lines and ΔNeo 
refers to a crossed-out Neo cassette 
 
5.4 Histo-cytometric analysis of DC precursor fate in the small 
intestine using Clec9a+/CreROSA+/confetti mice 
As Clec9a-CreERT2 mice proved not to allow for DC labelling, analyses of how 
individual preDCs seed tissues and if preDC behaviour changes under 
inflammatory conditions were performed with Cleca9-Cre mice (Schraml et al., 
2013). These mice were crossed to ROSA26-confetti mice, so that DC precursors 
were stochastically labelled with one of four fluorescent proteins: nuclear GFP, 
cytoplasmic YFP, cytoplasmic RFP or membrane-bound CFP (Snippert et al., 
2010). All mice used here harboured one copy of Cre and one copy of the confetti 
locus and are called Clec9a+/CreROSA+/confetti mice throughout.  
Clec9a+/CreROSA+/confetti mice were used to address the kinetics and dynamics of 
tissue seeding by DCs. Specifically, to test whether preDCs arrive in tissues and 
directly differentiate into a DC without prior division, or divide locally before 
differentiating into one or multiple DC subsets. In the former situation the pattern of 
DC labelling would be random, while in the latter situation the labelled DCs would 
form clusters of one colour. Therefore, a microscopy-based approach was 
developed in collaboration with Ronald Germain and Michael Gerner to analyse DC 
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precursor fate. The small intestine was chosen for the initial analysis, as its 
mononuclear phagocytes are well characterised and the villus-crypt structure 
imposes spatial restrictions to motile DCs, facilitating analysis. To this end, small 
intestines of Clec9a+/CreROSA+/confetti mice were frozen according to the PLP 
protocol before sectioning (Bajénoff, Granjeaud and Guerder, 2003; Gerner et al., 
2012). Tissue sections were rehydrated and analysed by confocal microscopy. As 
the emission spectra of CFP, GFP and YFP show considerable overlap, lambda 
mode scanning and subsequent unmixing were used to faithfully detect all confetti 
colours, using the 458nm, 514nm and 561nm lasers to excite the four fluorescent 
proteins (see Figure 5.7 for emission spectra and microscope setup). As shown in 
Figure 5.8 the PLP protocol worked well for preserving fluorescence and the 
lambda mode scanning and unmixing faithfully separated the four fluorescent 
proteins. The image of the small intestine in Figure 5.8A shows that the tissue 
autofluorescence can be used to identify the villi and that there are many confetti-
labelled cells in isolated lymphoid follicles and mesLNs (Figure 5.8AB).  
 
Even though the ROSA26-confetti locus is constructed in such a way that only one 
fluorescent protein can be transcribed at a time ((Snippert et al., 2010) and Figure 
5.1), and the mice analysed here only had one copy of the ROSA26-confetti locus, 
cells double-positive for CFP and RFP could be identified in both the small intestine 
as well as the mesLNs (Figure 5.8AB). The most likely explanation for this 
phenomenon is that these cells continuously express Cre recombinase and 
therefore constantly ‘flip’ the CFP-RFP cassette of the confetti construct, as shown 
on the bottom right of Figure 5.1. Fluorescent proteins have a half-life of around 
one day and therefore cells that express Cre can accumulate both RFP and CFP 
protein, despite only transcribing and translating one of them at any given time. 
Interestingly, only CFP-RFP double-positive cells and not GFP-YFP cells were 
observed. This discrepancy probably reflects a preference of the GFP-YFP 
cassette for YFP, as was also reported in the original paper describing the 
ROSA26-confetti mice (Snippert et al., 2010). As Cre expression is regulated by 
the clec9a locus, it is expected that these CFP-RFP double-positive cells are the 
DNGR-1-expressing CD8α-like DCs, although this hypothesis remains to be tested.  
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Figure 5.7 Overview of fluorophores and microscope setup 
(A) Representation of the emission spectra of the fluorophores used in the analysis 
of Clec9a+/CreROSA+/confetti mice by histo-cytometry. In some experiments APC was 
used instead of AF647 (which have similar emission spectra). (B) Schematic 
overview of the setup of the Zeiss LSM880 Invert confocal microscope for lambda 
mode scanning (32-channel GaAsP detector) with an additional PMT detector to 
acquire 686-735nm emission. 
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Figure 5.8 Visualisation of confetti colours in small intestine and mesLN of 
Clec9a+/CreROSA+/confetti mice 
30µm frozen sections of small intestine (A) and mesLN (B) of 
Clec9a+/CreROSA+/confetti mice were rehydrated and analysed by microscopy using 
lambda mode scanning and unmixing. (A) Labelled cells in villi (insert 1) and 
isolated lymphoid follicle (insert 2) are shown. In the overview image 
autofluorescence of the tissue shows the villi. (B) The T cell zone of the mesLN is 
shown. Arrowheads in insert 2 identify cells that express both RFP and CFP.  
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As shown in Figure 5.8A, the tissues autofluorescence can give and idea of tissue 
organisation, but this signal is often faint and unreliable to be useful for 
quantification. So, ideally tissue sections should be stained with a marker 
identifying villi and crypts before analysis by microscopy. Additionally, further 
analysis of the confetti-positive cells would be greatly aided by an extra marker for 
DCs. To incorporate two antibody stains, the lambda mode scanning and unmixing 
protocol was expanded so that antibodies coupled to the fluorophores AF594 and 
AF647 or APC could be used to stain the confetti sections (Figure 5.7 for emission 
spectra). The 458/514/561nm lasers were still used to excite the confetti 
fluorophores. The 561nm laser additionally excited AF594, while the 633nm laser 
excited AF647. An antibody against E-cadherin (CD324) coupled to AF594 was 
delineated the villi and crypts and one against MHCII coupled to AF647 helped 
identifying confetti-positive DCs. As shown in Figure 5.9, this configuration allowed 
for the separation of all six fluorophores. As anticipated, the E-cadherin stain 
greatly aided the identification of villi and crypts and the MHCII stain mainly stained 
cells in the lamina propria. These MHCII+ cells are DCs, but also other myeloid 
cells and B cells.  
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Figure 5.9 Analysis of small intestinal sections of Clec9a+/CreROSA+/confetti mice for 
confetti colours, MHCII and E-cadherin 
A 100µm frozen section of small intestine of Clec9a+/CreROSA+/confetti mice was 
stained with antibodies against MHCII and E-cadherin, coupled to AF647 and 
AF594 respectively, and analysed by microscopy using lambda mode scanning and 
unmixing. In the insert arrows denote CFP-positive cells and arrowheads GFP-
positive cells in a single villus.  
 
Although the six-fluorophore panel used in Figure 5.9 was sufficient to identify 
MHCII+ confetti cells and the villus-crypt structure of the tissue, this panel was 
insufficient to identify different DC subsets within the confetti-positive population. 
This distinction is important to address if one DC precursor can give rise to only 
one or multiple DC subsets in the tissue. To identify DC subsets in the small 
intestine by flow cytometry, a combination of CD11c, MHCII, CD64, CD11b and 
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CD103 (or CD24) is normally used, with DCs being CD11c+ MHCII+ and CD64-, 
and CD11b and CD103 (or CD24) identifying the three different DC subsets in the 
intestine (Figure 2.2). However, it is not feasible to perform confocal microscopy on 
five markers to identify DCs on top of four confetti colours and a structural marker. 
Therefore, it was decided to only use MHCII to help identifying confetti-positive 
DCs and find two markers that could be used for microscopy to identify the DC 
subsets in the intestine. The first obvious choice was to use CD11b and CD103 to 
stain DC subsets in tissues. Although an antibody against CD11b worked nicely for 
microscopy, antibodies against CD103 failed to show any staining (data not shown). 
Antibodies against CD24 and DNGR-1 also did not work (data not shown), but an 
antibody against the transcription factor IRF8 looked promising. Within the DC 
population, IRF8 expression was confirmed to be restricted to CD103+ CD11b- DCs 
in the small intestine by flow cytometry (Figure 5.10A). A MHCII- CD11c- CD11b+ 
population also expresses IRF8 and these cells are likely to be eosinophils based 
on their scatter profile (data not shown). Nonetheless, within the DC population 
IRF8 and CD11b expression clearly separated CD103+ CD11b- DCs from CD103+ 
CD11b+ DCs and CD103- CD11b+ DCs (Figure 5.10A). Unfortunately, IRF8 and 
CD11b expression could not separate CD103+ CD11b+ DCs from CD103- CD11b+ 
DCs, but at least CD8α-like and CD11b+ DCs could be identified via IRF8 and 
CD11b expression. Indeed, analysis of intestinal sections of Clec9a+/CreROSA+/confetti 
mice stained with CD11b, IRF8 and MHCII revealed that confetti-positive cells 
could be found that were either positive for IRF8 or for CD11b (Figure 5.10B). So, 
staining for IRF8 and CD11b can identify CD8α-like and CD11b+ DCs in the 
intestine by microscopy. 
 
For microscopy antibodies against IRF8 and CD11b coupled to AF594 or APC 
were used, which meant that antibodies against MHCII and a structural marker had 
to be conjugated to different fluorophores than in Figure 5.9. MHCII could be 
detected with an antibody coupled to AF700, when excited by the 633nm laser. 
However, the 32-channel GaAsP detector had a limit of detection of 687nm, which 
meant that AF700 emission could not be detected with the standard lambda mode 
setup. To solve this problem, a second, conventional channel was added that 
detected emitted light of 686-735nm and could therefore pick up the AF700 
emission (see Figure 5.7 for emission spectra and microscope setup). This channel 
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was incorporated in the unmixing as a 33rd channel, in addition to the 32 channels 
from the GaAsP detector. To visualise the villus-crypt structure, an antibody against 
EpCAM was used instead of E-cadherin, as this antibody worked very well when 
coupled to BV421 and nicely stained the intestinal epithelium. BV421 was excited 
with the 405nm laser and detected via lambda mode scanning. However, when the 
405nm dichroic was used, the laser power reaching the sample was too strong, 
leading to increased autofluorescence and imbalance between BV421 and CFP. 
Therefore, instead of the 405nm dichroic, a plate was used that reflected most of 
the laser light and only allowed a small percentage to reach the sample. This 
modification resulted in an artificially turned down laser power that was sufficient to 
excite the BV421 fluorophore, without increased autofluorescence or problems in 
detecting CFP (see Figure 5.7). 
Indeed this configuration to simultaneously detect eight colours by confocal 
microscopy allowed for the visualisation of villi and crypts by EpCAM staining, 
showed confetti-positive cells and could refine the phenotypical analysis of these 
cells by MHCII, IRF8 and CD11b expression. Figure 5.11 and Figure 5.12 show 
two examples of images of intestinal sections of a Clec9a+/CreROSA+/confetti mouse 
stained with anti-EpCAM-BV421, anti-CD11b-AF594, anti-IRF8-APC and anti-
MHCII-AF700. 
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Figure 5.10 IRF8 and CD11b can be used to identify DC subsets in the small 
intestine by microscopy 
(A) CD103+ CD11b- DCs (CD11c+ MHCII+ CD64- CD24+ CD11b-), CD103+ CD11b+ 
DCs (CD11c+ MHCII+ CD64- CD24+ CD11b+) and CD103- CD11b+ DCs (CD11c+ 
MHCII+ CD64- CD24- CD11b+) in the small intestine of C57Bl/6J mice were 
identified by flow cytometry and expression of IRF8 and CD11b was assessed in 
an overlay graph. Plots are representative of three mice. (B) A 30µm frozen section 
of small intestine of Clec9a+/CreROSA+/confetti mice was stained with antibodies 
against MHCII, CD11b and IRF8, and analysed by microscopy using lambda mode 
scanning and unmixing. The images shown here are close-ups of Figure 5.12. 
Arrows show confetti cells that are positive for CD11b and arrowheads show 
confetti cells positive for IRF8.  
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Figure 5.11 8-Colour analysis of the small intestine of Clec9a+/CreROSA+/confetti 
mice (1) 
A 30µm frozen section of small intestine of Clec9a+/CreROSA+/confetti mice was 
stained with antibodies against MHCII, CD11b, IRF8 and EpCAM and analysed by 
microscopy using lambda mode scanning and unmixing. Scale bar is 100µm. 
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Figure 5.12 8-Colour analysis of the small intestine of Clec9a+/CreROSA+/confetti 
mice (2) 
A 30µm frozen section of small intestine of Clec9a+/CreROSA+/confetti mice was 
stained with antibodies against MHCII, CD11b, IRF8 and EpCAM and analysed by 
microscopy using lambda mode scanning and unmixing. Scale bar is 100µm. 
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The images shown in Figure 5.10B, Figure 5.11 and Figure 5.12 already provide 
useful information on the clonality of confetti-positive cells within villi and their 
subset distribution. However, these 8-colour images are also difficult to interpret 
and additional information remains hidden in the complexity of the data. 
Furthermore, these images as such are not suitable for more quantitative analyses. 
Therefore, images were quantified by histo-cytometry (Gerner et al., 2012; Gerner, 
Torabi-Parizi and Germain, 2015). In order to quantify the confetti-positive cells, 
surfaces were generated on the individual cells by using the surface rendering tool 
built into Imaris imaging software. Surface rendering was performed subsequently 
on the CFP, GFP, YFP and RFP channel. An example of the surfaces generated in 
an isolated lymphoid follicle is shown in Figure 5.13A, while all surfaces for the 
image in Figure 5.11 are shown in Figure 5.13B. The software correctly identified 
all confetti cells that were visible by eye, however, it also assigned surfaces to 
autofluorescent structures such as the blood vessel in the bottom left corner of 
Figure 5.13A.  
 
To further analyse these confetti surfaces, surface parameters (intensities of 
separate channels and location) were imported into FlowJo 10 to perform flow 
cytometry-like gating. The first step comprised of removing MHCII- surfaces from 
the analysis, as these surfaces likely correspond to autofluorescent structures 
(Figure 5.14A and Figure 5.15A). The original image was always used as a 
reference when performing gating. The XY-coordinates of these surfaces were then 
superimposed on a density plot of surfaces generated on the EpCAM channel to 
visualise the villi, as shown in Figure 5.14B and Figure 5.15B. Furthermore, the 
expression of IRF8 and CD11b by confetti surfaces could be visualised (Figure 
5.14C and Figure 5.15C). Based on the flow cytometry data in Figure 5.10A, almost 
all confetti surfaces should be either IRF8+ or CD11b+, but cannot be positive for 
both or negative for both. Consistent with this notion, very few IRF8+ CD11b+ 
surfaces were identified. However, many surfaces appeared to be negative for both 
IRF8 and CD11b by histo-cytometry (Figure 5.14C and Figure 5.15C). For the 
GFP+ surfaces this result is not surprising, as GFP is a nuclear marker and the 
surface generated on a GFP object will only capture the nucleus of the cell with 
very little cytoplasm or membrane, which means that a membrane marker such as 
CD11b would not be captured by the GFP surface. However, also many CFP+, 
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YFP+ and RFP+ surfaces appeared to be negative for both IRF8 and CD11b, which 
exemplifies that histo-cytometry is less sensitive than flow cytometry to measure 
marker expression of cells. Unfortunately, a specific DC subset can only be 
attributed to surfaces that are either positive for IRF8 or for CD11b.  
 
The images of small intestinal villi presented throughout this chapter clearly show 
the presence of cells of the same colour in individual villi. Examples can be found in 
insert 1 of Figure 5.8A and the GFP+ cluster identified by arrowheads and the CFP+ 
cluster identified by arrows in the insert of Figure 5.9. These clusters of cells of the 
same colour are even easier to identify in the FlowJo quantifications of Figure 5.11 
and Figure 5.12. Cells of the same colour in individual villi can also be gated on 
and displayed in a plot showing their XY-coordinates and the outline of the villi 
(Figure 5.14D and Figure 5.15D). These groups of cells of the same colour and 
same villus suggest a clonal origin and as shown in Figure 5.14BD and Figure 
5.15BD, many of these putative clones can be identified in a single image. Most 
putative clones are fairly small, only two or three cells, but some are larger and 
comprise up to six cells per clone for Figure 5.15D. Even larger putative clones can 
be identified in Figure 5.9. In FlowJo, these individual putative clones can also be 
analysed for IRF8 and CD11b expression (Figure 5.14E and Figure 5.15E). Despite 
the limitation that some surfaces appear to be negative for both IRF8 and CD11b, 
very few putative clones could be identified that harbour both IRF8+ cells and 
CD11b+ cells, These results indicate that DC precursors arriving in the small 
intestine divide locally before differentiating and that individual DC precursors may 
have a preference to differentiate into one subset or another. However, both for the 
clonal analysis and the subset distribution within clones more images have to be 
acquired and quantified. Moreover, the degree of clonality should be estimated 
using computational approaches. 
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Figure 5.13 Surface rendering on confetti channels by Imaris 
The surface rendering example shown here is based on the image in Figure 5.11. 
Surfaces were created for each of the four confetti channels using the built-in 
surface rendering tool in Bitplane Imaris software. (A) The left panel shows the 
original confetti channels for the isolated lymphoid follicle of Figure 5.11, the right 
panel shows the surfaces created on these channels. (B) Overview of all confetti 
surfaces generated for the image in Figure 5.11. 
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Figure 5.14 Analysis of confetti surfaces based on the images in Figure 5.11 by 
FlowJo  
Statistics on confetti surfaces as identified in Figure 5.13 were exported from Imaris 
and imported into FlowJo 10. (A) MHCII+ surfaces were selected. (B) XY 
coordinates of MHCII+ confetti surfaces were plotted as dots, the outline of the villi 
was plotted as density plot of EpCAM surfaces and the two graphs were combined 
in Illustrator. (C) IRF8 and CD11b expression of MHCII+ confetti surfaces. (D) Cells 
of the same confetti colour in a single villus were identified (‘clone’) and plotted as 
in (B). Each clone has its own colour. CFP clones are different shades of blue, GFP 
clones are different shades of green, YFP clones are different shades of orange 
and RFP clones are different shades of red. (E) IRF8 and CD11b expression of 
single clones as identified in (D). Colours correspond to the ones used in (D). 
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Figure 5.15 Analysis of confetti surfaces based on the images in Figure 5.12 by 
FlowJo 
Same analysis as in Figure 5.14, but then for the image shown in Figure 5.12. 
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5.5 Discussion 
In recent years our understanding of DC precursors has been substantially refined. 
CDPs were originally defined to exclusively give rise to both cDCs and pDCs, but 
more recent studies have shown that this population is heterogeneous and 
contains precursors that are either committed to generate either one or the other 
(Naik et al., 2007; Onai et al., 2007; K. Liu et al., 2009; Satpathy, KC, et al., 2012; 
Schraml et al., 2013; Onai et al., 2013). The same holds true for preDCs, where 
two subpopulations can be identified that generate either CD8α-like DCs or CD11b+ 
DCs (Naik et al., 2006; Schlitzer, McGovern and Ginhoux, 2015; Grajales-Reyes et 
al., 2015). However, the vast majority of research on DC precursors has been done 
on bulk populations, precluding the analysis of the fate of single precursors and 
possibly masking heterogeneity within the studied population. Thus far, the fate of 
single precursors has only been studied in an in vitro culture setting, which may be 
of limited biological relevance (Schlitzer, McGovern and Ginhoux, 2015).  
To overcome these limitations, a novel approach was devised to study DC 
precursor fate in vivo under physiological conditions. Clec9a+/CreROSA+/confetti mice 
were employed to stochastically and irreversibly label precursors with one of four 
fluorescent proteins and chase their fate in peripheral tissues. Ideally, an inducible 
form of Cre is used in these types of experiments, so that labelling of DC 
precursors can be temporally controlled and the fate of one cohort of DC 
precursors can be chased in vivo. As these mice did not exist, mice were 
generated that express CreERT2 under control of the Clec9a locus via a knock-in 
approach that was previously employed to generate Clec9a-GFP and Clec9a-Cre 
mice (Sancho et al., 2009; Schraml et al., 2013). Two Clec9a-CreERT2 mouse 
lines were successfully established from two targeted ES cell clones. Unfortunately, 
when crossed to ROSA26 reporter lines, none of these mice induced reporter 
expression when tamoxifen was administered orally or parentally. Furthermore, 
treatment with 4OH-tamoxifen of Flt3l BMDC cultures from these mice also failed to 
induce Cre-mediated recombination. The reason why Clec9a-CreERT2 mice failed 
to work is unknown. The locus was correctly targeted, sequencing of the Creert2 
gene and proximal promoter failed to detect any aberrations and Creert2 mRNA 
was expressed in Flt3l BMDCs, which makes it very unlikely that errors were 
introduced during the generation of these mice. Non-functional CreERT2 mouse 
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lines are not without precedent though. Tie2-CreERT2 mice were generated for the 
labelling of HSCs, but failed to show any signs of recombination (Busch et al., 
2015). Interestingly, remaking these mice using a different type of inducible Cre 
solved the problem and resulted in a functional inducible Cre system (Busch et al., 
2015). So, in principle chances are that newly generated mice expressing a 
different inducible version of Cre under control of the Clec9a locus will allow for 
tamoxifen-induced Cre recombination.  
 
Unfortunately, remaking these mice was not feasible for the current study and 
therefore Clec9a-Cre mice were crossed to ROSA26-confetti mice to assess DC 
precursor fate in vivo. Clec9a-Cre mice continuously induce reporter expression in 
CDPs and preDCs when crossed to ROSA26-YFP mice, but labelling efficiency is 
not complete and therefore not all DCs are labelled in these mice (Schraml et al., 
2013). The exception are CD8α-like DCs that express DNGR-1 and consequently 
Cre and therefore have an extra opportunity to recombine the ROSA26 locus 
(Schraml et al., 2013). Clec9a+/CreROSA+/confetti mice have not been characterised 
by flow cytometry as it has proven to be difficult to detect CFP in these mice, due to 
a suboptimal laser configuration on flow cytometers.  
 
Analysis of DC precursor fate in Clec9a+/CreROSA+/confetti mice by microscopy was 
limited here to the small intestine. This tissue has a well-defined DC compartment 
and due to the villus architecture, DCs are naturally confined in their migration. This 
latter point is of particular importance, as DCs are motile cells and if daughter cells 
migrate away too quickly, they will not be recognisable as a clone. The villi of the 
small intestine naturally confine DCs in their movements, which makes it more 
likely that daughter cells stay together in the same villus and can be identified as 
one clone. In the mesLN for example, DC movement is much less restricted and 
there are also many more labelled cells, which makes it impossible to infer any 
information on DC precursor clonality from these images.  
 
To analyse clonal burst size and DC subset distribution of clones in the small 
intestine of Clec9a+/CreROSA+/confetti mice, a method was developed to perform 8-
colour confocal microscopy and histo-cytometric analysis of the images (Gerner et 
al., 2012; Gerner, Torabi-Parizi and Germain, 2015). CFP, GFP, YFP and RFP 
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expressed in Clec9a+/CreROSA+/confetti mice and four antibodies coupled to BV421, 
AF594, AF647 or APC and AF700 could be resolved by microscopy. Analysis of 
the images presented here revealed that groups of cells of the same colour could 
be identified in single villi, which suggest a clonal origin of these cells. Although 
most of these putative clones were fairly small, comprising two or three cells of the 
same colour, larger putative clones were also detected. Nevertheless, these 
images also revealed many cells that did not appear to belong to a putative clone. 
These single cells might be genuine events in which a precursor arrived in the 
tissue and differentiated into one DC, but may also reflect limitations in the 
experimental setup. The sections examined here are only 30µm thick and do not 
capture the whole villus, and therefore cells belonging to a genuine clone will be 
missed if they reside above or below the section examined. Furthermore, labelling 
of precursors is continuous with Clec9a-Cre mice and the images presented here 
give a snapshot of a mixed DC population, showing DCs that have recently 
differentiated, DC about to die or migrate out of the tissue and even a rare 
precursor itself that had just arrived. The cells not belonging to a putative clone 
may for example reflect events in which other daughter cells have already migrated 
out of the tissue, but one daugther is still present. These limitations may equally 
affect the observed size of putative clones. Finally, a small percentage of CD64+ 
intestinal macrophages is labelled in Clec9a+/CreROSA+/YFP mice and will likely be 
labelled in Clec9a+/CreROSA+/confetti mice (Schraml et al., 2013). These macrophages 
originate from different precursors and have different turnover kinetics from DCs, 
but are difficult to distinguish from DCs in the images, as CD64 is not used to stain 
tissue sections. So, the fact that single cells are observed in the images presented 
here may have various explanations and the size of the putative clones may be 
underestimated. Nonetheless, the fact that putative clones are present suggests 
that at least some preDCs divide locally upon arrival in the small intestine.  
 
The analysis of putative clones can be further refined by assessing which DC 
subsets are found in an individual clone. This analysis will shed light on whether a 
preDC arriving in the small intestine can give rise to multiple subsets of DCs or is 
restricted to only one subset. Recent work has suggested that preDCs are already 
committed in the BM to give rise to either CD8α-like DCs or CD11b+ DCs when 
arriving in tissues (Schlitzer, McGovern and Ginhoux, 2015; Grajales-Reyes et al., 
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2015). However, these analyses were either performed in vitro or by adoptively 
transferring sorted populations of preDCs and investigating their fate in the spleen. 
The microscopy-based approach described here provides a more refined way of 
assessing preDC commitment in the small intestine under physiological settings. 
Sadly, antibodies against CD103 did not work for microscopy, which meant that the 
CD11b- and CD103-based classification of intestinal DC subsets that is often used 
for flow cytometry could not be employed. Fortunately, an antibody against the 
transcription factor IRF8 did work for microscopy and a combination of IRF8 and 
CD11b expression could distinguish CD103+ CD11b- DCs from CD103+ CD11b+ 
DCs and CD103- CD11b+ DCs. Regrettably, the resolution of IRF8 and CD11b 
expression by microscopy was not as good as by flow cytometry and many confetti-
positive cells appeared to be negative for both CD11b and IRF8. These cells would 
have to be excluded from the DC subset analysis.  
 
The research project presented here will require future work to support firm 
conclusions. Clec9a+/CreROSA+/confetti mice will need to be characterised by flow 
cytometry to quantify labelling efficiencies of DC subsets in the small intestine and 
to assess if other cell types, such as macrophages, are labelled. Furthermore, 
identification, quantification and phenotyping of cells expressing CFP and RFP, or 
GFP and YFP, are straightforward by flow cytometry. More images of small 
intestinal sections of Clec9a+/CreROSA+/confetti mice will be generated, so that DC 
precursor fate can be quantified via computational methods. Furthermore, whole 
villi, instead of sections of villi, should be analysed by microscopy, to capture all 
confetti cells in a single villus and reduce the bias by missing confetti-positive cells 
that are below or above the section imaged. Recent advancements in tissue 
clarification techniques should aid the imaging of whole tissues while preserving 
fluorescence. Ideally though, the arrival of preDCs in the small intestine and their 
division and differentiation is followed over time. However, this approach is not 
feasible with currently available techniques, as microscopes cannot penetrate deep 
enough into the tissue to image the villi and the mice would have to be imaged for 
days by intravital microscopy. 
Despite the failure of Clec9a-CreERT2 mice to induce recombination, temporal 
resolution of labelled cells may still be achieved in Clec9a+/CreROSA+/confetti mice via 
different means. One promising approach is to treat mice with EdU, a BrdU 
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analogue, that gets incorporated into the DNA of dividing cells and can be 
visualised in tissue sections. A pulse of EdU administered to 
Clec9a+/CreROSA+/confetti mice will label all dividing cells, including DC precursors, 
which can then be chased over the course of a few days. At time of analysis, cells 
that are both confetti- and EdU positive are known to have come from DC 
precursors that have divided during a specific time window and can be treated as a 
single cohort.  
Once DC precursor fate is analysed in steady state, these analyses will be 
repeated under conditions of disturbed gut homeostasis, to assess if DC precursor 
behaviour changes when the intestinal environment changes. One method to alter 
the gut microenvironment is to treat the mice with a cocktail of antibiotics in the 
drinking water, which reduces the microbiota and changes its composition. 
Alternatively, mice can be orally infected with the natural mouse pathogen 
Citrobacter rodentium that causes a mild colitis in immunocompetent mice. 
 
In the future Clec9a+/CreROSA+/confetti mice can also be used to address DC 
precursor fate in other non-lymphoid tissues, such as the lung or skin, and compare 
results with the ones obtained in the small intestine. Furthermore, the influence of 
different types of infection, like influenza or Candida albicans, or inflammatory 
stimuli, on the behaviour of DC precursors can be assessed. Moreover, 
Clec9a+/CreROSA+/confetti mice can be crossed to mouse strains constitutively or 
conditionally lacking transcription factors, signalling molecules, receptors etcetera, 
to address their influence on DC precursor biology. When Clec9a+/CreROSA+/confetti 
mice are for example crossed with mice harbouring a floxed version of one of the 
genes encoding TLR receptors, or their adaptor protein MyD88, the influence of 
TLR signalling on DC precursor fate can be interrogated.  
 
In summary, analysis of Clec9a+/CreROSA+/confetti mice by 8-colour microscopy and 
histo-cytometry is a very useful tool to study DC precursor biology in a 
physiological in vivo setting. Preliminary results show that at least some preDCs 
divide a few times upon arrival in the small intestine, before differentiating into one 
or multiple DC subsets. However, further work needs to be done to confirm these 
observations. 
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Chapter 6. Discussion 
6.1 How to classify mononuclear phagocytes? 
Mononuclear phagocytes have historically been classified as monocytes, 
macrophages or DCs based on surface marker expression, morphology and 
functionality. However, many of these attributes overlap among the different 
mononuclear phagocytes, leading to considerable debates in the field as how to 
classify certain subsets of mononuclear phagocytes, and to the same subset 
having different names. Technical advancements, particularly in the field of flow 
cytometry, and the availability of transgenic mouse lines have brought novel 
insights into mononuclear phagocyte heterogeneity, function and ontogeny. 
Multicolour flow cytometry and mass cytometry, in combination with the 
identification of novel myeloid markers, have revealed increasing complexity and 
have permitted the identification of novel subsets of mononuclear phagocytes. For 
example, DCs in the spleen can be divided into CD8α+ DCs and CD11b+ DCs, but 
both of these subsets can be further separated into CD205+ CX3CR1- CD8α+ DCs 
and CD205- CX3CR1+ CD8α+ DCs, and ESAMhi CD11b+ DCs and ESAMlow 
CD11b+ DCs, respectively (Bar-On and Jung, 2010; Lewis et al., 2011). Importantly, 
it is often unclear if this identification of subsets of subsets is biologically relevant, 
especially because surface marker expression is not immutable and can change 
during the life span of a cell. CD103 expression on CD8α-like DCs is for example 
induced by GM-CSF and CD103 levels may therefore differ depending on the 
strength of GM-CSF receptor signalling (Zhan et al., 2011; Sathe et al., 2011). 
Furthermore, in the spleen CD11b+ DCs can be stratified into a CD4 negative and 
CD4 positive population, but it has been shown that both populations have similar 
expression patterns of other surface markers and transcription factor dependencies, 
arguing that CD4 negative and CD4 positive CD11b+ DCs belong to the same 
subset (Edwards et al., 2003; Becher et al., 2014). On the contrary, studies have 
revealed that cells with similar surface marker expression and morphology may 
have different origins. One obvious example are CD11c+ MHCII+ cells, once almost 
synonymous for ‘dendritic cell’, but now understood to include also some 
monocyte-derived cells and macrophages.  
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Classifying mononuclear phagocytes based on functionality has its flaws. DCs have 
often been ascribed superior abilities to initiate T cell responses, while 
macrophages are described as highly phagocytic cells that can modulate 
inflammatory processes (Geissmann, Manz, et al., 2010; Steinman and Idoyaga, 
2010; Hashimoto, J. Miller and Merad, 2011; Merad et al., 2013; Varol, Mildner and 
Jung, 2015). Yet, these descriptions ignore the fact that macrophages and 
monocytes can also present antigen and initiate T cell responses (see 1.1.4.1) and 
that DCs have functions that are independent of T cells, such as interacting with 
other innate immune cells or stromal cells (see 1.1.4.2 and 1.1.4.3). DCs can, like 
macrophages, also modulate inflammatory processes and phagocytose cargo 
(Inaba et al., 1998; Roche and Furuta, 2015). 
 
An alternative approach to distinguish monocytes, macrophages, DCs and their 
subsets is based on differential requirements for growth factors and transcription 
factors (see 1.1.2) (Satpathy, Wu, et al., 2012; Schraml and Reis e Sousa, 2014). 
The key growth factor regulating DC development is Flt3l and exogenous Flt3l 
administration expands DCs in vivo, while mice lacking Flt3l or its receptor Flt3 
have strongly reduced DC numbers (Maraskovsky et al., 1996; McKenna et al., 
2000; Manfra et al., 2003; Waskow et al., 2008; Kingston et al., 2009). However, 
some DCs still develop in Flt3l-/- and Flt3-/- mice and loss of Flt3l signalling also 
impacts on NK cells, B cells and T cells (McKenna et al., 2000).  
On the other hand, macrophages depend on signalling through the M-CSFR, either 
by M-CSF for most macrophage populations, or by the alternative ligand IL-34 for 
LCs (Pixley and Stanley, 2004; Y. Wang et al., 2012; Greter, Lelios, et al., 2012). 
However, analogous to Flt3l-dependency of DCs, some macrophages can still 
develop independently of M-CSFR signalling (Cecchini et al., 1994; Pixley and 
Stanley, 2004). Macrophage development is dependent on the transcription factor 
Pu.1 and Pu.1-/- mice are devoid of macrophages (E. W. Scott et al., 1994; 
McKercher et al., 1996). However, Pu.1 deficiency affects many other 
haematopoietic lineages as well, and importantly has been argued to additionally 
affect DCs (E. W. Scott et al., 1994; McKercher et al., 1996; Guerriero et al., 2000; 
Anderson et al., 2000). Pu.1 dependency can therefore not be used to 
unambiguously distinguish macrophages from DCs.  
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A master regulator of the DC lineage has not been identified yet either. Although 
Zbtb46 expression is relatively restricted to DCs within the haematopoietic system, 
Zbtb46 expression can also be upregulated in activated monocytes, while it is 
downregulated upon DC stimulation and, importantly, absence of Zbtb46 does not 
negatively impact the development of DCs (Meredith, Liu, Darrasse-Jeze, et al., 
2012; Satpathy, KC, et al., 2012; Meredith, Liu, Kamphorst, et al., 2012). Zbtb46 
expression should therefore be used with caution when distinguishing DCs from 
monocytes and macrophages. Although growth factor and transcription factor 
dependency have thus far failed to unequivocally distinguish DCs from monocytes 
and macrophages, transcription factor dependency has been used more 
successfully to identify DC subsets. pDCs for example critically depend on the 
transcription factor E2-2, while CD8α-like DCs largely depend on Batf3 (Cisse et 
al., 2008; Hildner et al., 2008; Ghosh et al., 2010). 
 
A different approach relies on transcriptomics analysis of purified subsets of cells 
followed by supervised or unsupervised clustering to quantify relatedness of 
subsets and define key transcriptional profiles. This has been done for different 
mononuclear phagocyte subsets, for example by the Immgen consortium for DCs 
and macrophages (Robbins et al., 2008; J. C. Miller et al., 2012; Gautier et al., 
2012). However, as these analyses were performed on sorted populations of cells, 
they rely heavily on sample homogeneity. This limitation can be overcome by 
performing single-cell transcriptomics analyses, which are now becoming feasible 
due to recent technical advancements, and have indeed been performed on GM-
CSF derived BMDCs (Shalek et al., 2013). Alternatively, high-dimension mass 
cytometry (or flow cytometry) can be used to analyse marker expression of single 
cells and classify mononuclear phagocyte subsets (Becher et al., 2014). 
 
More recently, an ontogeny-based classification of DCs, monocytes and 
macrophages has been proposed (Guilliams et al., 2014). In this proposal 
mononuclear phagocytes are grouped according to the precursor from which they 
originate. Mononuclear phagocytes should only be called macrophages if they have 
an embryonic origin, while the term DC is restricted to cells derived from the CDP 
and cells originating from cMoPs should be called monocyte-derived cells. This 
approach has obvious advantages over classifications based on surface marker 
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expression, morphology and functionality. It may also complement transcription 
factor-based classifications, as precursors may depend on specific transcription 
factors. Furthermore, ontogeny from a common precursor does not define specific 
monocyte, macrophage or DC subsets, while transcription factor dependency 
differs for different subsets.  
However, an ontogeny-based classification has its limitations as well, both in 
practical and more philosophical terms. Practically, the ontogeny-based approach 
critically depends on the unambiguous identification of dedicated precursors, either 
by flow cytometry to perform adoptive transfer experiments, or by selective 
expression of inducible or constitutive Cre recombinase for lineage tracing 
experiments. In the case of adoptive transfer experiments, precursor populations 
have to be sorted to high purity to avoid contamination with other cells and even 
then the sorted population may be heterogeneous. Furthermore, adoptive transfer 
studies are not always feasible due to low cell numbers, as may be the case with 
embryonic precursors, and the isolation and subsequent intravenous transfer may 
introduce artefacts. Lineage tracing experiments depend on the availability of 
transgenic mouse lines that express inducible or constitutive Cre recombinase 
specifically and efficiently in the precursor of interest, so that when crossed to a 
fluorescent reporter mouse strain all precursors and no other cells are irreversibly 
labelled. Labelling of cells other than the precursor of interest may lead to 
ambiguity in assessing the origin of labelled differentiated cells and if not all 
precursors are labelled, no formal conclusions can be drawn on unlabelled 
differentiated cells. 
On a more philosophical level the ontogeny-based approach to classify 
mononuclear phagocytes assumes that precursors cannot substantially change 
their fate anymore once they are committed to a certain lineage and that a uniform 
population of cells cannot originate from multiple precursors. The first assumption 
that precursor fate is irreversible, is widely assumed and is in line with results from 
adoptive transfer experiments and single cell clonality assays performed with 
various haematopoietic precursors. However, haematopoiesis and lineage 
commitment is a gradual process, not a stochastic one. The grouping of 
haematopoietic cells into HSCs, GMPs, MDPs, CDPs etcetera is an arbitrary (albeit 
useful) process based on the expression of certain surface markers, while in reality 
it is a continuous transformation without defined boundaries. Cell fate choices 
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during haematopoiesis are regulated by a complex interplay of internal regulatory 
networks and external stimuli that allow for some plasticity. It is therefore possible 
that cells that have started to express a certain cell fate program, and may even 
show surface marker patters associated with this cell fate, could still change their 
fate, either stochastically or due to external factors. This reasoning may for 
example explain why Clec9a-Cre mice crossed to a fluorescent reporter strain also 
label a small fraction of macrophages, when some CDPs are not fully committed 
yet and can change their fate to generate other myeloid cells (Schraml et al., 2013). 
On the other hand, recent barcoding experiments suggested that DC commitment 
can take place much earlier during haematopoiesis, as a population of LMPPs can 
be identified that exclusively gives rise to DCs, apparently bypassing the classical 
GMP and MDP stages (Naik et al., 2013; Perié et al., 2014). Importantly, the LMPP 
fraction also contains more ‘conventional’ precursors that can still give rise to DCs 
and myeloid and/or B cells (Naik et al., 2013; Perié et al., 2014). These results 
suggest that lineage commitment is more complex than described by the classical 
haematopoietic ‘tree’ model, which complicates an ontogeny-based classification of 
mononuclear phagocytes.  
Furthermore, highly similar cell populations may display multiple origins. For 
example, it has been suggested that DCs, especially thymic DCs and pDCs, can 
originate from lymphoid progenitors. Adoptive transfer of common lymphoid 
progenitors (CLPs) generated DCs in spleen and thymus and some pDCs show 
VDJ gene rearrangements, despite being functionally and phenotypically 
undistinguishable from CMP-derived cells (Traver et al., 2000; Corcoran et al., 
2003; Sathe et al., 2013). Macrophage populations that are otherwise 
indistinguishable may have a dual origin in which embryonic macrophages are 
gradually replaced by monocyte-derived cells during life, as is for instance the case 
with alveolar macrophages (Ginhoux et al., 2010; C Schulz et al., 2012; Perdiguero 
et al., 2014; Epelman et al., 2014). For macrophages it was shown that the tissue 
microenvironment has a dominant role in defining macrophage identity (Lavin et al., 
2014; Gosselin et al., 2014). Tissue imprinting is even strong enough to reprogram 
fully differentiated macrophages when they are transplanted from one tissue to 
another (Lavin et al., 2014).  
In these examples an ontogeny-based classification will classify CLP-derived DCs 
and MDP-derived DCs into separate lineages and embryonic macrophages and 
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macrophages with a monocytic origin into separate lineages, even though in both 
cases there is no functional, phenotypical or transcriptional evidence justifying such 
a division.  
 
In summary, an ontogeny-based classification of mononuclear phagocytes 
overcomes many of the limitations of classifications based on surface marker 
expression, morphology and functionality. Practical limitations relating to the 
unambiguous identification of precursors may be addressed with time by 
technological innovation and a more detailed understanding of precursor biology. 
However, issues relating to precursor plasticity and cell populations originating from 
different precursors are fundamental limitations to the ontogeny-based approach 
and may require refining the ontogeny-based framework with transcription factor 
dependencies and/or single-cell transcriptomics or high-dimension cytometry data.  
 
6.2 The perfect mouse model to study dendritic cell biology 
To unravel the intricacies of DC biology, researchers increasingly rely on 
transgenic mouse models. Although current models are extremely useful, they are 
certainly not perfect. The perfect model should target only the DC population of 
interest with high efficiency and, depending on the research question, should 
constitutively or inducibly ablate this population, label it with a fluorescent protein or 
other tag, or delete or express a gene of interest. It is impossible to combine all 
these attributes into one single transgenic mouse and therefore it is probably more 
appropriate to talk about the ideal toolbox to study DC biology in vivo. This toolbox 
comprises of mice that target DC precursors (that can also be used to manipulate 
all DCs) or specific subsets of DCs, such as CD8α-like DCs or CD11b+ DCs, and 
for each population of interest should at least consist of a constitutive and an 
inducible Cre recombinase, to improve the flexibility of the toolbox. The discovery 
of the genome-editing capabilities of the CRISPR-Cas9 system will greatly facilitate 
the generation of such novel transgenic strains (Pelletier, Gingras and Green, 
2015). 
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Efficient DC-restricted expression of a transgene is crucially important in novel 
transgenic mice to study DC biology. Most transgenic mouse models currently 
available to target all DCs also target other cells and/or do not show complete 
penetrance. For example, transgenic mice that make use of the CD11c expression 
pattern additionally target many other immune cells and zbtb46 is also expressed 
on erythroid progenitors, endothelial cells and some activated monocytes (Jung et 
al., 2002; Probst, Tschannen, et al., 2005; Hochweller et al., 2008; Meredith, Liu, 
Darrasse-Jeze, et al., 2012; Satpathy, KC, et al., 2012). Mice targeting the Clec9a 
locus, as used in the data presented here, are not ideal either, as DNGR-1 is 
expressed both on cDC precursors and on certain differentiated DCs (Sancho et 
al., 2008; Caminschi et al., 2008; Schraml et al., 2013). Furthermore, in Clec9a-Cre 
mice the penetrance of Cre-mediated recombination in differentiated cDCs not 
expressing DNGR-1 is incomplete, while on the other hand a small proportion of 
macrophages is labelled (Schraml et al., 2013).  
Unfortunately, the identification of good promoters to target DC precursors or 
specific DC subsets is not straightforward. The identification of transcription factors, 
if they exist, that specifically control DCs or DC subsets would be hugely beneficial, 
as the genetic loci encoding these transcription factors can then be exploited for 
the generation of transgenic lines to study DC biology. Identification of receptors or 
other proteins that are uniquely expressed on DCs or specific subsets could be 
used in a similar way. Alternatively, locus control regions of human genes whose 
expression is restricted to DCs or DC subsets can be used in the mouse, as long 
as the transcription factors binging the promoter are sufficiently conserved. This 
strategy has for example been successfully used for targeting pDCs or LCs via the 
human locus control region normally encoding BDCA-2 or langerin, respectively 
(Bursch et al., 2007; Swiecki et al., 2010; Bobr et al., 2010). Promoters to 
specifically and efficiently target DC subsets have been identified in certain cases. 
CD8α-like DCs can for example be specifically manipulated via transgene 
expression under control of the Xcr1 locus (Swiecki et al., 2010; Yamazaki et al., 
2013). However, no promoters have currently been identified to specifically 
manipulate CD11b+ DCs or subsets of CD8α-like DCs or CD11b+ DCs, for example 
in certain tissues.  
If no good promoter can be found to generate a transgenic mouse that specifically 
targets the cells of interest, an alternative is to use a combination of two less 
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specific promoters. Utilisation of LysM and Csf1R expression was for example used 
to generate LysMCreCsf1RiDTR mice in which monocytes and macrophages can be 
inducibly depleted (Schreiber et al., 2013). Similarly, CD11cCreCX3CR1iDTR were 
generated to specifically deplete CD11c+ CX3CR1hi cells via DT injection (Diehl et 
al., 2013). Alternatively, a split-Cre or split-CreERT2 system can be used in 
combination with two less specific promoters (Hirrlinger, Scheller, et al., 2009; 
Hirrlinger, Requardt, et al., 2009; P. Wang et al., 2012). In this case two inactive 
Cre or CreERT2 fragments are expressed under the control of two different 
promoters, and only in cells in which both promoters are active the two fragments 
are expressed simultaneously, generating a working enzyme. This approach could 
be used to generate transgenic mice in which Cre activity is confined to DC 
precursors by expressing one fragment of the split-Cre under control of the Clec9a 
locus and the other part under control of the Csf1r locus (encoding M-CSFR or 
CD115). In Clec9a-Cre mice it has already been shown that Cre activity controlled 
by the Clec9a locus is confined to DC precursors, pDCs and CD8α-like DCs. 
Among these populations only DC precursors express detectable amounts of M-
CSFR (Onai et al., 2007; K. Liu et al., 2009). The Clec9a and Csf1r loci are 
therefore likely to be only concomitantly active at the DC precursor stage, and 
therefore a split-Cre system using these two loci should only generate an active 
Cre recombinase at the DC precursor stage. However, as the penetrance of Cre-
mediated recombination is incomplete in Clec9a-Cre mice, a split-Cre system using 
the Clec9a and Csf1r loci would likely suffer from the same limitation (Schraml et 
al., 2013). Other potentially interesting options for the split-Cre system are utilising 
expression patterns of both CD8α and CD11c to target resident CD8α+ DCs in 
lymphoid organs, CCR7 and CD11c to target migratory myeloid cells, or Zbtb46 
and CD11c to more specifically target DCs than with either using CD11c or Zbtb46 
expression alone.  
However, the split-Cre system has not been extensively used yet for transgenic 
mouse generation and it is therefore at present unknown how the recombination 
efficiency of split-Cre compares to conventional Cre. Furthermore, the split-Cre 
system involves the generation of two transgenic mouse lines instead of one to 
obtain an active Cre recombinase in the desired cells, which doubles the amount of 
work to generate the mice and also considerably complicates breeding strategies. 
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In addition to identifying good promoters to target the intended DC subset, tools are 
needed to manipulate or label these cells. Many transgenic mice are already 
available that harbour floxed versions of genes that are of interest for DC biology, 
for example genes encoding TLRs, transcription factors or chemokine receptors. 
When crossed to mice expressing Cre or CreERT2 in the appropriate cell type, 
these mice are powerful tools to elucidate the function of such proteins in DCs.  
 
Efficient and constitutive ablation of the desired cell population can be achieved via 
the expression of DTA, either via placing the gene encoding DTA under direct 
control of a cell-specific promoter, or by crossing mice expressing Cre recombinase 
in the desired population with ROSA26-DTA mice (Ivanova et al., 2005; 
Voehringer, Liang and Locksley, 2008). To inducibly deplete cells in vivo the DTR 
system has been widely used, in which expression of simian or human DTR 
renders cells sensitive for DT-mediated depletion, while all other murine cells 
remain insensitive to DT. Although the DTR-mediated depletion has proven to be 
efficient and fast, data presented in Chapter 3 of this thesis show that human or 
simian DTR can be biologically active in mice, and when expressed on DCs leads 
to LN hypocellularity and reduced frequencies of DCs in the absence of DT 
administration. It has also been suggested that DT itself can be immunogenic 
irrespective of the presence of DTR (Chapman and Georas, 2013). Furthermore, 
long-term depletion cannot be achieved with the DTR system, as mice start 
generating neutralising antibodies against DT after around two weeks of treatment.  
Alternatively, inducible depletion can be achieved by crossing CreERT2-expressing 
mice with ROSA26-DTA mice (Ivanova et al., 2005; Voehringer, Liang and 
Locksley, 2008). In this approach tamoxifen administration induces recombination 
of the ROSA26 locus and expression of DTA, killing the cells expressing CreERT2. 
Furthermore, mice do not generate neutralising antibodies against tamoxifen, which 
means that depletion should be achieved over longer periods of time. However, 
successful implementation of this approach relies on efficient CreERT2 
recombination to ablate the whole cell population of interest, and most CreERT2 
mouse lines currently available lack this high efficiency.  
Inducible depletion can additionally be achieved by generating transgenic mice that 
express an inducible suicide gene in the cells of interest. MAFIA mice for instance 
express GFP and a drug-inducible suicide gene under control of the c-fms 
Chapter 6. Discussion 
 
179 
 
promoter (encoding M-CSFR) that induces Fas-mediated apoptosis when the 
dimerising drug is administered (Burnett et al., 2004). However, depletion of 
macrophages in MAFIA mice required injections of the dimeriser during multiple 
days and the depletion was not complete, indicating that the use of inducible 
suicide genes for cell ablation in vivo may not be as efficient and fast as with a 
DTR-based system or CreERT2-DTA-based system (Burnett et al., 2004). 
Advantages and limitations of inducible depletion systems should therefore be 
carefully considered when generating novel transgenic mice to inducibly deplete 
cell populations.  
 
To facilitate microscopic analyses of DC subsets, these cells should be labelled 
with fluorescent proteins. Many different fluorescent proteins are available and the 
decision on which one(s) to use will mainly be based on their respective intensities 
and excitation and emission spectra. Furthermore, fluorescent proteins can be 
localised in the cytoplasm or targeted to the nucleus or membrane. The gene 
encoding the fluorescent protein can be placed under direct control of a cell-
specific promoter, or alternatively, mice expressing Cre or CreERT2 in the desired 
population can be crossed to ROSA26 mice harbouring one or multiple fluorescent 
proteins. When CreERT2-expressing mice are used, inducible labelling can be 
achieved via the administration of tamoxifen. Many ROSA26 mice have been 
generated that express one fluorescent protein, such as YFP or dTomato, upon 
Cre-mediated recombination (Srinivas et al., 2001; Madisen et al., 2010). More 
complex models have also been developed, such as the ROSA26-mTmG mice that 
constitutively express membrane-bound Tomato before recombination and 
membrane-bound GFP after recombination, or ROSA26-confetti mice that 
stochastically express one of four fluorescent proteins upon Cre-mediated 
recombination (Muzumdar et al., 2007; Snippert et al., 2010). However, loxP 
recombination efficiency differs for different ROSA26 reporter lines which should be 
taken into account when designing experiments, for example when different 
ROSA26 reporter lines crossed to the same Cre driver are compared (Madisen et 
al., 2010; J. Liu et al., 2013). 
 
In summary, the perfect mouse model to study DC biology does not exist and will 
never be generated as such, as the ideal transgenic model will differ depending on 
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the research question. However, a good toolbox to study DC biology in vivo should 
at least comprise of mice expressing constitutive or inducible Cre exclusively in all 
DCs, or in specific DC subsets. These mice can then be crossed to the many 
floxed mouse strains already available, such as the ROSA26 lines expressing DTR, 
DTA or fluorescent proteins, generating a flexible and versatile toolbox that can be 
used to study DC biology. This strategy crucially depends on the identification of 
promoters that are specific for all DCs or the different DC subsets, or when split-
Cre or split-CreERT2 are used, on the identification of a promoter pair that is 
unique for the population intended to be manipulated. 
Appendix 
 
181 
 
Chapter 7. Appendix 
The following publications are included as appendix: 
 
van Blijswijk, J., Schraml, B. U. and Reis e Sousa, C. (2013) ‘Advantages and 
limitations of mouse models to deplete dendritic cells.’, European journal of 
immunology, 43(1), pp. 22–26. doi: 10.1002/eji.201243022. 
 
van Blijswijk, J., Schraml, B. U., Rogers, N. C., Whitney, P. G., Zelenay, S., Acton, 
S. E. and Reis e Sousa, C. (2015) ‘Altered lymph node composition in diphtheria 
toxin receptor-based mouse models to ablate dendritic cells.’, Journal of 
immunology (Baltimore, Md : 1950), 194(1), pp. 307–315. doi: 
10.4049/jimmunol.1401999. 
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